

Identification and characterization of regulators of GLUT4 trafficking

By

Daniel Richard Gulbranson

B. S., Saint Cloud State, 2008

A thesis submitted to the
Faculty of the Graduate School of the
University of Colorado in partial fulfillment
of the requirement for the degree of
Doctor of Philosophy
Department of Molecular, Cellular and Developmental Biology

2017

This thesis entitled:

Identification and characterization of regulators of GLUT4 trafficking

written by Daniel Richard Gulbranson

has been approved for the Department of Molecular, Cellular and Developmental Biology

Jingshi Shen

Michael Stowell

Date_____

The final copy of this thesis has been examined by the signatories, and we find that both the content and the form meet acceptable presentation standards of scholarly work in the above mentioned discipline.

Gulbranson, Daniel Richard (Ph.D. Molecular, Cellular and Developmental Biology)

Identification and characterization of regulators of GLUT4 trafficking

Thesis directed by Associate Professor Jingshi Shen

Cargo proteins moving between organelles are transported by membrane-enclosed vesicles. Identifying the factors regulating vesicle-mediated transport remains a major challenge in mammalian cells. Here, we performed unbiased genome-wide CRISPR-Cas9 genetic screens to systematically dissect insulin-dependent translocation of glucose transporters (GLUTs), a classic vesicle transport pathway crucial to mammalian physiology. These screens identified known regulators of the pathway as well as a large number of unknown regulatory factors that we validated in secondary screens. The identified genes encode established or predicted factors involved in vesicle budding or fusion, cargo sorting, signal transduction, cell motility, and cellular metabolism, as well as proteins lacking annotated functions. Mechanistic analysis demonstrated that Rab-interacting factor (RABIF), a putative guanine nucleotide exchange factor (GEF), positively regulates GLUT translocation by stabilizing Rab GTPases, a new function independent of its GEF catalytic activity. Alpha- and gamma-adaptin binding protein (AAGAB), identified as a negative regulator of GLUT translocation, acts as a key regulator of AP2 adaptor formation in clathrin-mediated endocytosis. Mass spectrometry-based proteomic analysis showed that both AAGAB and RABIF regulate diverse cargo proteins, suggesting that the factors identified in our screens play broad roles in vesicle transport regulation. Our findings reveal new facets of vesicle-mediated cargo transport and suggest a general strategy for genetically dissecting complex membrane processes in mammalian cells.

ACKNOWLEDGEMENTS

I thank current and former members of the Shen laboratory for their support and discussions throughout this work. The MCDB department has been an excellent training environment, and I have benefitted greatly from discussions with researchers with a wide array of expertise. My thesis committee has provided critical guidance and support throughout graduate school. Jingshi has been a great mentor, taught me a lot, and provided the necessary support at critical junctures. Finally, I would like to thank Brittany for her unwavering support. It's been so much fun to go through graduate school with you!

TABLE OF CONTENTS:

CHAPTER 1: GLUT4 vesicle trafficking screens

| | |
|---|----|
| Introduction..... | 1 |
| Live cell vesicle trafficking reporter..... | 2 |
| Genetic library creation..... | 4 |
| Fluorescence activated cell sorting can be used for phenotypic selection..... | 5 |
| Secondary screens validate the candidate list..... | 8 |
| The screens identified known and novel regulators of GLUT4 localization..... | 11 |
| Experimental procedures..... | 33 |

CHAPTER 2: AAGAB regulates Adapter protein 2 complex formation on the plasma membrane

| | |
|--|----|
| Introduction..... | 40 |
| Clathrin mediated endocytosis..... | 40 |
| <i>AAGAB</i> mutation in human disease..... | 42 |
| <i>AAGAB</i> KO results in trafficking defect and acts downstream of insulin signaling..... | 44 |
| <i>AAGAB</i> KO results in an endocytosis defect..... | 46 |
| <i>AAGAB</i> regulates AP2 adaptor formation on the plasma membrane..... | 47 |
| Surface proteomics identifies many cargo similarly regulated by <i>AAGAB</i> or <i>AP2SI</i> KO..... | 51 |
| Discussion..... | 53 |

| | |
|------------------------------|----|
| Experimental procedures..... | 59 |
|------------------------------|----|

CHAPTER 3: RABIF regulates RAB10 expression

| | |
|--|----|
| Introduction..... | 64 |
| <i>RABIF</i> KO results in defective insulin response..... | 64 |
| RABIF interacts with RAB10 and prevents RAB10 degradation..... | 67 |
| RABIF's role in GLUT4 trafficking is independent of its putative GEF domain..... | 70 |
| Whole cell proteomics show that RABIF regulates a small subset of RABs..... | 75 |
| Discussion..... | 77 |
| Experimental procedures..... | 82 |

| | |
|---------------------------|----|
| BIBLIOGRAPHY | 88 |
|---------------------------|----|

TABLES:

| | |
|--|----|
| Table 1.1: Summary of top ranking genes in either the translocation defective screens or the constitutive translocation screens..... | 18 |
| Table 1.2: Illumina sequencing primers..... | 38 |
| Table 1.3 gRNAs used in individual CRISPR KO experiments..... | 40 |
| Table 2.1: Surface proteomics for either <i>AP2SI</i> or <i>AAGAB</i> KO..... | 55 |
| Table 3.1. Proteomic analysis of WT and <i>RABIF</i> KO cells..... | 78 |

FIGURES:

Figure 1.1: Diagram of the GFP-GLUT4-HA reporter used to monitor insulin-dependent GLUT trafficking.....3

Figure 1.2: GLUT4 regulation is conserved between HeLa cells and adipocytes.....4

Figure 1.3: Illustration of the genome-wide genetic screens of insulin-dependent GLUT translocation.....5

Figure 1.4: Flow cytometry selection for GLUT4 translocation mutants in genome-wide screen..6

Fig 1.5: Enrichment of sgRNA in selected populations.....7

Figure 1.6: Flow cytometry selection for GLUT4 translocation mutants in secondary screen.....9

Figure 1.7: List of the genes identified in the genetic screens.....10

Figure 1.8: Regulatory factors identified in the CRISPR screens form protein complexes or functional modules.....11

Figure 1.9: Summary of genes validated by the secondary screens.....12

Figure 1.10: Genes identified in the HeLa cell screen could be validated in adipocytes.....15

Figure 1.11: Ranking of genes in the translocation defective screen based on p-value.....16

Figure 1.11: Ranking of genes in the constitutive translocation screen based on p-value.....17

Figure 2.1 Phenotype observed in patients with loss of function mutation in AAGAB. (Pohler et al., 2012).....43

Figure 2.2 *AAGAB* knockout results in a trafficking defect and acts downstream of insulin signaling.....44

Figure 2.3: *AAGAB* KO results in GLUT4 plasma membrane localization.....45

Figure 2.4: *AAKAB* KO disrupts endocytosis.....46

| | |
|--|----|
| Figure 2.5: AAGAB regulates AP2 formation on the plasma membrane..... | 48 |
| Figure 2.6: AAGAB regulates total α -adaptin levels..... | 49 |
| Figure 2.7: α -adaptin overexpression partially rescues AAGAB KO..... | 49 |
| Figure 2.8: AAGAB does not colocalize with α -adaptin..... | 50 |
| Figure 2.9: LAMP1 trafficking is intact in <i>AAGAB</i> KO cells..... | 50 |
| Figure 2.10 <i>AAGAB</i> KO effects the cellular localization of endogenous CME cargo..... | 52 |
| Figure 3.1: <i>RABIF</i> KO results in decreased insulin response..... | 65 |
| Figure 3.2: <i>RABIF</i> KO results in decreased insulin response..... | 66 |
| Figure 3.3: Rabif acts downstream of insulin signaling to regulate GLUT4 exocytosis..... | 67 |
| Figure 3.4: RABIF interacts with RAB10..... | 68 |
| Figure 3.5: <i>RABIF</i> KO results in RAB10 degradation via proteasome..... | 69 |
| Figure 3.6: Catalytic domain mutants disrupt RABIF GEF activity..... | 71 |
| Figure 3.7: GEF catalytic domain mutation does not disrupt GLUT4 exocytosis activity..... | 72 |
| Figure 3.8: <i>RAB10</i> overexpression rescues <i>RABIF</i> KO GLUT4 exocytosis..... | 73 |
| Figure 3.9: Overexpression of <i>DENND4C</i> does not rescue GLUT translocation defects in <i>RABIF</i> KO cells..... | 74 |
| Figure 3.10: RABIF regulates a small subset of RAB proteins..... | 75 |
| Figure 3.11: RABIF regulates a subset of RAB proteins..... | 76 |
| Figure 3.12: RABIF regulates the expression of RAB10..... | 77 |

Chapter 1

GLUT4 vesicle trafficking screens

Introduction

A universal feature of eukaryotic cells is a compartmentalized cytoplasm filled with functionally specialized membrane-bound organelles (Palade, 1975). Maintenance and propagation of the organelles require constant inter-organelle transport of cargo proteins via membrane-enclosed vesicles (Schekman and Novick, 2004; Sudhof and Rothman, 2009). Vesicle-mediated cargo transport was first genetically dissected in yeasts, leading to the identification of vesicle transport mediators conserved in all eukaryotes (Schekman and Novick, 2004). Vesicle transport is substantially more complex in mammalian cells and is often tightly regulated by extracellular and intracellular stimuli such that the speed and direction of cargo flow can be adjusted according to physiological demands (Bonifacino and Glick, 2004; Bryant et al., 2002). Mammalian vesicle transport, however, has not been systematically characterized using genetic screens due to a lack of robust genetic tools. The recent advent of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas9 system has revolutionized mammalian cell genetics by enabling efficient and complete ablation of target genes (Cong et al., 2013; Doudna and Charpentier, 2014; Gilbert et al., 2014; Mali et al., 2013). Pooled CRISPR libraries introduced into cultured cells generate mutant populations that can be subsequently selected

based on cellular phenotypes (Gilbert et al., 2014; Koike-Yusa et al., 2014; Shalem et al., 2014; Wang et al., 2014; Zhou et al., 2014).

One widespread regulated vesicle transport pathway is the insulin-dependent translocation of glucose transporters (GLUTs), which controls nutrient homeostasis in cell types ranging from adipocytes to neurons and tumors (Bryant et al., 2002; Huang and Czech, 2007; Simpson et al., 2008). Upon binding to its receptor, the anabolic hormone insulin facilitates glucose uptake by acutely relocating GLUTs (e.g., GLUT4) from intracellular organelles to the cell surface (Antonescu et al., 2014; Bryant et al., 2002; Saltiel and Kahn, 2001). To dissect insulin-dependent GLUT translocation, we took advantage of the newly introduced Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas9 genetic screens (Gilbert et al., 2014; Koike-Yusa et al., 2014; Shalem et al., 2014; Wang et al., 2014; Zhou et al., 2014).

Live cell vesicle trafficking reporter

Insulin-dependent GLUT translocation was monitored using a dual-tag GLUT reporter in which GFP was fused to a cytosolic domain of GLUT4 and a hemagglutinin (HA) epitope was inserted into an exoplasmic loop (Fig. 1.1a) (Muretta et al., 2008). Surface levels of the reporter were tracked by staining the HA tag using anti-HA antibodies and allophycocyanin (APC)-conjugated secondary antibodies. The total reporter levels were reflected by GFP fluorescence. The ratio of APC and GFP fluorescence was measured by flow cytometry to quantify the relative surface levels of the reporter in live cells (Fig. 1.1).




Figure 1.1: Diagram of the GFP-GLUT4-HA reporter used to monitor insulin-dependent GLUT trafficking.

Insulin stimulation markedly increased the surface levels of the GLUT reporter in HeLa cells (Fig. 1.2a), consistent with the previously reported insulin responsiveness of these cells (Trefely et al., 2015). Insulin-triggered GLUT reporter translocation was abolished by wortmannin, a phosphoinositide-3 kinase inhibitor that interferes with insulin signaling (Fig. 1.2a). Knockout (KO) of *RAB10*, which encodes a known positive regulator (Sano et al., 2007), abrogated insulin-triggered GLUT reporter translocation (Fig. 1.2). KO of *TBC1D4*, which encodes a known negative regulator (Eguez et al., 2005), resulted in constitutive surface translocation of the reporter (Fig. 1.2a). These data are reminiscent of the observations in other insulin-responsive tissues such as adipocytes (Fig. 1.2b) (Eguez et al., 2005; Sano et al., 2007), suggesting that the GLUT translocation pathway is governed by a conserved mechanism. Therefore, we chose to perform genome-wide CRISPR screens in the readily expandable HeLa cells and then extended the findings to other cell types and pathways.




Figure 1.2: GLUT4 regulation is conserved between HeLa cells and adipocytes. HeLa cells (a) or adipocytes (b) expressing the GFP-GLUT4-HA reporter were either untreated or treated with 100 nM insulin for 30 min before the surface reporters were stained with anti-HA antibodies and APC-conjugated secondary antibodies. To inhibit insulin signaling, the cells were incubated with 100 nM wortmannin for 10 minutes prior to insulin stimulation. The ratio of APC and GFP fluorescence was measured by flow cytometry and the mean fluorescence was normalized to that of untreated WT cells. Error bars indicate standard deviation. *RAB10* and *TBC1D4* KO cell lines were generated using CRISPR-Cas9 genome editing.

Genetic library creation

We first selected for HeLa cells with a large dynamic range in insulin response. Using a population of HeLa cells stably expressing the GLUT reporter we treated the cells with insulin and used cell sorting to enrich for cells with the largest fraction of GLUT reporter on the surface. Subsequently, after expanding the sorted population, we selected for cells with the lowest level of GLUT reporter on the surface in the absence of insulin. Finally, a third enrichment step was performed, again enriching for cells with the highest level of GLUT reporter on the surface after

insulin treatment. These highly responsive HeLa cells were subsequently cloned prior to building the mutant library. This clonal cell line was then mutagenized by a pooled lentiviral CRISPR library containing 123,411 independent single guide RNAs (sgRNAs) targeting 19,050 protein-coding genes and 1,864 miRNAs (Sanjana et al., 2014). Using this mutant collection, we performed two complementary genome-wide genetic screens (Figure 1.3).




Figure 1.3: Illustration of the genome-wide genetic screens of insulin-dependent GLUT translocation.

Fluorescence activated cell sorting can be used for phenotypic selection

In the translocation defective screen (Fig. 1.4a), which was designed to identify positive regulators of GLUT translocation, flow cytometry was used to isolate mutant cells exhibiting reduced insulin-triggered GLUT translocation. In the constitutive translocation screen (Fig. 1.4b)

we collected mutant cells with high surface GLUT reporter levels in the absence of insulin stimulation, aiming to identify negative regulators of GLUT translocation.




Figure 1.4: Flow cytometry selection for GLUT4 translocation mutants in genome-wide screen. **a**, Flow cytometry analysis of starting mutant population and final sorted population (after three rounds of sorting) in the genome-wide translocation defective screen. Cells were treated with 100 nM insulin for 30 minutes before the cells were stained and analyzed by flow cytometry. **b**, Flow cytometry analysis of starting mutant population and final sorted population (after three rounds of sorting) in the genome-wide constitutive translocation screen. Cells were stained and analyzed without insulin stimulation.

To effectively enrich true positives, the mutagenized cells were successively sorted for three rounds (Fig. 1.3) before sgRNAs were recovered and analyzed by deep sequencing. The abundance of many sgRNAs in the sorted populations was substantially increased compared to the unsorted control population grown under the same condition. Among them, sgRNAs targeting *SLC2A4*, *RAB1F*, *AP2S1* and *AAGAB* were highly enriched (Fig. 1.5 a,b). By contrast, non-targeting control sgRNAs overall exhibited little enrichment (Fig. 1.5 a,b). Genes were ranked based on the enrichment of their targeting sgRNAs using the MAGeCK algorithm (Li et al., 2014).




Fig 1.5: Enrichment of sgRNA in selected populations.


a, Relative abundance of sgRNAs in the genome-wide translocation defective screen. **b**, Relative abundance of sgRNAs in the genome-wide constitutive translocation screen. Data in a and b are shown as log₂ of sgRNA abundance.

Secondary screens validate the candidate list

To identify true regulators, we performed deeper secondary screens by building a pooled CRISPR library targeting the top 1,170 candidate genes from the two genome-wide screens with 10 new sgRNAs for each gene. HeLa cells expressing the GLUT reporter were mutagenized by the secondary CRISPR library and sorted by flow cytometry (Fig. 1.6). Enrichment of sgRNAs in the sorted populations was then determined. A gene is considered significant only if its corresponding sgRNAs were enriched in both the primary and secondary screens. Altogether, 329 significant genes were identified in the translocation defective screens and 235 in the constitutive translocation screens (Fig 1.7).

a

Sorting of Translocation Defective Mutants

**b**

Sorting of Constitutive Translocation Mutants




Figure 1.6: Flow cytometry selection for GLUT4 translocation mutants in secondary screen. **a**, Flow cytometry analysis of starting mutant population and final sorted population (after two rounds of sorting) in the secondary translocation defective screen. Cells were treated with 100 nM insulin for 30 minutes before the cells were stained and analyzed by flow cytometry. **b**, Flow cytometry analysis of starting mutant population and final sorted population (after three rounds of sorting) in the secondary constitutive translocation screen. Cells were stained and analyzed without insulin stimulation.

Translocation Defective Screen

| | | | | | |
|---------|----------|---------|---------|----------|----------|
| LIAS | CRTC3 | NEO1 | NDUFAF7 | INSR | KCTD9 |
| RAB10 | MRPS35 | CDIP1 | TRMT10B | MTMR9 | PXK |
| DLD | COQ2 | CGGBP1 | MFAP3 | G3BP2 | TBCEL |
| SDHD | IRF1 | GRSF1 | COX16 | SAFB | ZNF292 |
| EXOC7 | EXOC1 | LRRC20 | STK17A | TFDP2 | USP31 |
| LIPT1 | MDH2 | FH | MRPS16 | PIK3R4 | NDUFA11 |
| NDUFB2 | NDUFA3 | UBL3 | ENPP2 | SIKE1 | STX3 |
| FOXRED1 | PYROXD1 | TMED2 | NDUFS1 | C21orf2 | MPP5 |
| EXOC8 | NDUFB10 | ZNF251 | LNPEP | GTPBP1 | HMOX1 |
| MRPS18A | TARBP1 | NDUFS7 | HAUS7 | BZW2 | C6orf62 |
| NDUFB9 | HLA-DPB1 | MRPS31 | CRLF3 | SUMF2 | PPIL3 |
| NDUFA2 | PNKD | AIF1L | NDUFAF4 | C5orf28 | KIAA2018 |
| NDUFC1 | AP4S1 | PDXDC1 | ING2 | FKBP9 | AES |
| ASPH | ZNF254 | NDUFA1 | MORN4 | PKP4 | TTC12 |
| NDUFAF1 | MSRB1 | SERINC5 | PACRGL | TMEM135 | FLI1 |
| NDUFB3 | IFT81 | RAB4A | TTC4 | SUMO1 | ANKZF1 |
| NDUFAF3 | C8orf82 | PIK3CB | NGFRAP1 | MAFB | HGS |
| ZNF263 | PLEKHG1 | ABR | SORT1 | GRB2 | SNAP29 |
| DNAAF2 | PEX12 | MMADHC | ITCH | APOL1 | C6orf136 |
| PDHA1 | CDH13 | ATP1B3 | PAAF1 | COQ7 | HDHD1 |
| RPRD1A | VPS35 | PHLDB2 | NDUFB4 | ALG3 | PSEN1 |
| CS | IFNAR2 | NDUFS2 | IRAK4 | BTG1 | AAED1 |
| CCSER2 | KIF3A | EZH1 | ZBTB14 | GGA1 | PEL1 |
| CAMTA1 | RABIF | COQ4 | ALS2 | MTERF | DNAJB2 |
| TRUB1 | PLEKHF2 | IRS2 | TUBA1A | SLC25A36 | ENG |
| | | | | | USP38 |

| | | | | | |
|-----------|----------|---------|----------|----------|----------|
| MUC4 | VN1R2 | CYP2J2 | PNMT | CST9L | ZNF138 |
| CLVS2 | TAS2R39 | SLC24A | PF4 | FAM217A | ZNF737 |
| ARPP21 | DEFB125 | MTNR1A | CABP1 | MAGEB2 | C9orf172 |
| GPC2 | FAM78B | SLCO4C1 | PGM2L1 | SLCO6A1 | ZNF221 |
| MEP1A | SOD3 | EVA1A | ASB3 | SLC22A14 | ZNF708 |
| HEPACAM2 | RTBDN | NPNT | GABRG2 | ODF3 | ZNF845 |
| ACY1 | AOX1 | ST8SIA6 | SYN1 | ZCWPW1 | PDSS1 |
| C15orf62 | C19orf38 | TMEM125 | IL1RAPL1 | TSKS | PREX2 |
| GPR157 | FAM46A | PRX | GABRB1 | PRR23C | ZNF234 |
| RSPH9 | NUSAP1 | TCF7 | NIM1 | PIAS2 | ZNF709 |
| MAK | ARHGDI3 | TESPA1 | TMEM132D | VCX3B | WNT2B |
| CCDC147 | LAMP5 | CD84 | C8orf46 | PDZD9 | CD300C |
| APOBEC4 | BEST3 | GREB1 | ACTL6B | ZNF683 | FKBP1B |
| MDH1B | GOLGA7B | DIO3 | GRIN2A | SSMEM1 | TMEM261 |
| FHL2 | GALNTL6 | AREG | FGFBP1 | RAD9B | NOSTRIN |
| DCUN1D2 | PCSK1 | CLEC12B | NPPB | MAGEA6 | PUS7L |
| ACSM2B | KIAA2022 | OCA2 | ANKRD1 | LEMD1 | ZNF879 |
| UGT2B7 | RASGEF1A | IGSF6 | INHBC | USP26 | XYLT1 |
| CLCNKB | STAC2 | BACE2 | ANGPTL3 | TRIML1 | PTCHD4 |
| SLC5A12 | SSTR2 | SALL4 | GCKR | ZNF816 | HYKK |
| SOX14 | RHBDL3 | CEP19 | APOA2 | FGF13 | PLEKHA8 |
| VSI8 | GRIA3 | DDX3Y | SLC34A2 | ZBTB12 | CACHD1 |
| PDILT | SMIM22 | ZNF732 | PRH2 | APBB1IP | EML4 |
| MRGPRG | FOLR1 | UTS2B | ACHE | LIPT2 | GRAMD1C |
| CST9 | NPHP1 | DDHD1 | LCE2A | RANBP17 | DACT3 |
| KRTAP19-2 | PLCH1 | SENP8 | POU3F1 | CENPH | DNAJC17 |
| SIX6 | HOXB5 | ZNF19 | COL17A1 | DMXL2 | PPIC |
| DEFB116 | CXorf64 | CLDN11 | TMEM45A | C1orf210 | FCER1A |
| KRT38 | LIF | FAM53A | PRKACG | TNIK | ARHGEF19 |
| ASCL5 | OGN | FABP4 | KIF4B | | |

Constitutive Translocation Screen

| | | | | | |
|----------|----------|------------|---------|---------|----------|
| AP2S1 | TTC7B | TMUB2 | DCUN1D5 | GOT1 | ANGEL2 |
| AAGAB | SLC35A2 | IL16 | DPD | ACSS1 | RALGAPA2 |
| B3GNT2 | CCDC91 | GTF2A1 | SESN1 | RNF14 | TGS1 |
| FAM3A | SCAF8 | ADNP | FAM122B | LAPTM5 | OGT |
| ANKRD13D | C19orf66 | HLA-DRA | RNF5 | PARP6 | DNAJB14 |
| AP2M1 | RBM43 | VWA9 | RNF7 | COG3 | COG6 |
| HSD17B11 | STIM1 | AAED1 | JMJD4 | NFIX | ELMSAN1 |
| COG2 | LARP4 | MLH3 | SERBP1 | PACS2 | NUMBL |
| CBX7 | TBC1D4 | C12orf43 | SLC39A9 | ROCK2 | GALE |
| CIC | FARP1 | RND3 | DPY19L1 | CNOT7 | SIN3B |
| UBTD2 | RECK | HNRNPA3 | MSL1 | TAX1BP3 | UBE3C |
| MGAT1 | SLAIN1 | LTBR | GOLIM4 | COG7 | RAB24 |
| OSBPL8 | ABHD12 | HERC3 | GALK1 | FCHO2 | IMPDH1 |
| NDUFAF6 | VHL | NCKAP5L | SHAH1 | PEBP1 | NCF4 |
| SDCBP | LGALS3 | MLLT3 | SERINC1 | ATXN2L | C16orf13 |
| ZNF362 | ZNF222 | CDKN2AIPNL | ACCS | CNN3 | ZNF202 |

| | | | | | |
|-----------|---------|----------|---------|----------|----------|
| MCF2L2 | MYB | GRIP3 | SALL4 | ALPP | NTPCR |
| BRINP2 | S100P | TRPV4 | FAM53A | CHAT | NUAK2 |
| POU3F3 | KIF21B | ABCA4 | KATNAL2 | LGALS13 | CYP4X1 |
| KCTD4 | UNC5D | SLCO4C1 | CAPRIN2 | PRR4 | PRTFDC1 |
| DDX25 | FAM169A | A1CF | SDK2 | CCL28 | DLGAP5 |
| MOGAT3 | GNAZ | DNAJC25 | GLB1L | KLHL33 | PCDHB10 |
| ATO1 | RORB | CYP4B1 | SALL1 | KCNJ12 | TMED8 |
| PCK2 | FAM171B | CETP | NTRK1 | IL37 | CDC14B |
| TMEM40 | SORCS3 | KLRG1 | NETO1 | TFF2 | C8orf44 |
| GLTP | MAP1B | VIT | PTPN5 | TCP10 | TLR1 |
| C14orf105 | CDR1 | MCC | BRSK1 | LIP1 | ATXN7L2 |
| IGF2BP1 | TRABD2A | ADAMTSL4 | MAS1 | PTCHD3 | ARHGAP29 |
| TGM7 | B3GNT7 | SLC15A2 | TMEM235 | SPANXN3 | CYSLTR1 |
| IFNA5 | HKDC1 | GCNT2 | DYNAP | FOXR2 | ZFP14 |
| HOXB1 | LMX1A | SPDEF | MOGAT1 | DCAF8L1 | VASN |
| C9orf170 | RSPO1 | CAPN9 | CAPN12 | RFL4B | FLT3LG |
| ERVW-1 | DUOXA1 | KCNN4 | TNNI3 | HSPB9 | SAPCD2 |
| PTX3 | C2orf54 | KLHL30 | ANKRD1 | OTOS | BAIAP2L1 |
| KCNA4 | FBXL13 | ESPN | UMOD | MGAT2 | TMEM194B |
| CNGB1 | TTC26 | NXPH4 | SLC17A1 | KIAA1462 | GLIPR1 |
| SULT2A1 | CFTR | DPYSL3 | TMEM27 | CHKB | EFS |
| SIGLEC10 | LIF | KLRD1 | CLDN16 | IRAK2 | GDAP2 |
| EMR3 | RBM24 | FAM177B | CDH16 | OSBPL10 | DDO |
| | | | | | SLC5A7 |

Figure 1.7: List of the genes identified in the genetic screens. These genes were identified in the genome-wide genetic screens and validated in the secondary screens. Genes with ubiquitous expression are highlighted in blue whereas genes with tissue-specific expression are highlighted in red. The tissue distribution of a gene is based on RNA expression data in Human Protein Atlas (www.proteinatlas.org). Genes associated with human diseases are indicated with boxes. A gene is included if its disease connections are shown in both MalaCards (www.malacards.org) and UniProtKB (www.uniprot.org).

The screens identified known and novel regulators of GLUT4 localization

The top-ranking gene in the translocation defective screen is *SLC2A4*, which encodes GLUT4 itself (the GFP-GLUT4-HA reporter is also targeted by *SLC2A4* sgRNAs), highlighting the quantitative nature of the screens. The screens identified known regulators of insulin-dependent GLUT translocation including RAB10, TBC1D4, sortilin-1, AP2 adaptor, and insulin signaling molecules (Fig 1.8). Recovery of these known regulators indicates that the screens were sensitive and specific. The vast majority of the identified genes, however, have not previously been linked to the GLUT translocation pathway, including 92 genes lacking annotated functions (Fig. 1.9 a,b). These findings highlight that we are still at the early stage of understanding the regulatory networks of GLUT translocation.





Figure 1.8: Regulatory factors identified in the CRISPR screens form protein complexes or functional modules. Only selected complexes or modules related to insulin signaling or vesicle transport are shown. The genes are colored according to the screen in which they were identified.

Translocation Defective Screen



Constitutive Translocation Screen




Figure 1.9: Summary of genes validated by the secondary screens. a, Translocation defective screen. b, Constitutive translocation screen.

The genes were classified as either positive or negative regulators of GLUT translocation according to the screen in which they were identified (Fig 1.9). From these two functional groups, genes were further characterized according to their known or predicted biological function (Fig 1.9 a,b). Approximately half of the identified genes have been implicated in various aspects of vesicle transport regulation such as vesicle budding/fusion, cargo sorting, cell motility, and signal transduction (Fig. 1.9 a,b). Other genes encode enzymes involved in lipid/carbohydrate metabolism, mediators of gene expression, and solute transporters (Fig 1.9). A significant portion of the identified genes may indirectly impact GLUT translocation by controlling the expression or localization of a direct regulator. Nevertheless, these genes constitute critical components of the regulatory networks because their deficiency leads to dysregulation of GLUT translocation. Identification of these diverse genes indicates that the GLUT translocation pathway is considerably more complex than previously thought, and its exploitation of cellular processes is extensive.

Many identified factors form protein complexes or functional modules such as exocyst, conserved oligomeric Golgi complex, AP2 adaptor, and insulin signaling (Fig 1.8). Recovery of these functionally linked genes suggests that the screens were exhaustive. Missing components of a complex or module are likely due to functional redundancy, rather than incompleteness of the mutant library, because their corresponding sgRNAs were present in the control mutant population (Supplementary Table 1). For example, the translocation defective screen identified the entire insulin signaling pathway except AKT (Fig 1.8). The absence of AKT is readily explained by the known redundancy of AKT isoforms (Dummler et al., 2006). The constitutive translocation screen isolated the $\mu 2$ and $\sigma 2$ subunits of the tetrameric AP2 adaptor involved in

endocytosis (Fig 1.8) (Brodsky, 2012). The α and $\beta 2$ subunits of the A2P adaptor, however, were not recovered. This finding is in full agreement with the known redundancy of the genes encoding the α subunit (*AP2A1* and *AP2A2*) or the $\beta 2$ subunit (*AP2B1* and *AP1B1*) (Traub and Bonifacino, 2013). We anticipate that our screens will facilitate the identification of previously unrecognized gene redundancy.

A large fraction of the regulatory factors exhibit ubiquitous tissue distributions and/or disease connections (Fig 1.7), underscoring their importance in physiology. We next examined whether the new genes identified in the screens also regulate GLUT translocation in other insulin-responsive cell types. Deletion of *VPS35*, which encodes a subunit of the retromer complex, abrogated insulin-triggered GLUT translocation in adipocytes (Fig 1.10a.). Similarly, deletion of *RABIF*, a putative Rab GEF, diminished GLUT translocation in adipocytes (Fig 1.10a). Deletion of *AAGAB*, which was identified in the constitutive translocation screen, dramatically increased the basal surface levels of GLUT reporter in adipocytes (Fig 1.10b). To examine the dynamic range of the genes; we also tested lower-ranking (still above the cutoff) genes from the screens. KO of *OSBPL8* or *OSBPL10*, which encode putative lipid transfer proteins, resulted in about twofold increases in the basal surface levels of GLUT reporter in adipocytes (Fig 1.10b). Similarly, KO of *ANKRD13D*, a poorly characterized ubiquitin-binding factor, doubled the basal surface levels of GLUT reporter in adipocytes (Fig 1.10b). These results suggest that the findings of our HeLa screens are applicable to other cell types (Fig 1.11, Fig 1.12, Table 1.1).




Figure 1.10: Genes identified in the HeLa cell screen could be validated in adipocytes.

a, Selected genes from the translocation defective screen were individually mutated in mouse adipocytes using CRISPR-Cas9. Effects of the mutations on insulin-dependent GLUT translocation were measured by flow cytometry. **b**, Selected genes from the constitutive translocation screen were individually mutated in mouse adipocytes using CRISPR-Cas9. Effects of the mutations on surface reporter levels were measured by flow cytometry (without insulin treatment). The dashed line indicates the surface GLUT reporter level in WT cells without insulin stimulation. Error bars in e and f indicate standard deviation. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$.




Figure 1.11: Ranking of genes in the translocation defective screen based on p-value. Each dot represents a gene. Genes above the horizontal line were tested in the secondary screen. A gene is shown as a large dot if it was validated in the secondary screen. Genes regulating GLUT trafficking in both HeLa and adipocytes are shown in blue, and genes validated in figure 1.10 are shown in bold




Figure 1.12: Ranking of genes in the constitutive translocation screen based on p-value. Each dot represents a gene. Genes above the horizontal line were tested in the secondary screen. A gene is shown as a large dot if it was validated in the secondary screen. Genes regulating GLUT trafficking in both HeLa and adipocytes are shown in red, and genes validated in figure 1.10 are shown in bold

Table 1.1: Summary of top ranking genes in either the translocation defective screens or the constitutive translocation screens. (Genes enriched in both primary and secondary screens are highlighted)

| Ranking of genes enriched in the genome-wide translocation defective screen | | | | Ranking of genes enriched in the genome-wide constitutive translocation screen | | | |
|---|-----------------|-----------------|--------------------------|--|-----------------|-----------------|--------------------------|
| Rank in primary screen | Gene ID | <i>p</i> -value | Rank in secondary screen | Rank in primary screen | Gene ID | <i>p</i> -value | Rank in secondary screen |
| 1 | <i>SLC2A4</i> | 1.50E-11 | 33 | 1 | <i>AP2S1</i> | 2.66E-16 | 2 |
| 2 | <i>LIAS</i> | 1.12E-08 | 46 | 2 | <i>AAGAB</i> | 2.11E-07 | 12 |
| 3 | <i>RAB10</i> | 1.19E-07 | 13 | 3 | <i>B3GNT2</i> | 1.43E-06 | 17 |
| 4 | <i>DLD</i> | 6.02E-07 | 34 | 4 | <i>MGAT2</i> | 7.17E-06 | 3 |
| 5 | <i>IMPA1</i> | 3.71E-06 | 632 | 5 | <i>DUOXA1</i> | 8.61E-06 | 260 |
| 6 | <i>SDHD</i> | 4.90E-06 | 275 | 6 | <i>FAM3A</i> | 1.55E-05 | 7 |
| 7 | <i>EXOC7</i> | 7.79E-06 | 3 | 7 | <i>ANKRD13D</i> | 2.60E-05 | 428 |
| 8 | <i>FGF13</i> | 9.90E-06 | 384 | 8 | <i>FAM53A</i> | 3.40E-05 | 293 |
| 9 | <i>LIPT1</i> | 1.44E-05 | 318 | 9 | <i>AP2M1</i> | 6.95E-05 | 4 |
| 10 | <i>LCE2A</i> | 2.16E-05 | 478 | 10 | <i>CELSR1</i> | 8.72E-05 | 911 |
| 11 | <i>NDUFB2</i> | 2.61E-05 | 11 | 11 | <i>SCPEP1</i> | 9.87E-05 | 838 |
| 12 | <i>C10orf68</i> | 3.68E-05 | 639 | 12 | <i>CDC42EP5</i> | 0.00011191 | 636 |
| 13 | <i>FOXRED1</i> | 3.80E-05 | 5 | 13 | <i>RPRML</i> | 0.00011878 | 644 |
| 14 | <i>SMIM22</i> | 4.00E-05 | 497 | 14 | <i>KIAA1462</i> | 0.00013866 | 487 |
| 15 | <i>PRKACG</i> | 4.65E-05 | 431 | 15 | <i>ZNF74</i> | 0.00015641 | NA |
| 16 | <i>OR4F5</i> | 7.29E-05 | NA | 16 | <i>CHKB</i> | 0.00021099 | 54 |
| 17 | <i>EXOC8</i> | 7.72E-05 | 301 | 17 | <i>HS3ST6</i> | 0.00022209 | 548 |
| 18 | <i>MRPS18A</i> | 8.63E-05 | 524 | 18 | <i>WDR52</i> | 0.00028559 | 789 |
| 19 | <i>NDUFB9</i> | 9.30E-05 | 21 | 19 | <i>TCP10</i> | 0.00041319 | 344 |
| 20 | <i>NDUFA2</i> | 0.00011274 | 12 | 20 | <i>ZIK1</i> | 0.00042649 | 555 |
| 21 | <i>LUC7L3</i> | 0.00012981 | 1062 | 21 | <i>KCNU1</i> | 0.00043059 | 682 |
| 22 | <i>CEP19</i> | 0.00014179 | 220 | 22 | <i>ARAP1</i> | 0.00044134 | 912 |
| 23 | <i>PSRC1</i> | 0.00016294 | 629 | 23 | <i>GNAZ</i> | 0.00049154 | 117 |
| 24 | <i>SNRPE</i> | 0.0001698 | 1110 | 24 | <i>KCTD4</i> | 0.00049325 | 512 |
| 25 | <i>SLC34A2</i> | 0.00018174 | 78 | 25 | <i>SLC5A5</i> | 0.00054254 | 1054 |
| 26 | <i>NPHP1</i> | 0.00018849 | 515 | 26 | <i>IRAK2</i> | 0.00054516 | 524 |
| 27 | <i>CABP1</i> | 0.00019187 | 402 | 27 | <i>HSD17B11</i> | 0.00054716 | 74 |
| 28 | <i>DIO3</i> | 0.00020332 | 310 | 28 | <i>COG2</i> | 0.00058712 | 5 |
| 29 | <i>PCSK1</i> | 0.00020921 | 38 | 29 | <i>DENR</i> | 0.00059706 | 667 |
| 30 | <i>NDUFC1</i> | 0.00021771 | 19 | 30 | <i>LCA5L</i> | 0.00059897 | 595 |
| 31 | <i>ASPH</i> | 0.00021875 | 62 | 31 | <i>TEX13B</i> | 0.00063693 | 731 |
| 32 | <i>OCLM</i> | 0.00022501 | NA | 32 | <i>EED</i> | 0.00064897 | 699 |
| 33 | <i>HLTF</i> | 0.00022967 | 737 | 33 | <i>CBX7</i> | 0.00067059 | 249 |
| 34 | <i>SYNCRIP</i> | 0.00023366 | 781 | 34 | <i>OR52M1</i> | 0.00067435 | NA |

| | | | | | | | |
|----|-----------------|------------|------|----|-----------------|------------|------|
| 35 | <i>FLYWCH1</i> | 0.00024217 | 1134 | 35 | <i>CNGA2</i> | 0.00068602 | 729 |
| 36 | <i>NDUFAF1</i> | 0.00024262 | 24 | 36 | <i>SLC16A14</i> | 0.00070087 | 1053 |
| 37 | <i>OPA1</i> | 0.00024917 | 1107 | 37 | <i>ATPIA4</i> | 0.00070686 | NA |
| 38 | <i>SERPINB2</i> | 0.00026364 | 890 | 38 | <i>DYNAP</i> | 0.00074515 | 484 |
| 39 | <i>KIF4B</i> | 0.00028006 | 50 | 39 | <i>CMTM7</i> | 0.00075277 | 585 |
| 40 | <i>PGM2L1</i> | 0.00028027 | 313 | 40 | <i>CIC</i> | 0.0007896 | 472 |
| 41 | <i>SCN2B</i> | 0.00028557 | 590 | 41 | <i>TMEM105</i> | 0.00079329 | 1039 |
| 42 | <i>ZBTB12</i> | 0.00029872 | 492 | 42 | <i>PHAX</i> | 0.00080467 | 1020 |
| 43 | <i>SMARCA2</i> | 0.00030094 | 720 | 43 | <i>UBTD2</i> | 0.00083834 | 101 |
| 44 | <i>TXNDC5</i> | 0.000301 | 1049 | 44 | <i>MGAT1</i> | 0.00084451 | 11 |
| 45 | <i>NDUFB3</i> | 0.000308 | 23 | 45 | <i>CCL21</i> | 0.000846 | NA |
| 46 | <i>MRGPRG</i> | 0.00031648 | 414 | 46 | <i>ROBO1</i> | 0.00085656 | 740 |
| 47 | <i>ST8SIA6</i> | 0.00031923 | 453 | 47 | <i>CARD17</i> | 0.00092906 | 629 |
| 48 | <i>TGFBI</i> | 0.00032308 | 668 | 48 | <i>DFNB31</i> | 0.00095528 | 831 |
| 49 | <i>FHOD3</i> | 0.00033378 | 925 | 49 | <i>SULT2A1</i> | 0.00097053 | 400 |
| 50 | <i>NDUFAF3</i> | 0.00033878 | 17 | 50 | <i>POU3F3</i> | 0.00098695 | 129 |
| 51 | <i>CST9L</i> | 0.00035348 | 403 | 51 | <i>BTF3L4</i> | 0.0010122 | 1094 |
| 52 | <i>KRTAP9-6</i> | 0.00035507 | 867 | 52 | <i>AHDC1</i> | 0.0010202 | NA |
| 53 | <i>ZNF263</i> | 0.00037987 | 178 | 53 | <i>UNC5D</i> | 0.0010641 | 392 |
| 54 | <i>DNAAF2</i> | 0.00038258 | 405 | 54 | <i>ESR1</i> | 0.0010782 | 687 |
| 55 | <i>APBB1IP</i> | 0.00038388 | 181 | 55 | <i>SLC12A4</i> | 0.0010818 | 728 |
| 56 | <i>C19orf38</i> | 0.0003894 | 381 | 56 | <i>PCTP</i> | 0.0010969 | 908 |
| 57 | <i>KCNK9</i> | 0.0004035 | 909 | 57 | <i>OSBPL8</i> | 0.001116 | 540 |
| 58 | <i>PPIAL4F</i> | 0.00042404 | NA | 58 | <i>ARHGEF11</i> | 0.0011371 | 1086 |
| 59 | <i>PDHA1</i> | 0.00042611 | 199 | 59 | <i>OSBPL10</i> | 0.0011679 | 221 |
| 60 | <i>BLM</i> | 0.00044131 | 704 | 60 | <i>EPHA8</i> | 0.0012093 | 793 |
| 61 | <i>LIPT2</i> | 0.00044234 | 14 | 61 | <i>THAP9</i> | 0.0012198 | NA |
| 62 | <i>SPCS2</i> | 0.00047995 | 1065 | 62 | <i>ITGB2</i> | 0.0012716 | 781 |
| 63 | <i>CCDC64B</i> | 0.00048354 | 1019 | 63 | <i>NDUFAF6</i> | 0.0013235 | 18 |
| 64 | <i>RPRD1A</i> | 0.0004843 | 585 | 64 | <i>LCE2B</i> | 0.0013455 | NA |
| 65 | <i>CYP2J2</i> | 0.0004956 | 156 | 65 | <i>SLC5A7</i> | 0.0013754 | 108 |
| 66 | <i>RANBP17</i> | 0.00052583 | 212 | 66 | <i>TSHR</i> | 0.0013764 | 619 |
| 67 | <i>CAPZA1</i> | 0.00054513 | 821 | 67 | <i>POLR3B</i> | 0.001441 | 965 |
| 68 | <i>AKR1C2</i> | 0.00055808 | 736 | 68 | <i>SDCBP</i> | 0.0014791 | 495 |
| 69 | <i>INHBC</i> | 0.00056875 | 260 | 69 | <i>NCF1</i> | 0.0014972 | 645 |
| 70 | <i>DDX3Y</i> | 0.0005755 | 359 | 70 | <i>ZNF362</i> | 0.0015136 | 198 |
| 71 | <i>GOLGA7B</i> | 0.00059573 | 58 | 71 | <i>TTC7B</i> | 0.001531 | 353 |
| 72 | <i>FAM217A</i> | 0.00059703 | 556 | 72 | <i>WDR5B</i> | 0.0015478 | NA |
| 73 | <i>ASB3</i> | 0.00060926 | 352 | 73 | <i>S100P</i> | 0.0015829 | 209 |
| 74 | <i>FAM46A</i> | 0.00061011 | 158 | 74 | <i>OR5B2</i> | 0.0016039 | NA |
| 75 | <i>CS</i> | 0.00061706 | 29 | 75 | <i>TRIM15</i> | 0.0016347 | 543 |
| 76 | <i>CDK19</i> | 0.00062547 | 1021 | 76 | <i>HMGAI</i> | 0.0017154 | NA |
| 77 | <i>MEP1A</i> | 0.00062703 | 378 | 77 | <i>OSBPL7</i> | 0.0017286 | 950 |

| | | | | | | | |
|-----|-----------------|------------|------|-----|-----------------|-----------|------|
| 78 | <i>TGIF1</i> | 0.00063634 | 943 | 78 | <i>DIXDC1</i> | 0.0017384 | NA |
| 79 | <i>MRPL33</i> | 0.00064893 | 670 | 79 | <i>ATP6AP1</i> | 0.0017419 | 1134 |
| 80 | <i>SLC7A11</i> | 0.00066712 | 870 | 80 | <i>SLC35A2</i> | 0.0017485 | 15 |
| 81 | <i>CCSER2</i> | 0.00067477 | 338 | 81 | <i>ELFN2</i> | 0.0017805 | 883 |
| 82 | <i>ANKS3</i> | 0.0006846 | 621 | 82 | <i>TBC1D25</i> | 0.0017903 | NA |
| 83 | <i>PRM1</i> | 0.00068685 | 970 | 83 | <i>RORB</i> | 0.0017915 | 476 |
| 84 | <i>CAMTA1</i> | 0.00070083 | 420 | 84 | <i>CCDC91</i> | 0.0018025 | 51 |
| 85 | <i>TRUB1</i> | 0.00070721 | 436 | 85 | <i>SCAF8</i> | 0.0018249 | 91 |
| 86 | <i>CRTC3</i> | 0.00071792 | 297 | 86 | <i>C19orf66</i> | 0.0018415 | 328 |
| 87 | <i>HSD3B2</i> | 0.00072561 | 624 | 87 | <i>CLIC4</i> | 0.0018421 | NA |
| 88 | <i>CENPH</i> | 0.0007398 | 429 | 88 | <i>TENM3</i> | 0.0018455 | NA |
| 89 | <i>MRPS35</i> | 0.00076023 | 60 | 89 | <i>NTPCR</i> | 0.0018666 | 292 |
| 90 | <i>COCH</i> | 0.00077358 | 745 | 90 | <i>ANKRD61</i> | 0.001894 | NA |
| 91 | <i>CLUAP1</i> | 0.00077604 | 1100 | 91 | <i>TBKBP1</i> | 0.0019458 | 876 |
| 92 | <i>ZCCHC12</i> | 0.00078031 | 1032 | 92 | <i>RBM43</i> | 0.0019518 | 107 |
| 93 | <i>HSPA12A</i> | 0.00078842 | 747 | 93 | <i>BRAT1</i> | 0.0019977 | 1041 |
| 94 | <i>FAS</i> | 0.00078868 | 916 | 94 | <i>SALL1</i> | 0.0020359 | 431 |
| 95 | <i>COQ2</i> | 0.00079675 | 30 | 95 | <i>STIM1</i> | 0.0020495 | 373 |
| 96 | <i>FABP4</i> | 0.00081272 | 274 | 96 | <i>FRAT1</i> | 0.0020816 | 704 |
| 97 | <i>IRF1</i> | 0.00082423 | 204 | 97 | <i>KATNAL2</i> | 0.0021014 | 135 |
| 98 | <i>EXOC1</i> | 0.0008265 | 16 | 98 | <i>FLOT1</i> | 0.0021092 | 894 |
| 99 | <i>PARP3</i> | 0.00082913 | 1042 | 99 | <i>TNNI3</i> | 0.0021532 | 210 |
| 100 | <i>ANKLE2</i> | 0.00085652 | 1139 | 100 | <i>TCEAL1</i> | 0.0021907 | 1100 |
| 101 | <i>FAM64A</i> | 0.000893 | 818 | 101 | <i>GPATCH4</i> | 0.0021926 | 783 |
| 102 | <i>CCDC167</i> | 0.00089819 | 801 | 102 | <i>RAMP1</i> | 0.0022124 | NA |
| 103 | <i>LEPROTL1</i> | 0.00090017 | 835 | 103 | <i>SLC23A1</i> | 0.0022569 | 854 |
| 104 | <i>RALYL</i> | 0.00090841 | 885 | 104 | <i>STBD1</i> | 0.0022574 | NA |
| 105 | <i>MAGEB2</i> | 0.00092676 | 417 | 105 | <i>TLL7</i> | 0.0022788 | NA |
| 106 | <i>FCRL3</i> | 0.00093184 | 698 | 106 | <i>RPL29</i> | 0.002281 | 974 |
| 107 | <i>MDH2</i> | 0.00093674 | 489 | 107 | <i>SUN1</i> | 0.0023087 | 648 |
| 108 | <i>NDUFA3</i> | 0.00095939 | 8 | 108 | <i>LIPJ</i> | 0.0023606 | 53 |
| 109 | <i>PYROXD1</i> | 0.0009603 | 574 | 109 | <i>SLC15A2</i> | 0.0023795 | 339 |
| 110 | <i>PDILT</i> | 0.00097467 | 159 | 110 | <i>OTOS</i> | 0.0023801 | 531 |
| 111 | <i>NDUFB10</i> | 0.00098271 | 27 | 111 | <i>KRT84</i> | 0.0023888 | 792 |
| 112 | <i>TARBP1</i> | 0.00098584 | 262 | 112 | <i>FAM168B</i> | 0.0024124 | 630 |
| 113 | <i>CST9</i> | 0.00099485 | 512 | 113 | <i>ERVW-1</i> | 0.0024215 | 112 |
| 114 | <i>RSPH9</i> | 0.00099498 | 397 | 114 | <i>HDAC9</i> | 0.0024497 | NA |
| 115 | <i>SPHAR</i> | 0.00099963 | NA | 115 | <i>HMGB1</i> | 0.0024642 | 1143 |
| 116 | <i>SOX14</i> | 0.0010122 | 147 | 116 | <i>GSDMB</i> | 0.0025093 | NA |
| 117 | <i>HLA-DPB1</i> | 0.0010138 | 123 | 117 | <i>LRRC46</i> | 0.002516 | 570 |
| 118 | <i>GPC2</i> | 0.0010198 | 145 | 118 | <i>ZNF83</i> | 0.0025394 | NA |
| 119 | <i>OR5V1</i> | 0.0010213 | NA | 119 | <i>ZNF425</i> | 0.0025552 | NA |
| 120 | <i>MGRN1</i> | 0.0010363 | 982 | 120 | <i>GLTP</i> | 0.0025734 | 36 |

| | | | | | | | |
|-----|-----------------|-----------|------|-----|----------------|-----------|------|
| 121 | <i>ZNF732</i> | 0.0010641 | 474 | 121 | <i>C4B_2</i> | 0.0025799 | NA |
| 122 | <i>PNKD</i> | 0.0010727 | 163 | 122 | <i>CD86</i> | 0.0025918 | 1030 |
| 123 | <i>AGAP9</i> | 0.0010816 | 949 | 123 | <i>LARP4</i> | 0.0026197 | 177 |
| 124 | <i>AP4S1</i> | 0.0011012 | 68 | 124 | <i>RPS4Y1</i> | 0.0026626 | NA |
| 125 | <i>SMAD5</i> | 0.0011159 | NA | 125 | <i>ZNF234</i> | 0.0026715 | 556 |
| 126 | <i>ZNF254</i> | 0.0011249 | 567 | 126 | <i>ZNF559</i> | 0.0026827 | NA |
| 127 | <i>MSRB1</i> | 0.0011305 | 566 | 127 | <i>ABCA4</i> | 0.0027061 | 532 |
| 128 | <i>SLC5A12</i> | 0.0011532 | 66 | 128 | <i>TBC1D4</i> | 0.0027162 | 13 |
| 129 | <i>UTS2</i> | 0.0011639 | 1082 | 129 | <i>FARP1</i> | 0.0027233 | 273 |
| 130 | <i>IFT81</i> | 0.0011678 | 105 | 130 | <i>NAT6</i> | 0.0027534 | 787 |
| 131 | <i>DMXL2</i> | 0.0011713 | 406 | 131 | <i>RECK</i> | 0.0027619 | 231 |
| 132 | <i>ANGPTL3</i> | 0.0011852 | 110 | 132 | <i>ENPP7</i> | 0.0027746 | 904 |
| 133 | <i>C8orf82</i> | 0.0011853 | 333 | 133 | <i>PGRMC2</i> | 0.0028787 | 653 |
| 134 | <i>SLCO6A1</i> | 0.0012037 | 191 | 134 | <i>CAPN1</i> | 0.002886 | NA |
| 135 | <i>FHL3</i> | 0.0012079 | 810 | 135 | <i>ERO1L</i> | 0.0029305 | NA |
| 136 | <i>CEBPD</i> | 0.0012107 | 719 | 136 | <i>TMEM219</i> | 0.0029534 | 873 |
| 137 | <i>KIAA2022</i> | 0.0012197 | 82 | 137 | <i>NDUFAB1</i> | 0.0029815 | 1109 |
| 138 | <i>AREG</i> | 0.0012259 | 155 | 138 | <i>SLAIN1</i> | 0.0029823 | 197 |
| 139 | <i>PLEKHG1</i> | 0.0012492 | 299 | 139 | <i>VIT</i> | 0.0030341 | 258 |
| 140 | <i>MAK</i> | 0.0012734 | 466 | 140 | <i>ABHD12</i> | 0.0030748 | 417 |
| 141 | <i>GRINA</i> | 0.0012838 | 966 | 141 | <i>ALX1</i> | 0.0030859 | NA |
| 142 | <i>PEX12</i> | 0.0012987 | 271 | 142 | <i>KPNA3</i> | 0.003094 | 1011 |
| 143 | <i>OGT</i> | 0.0013023 | 964 | 143 | <i>VHL</i> | 0.003116 | 31 |
| 144 | <i>CDH13</i> | 0.0013194 | 129 | 144 | <i>CCNDBP1</i> | 0.0031377 | 932 |
| 145 | <i>TMEM125</i> | 0.0013235 | 311 | 145 | <i>LGALS3</i> | 0.0031384 | 61 |
| 146 | <i>FAM115A</i> | 0.0013243 | 843 | 146 | <i>OPALIN</i> | 0.0031436 | NA |
| 147 | <i>C1orf210</i> | 0.0013245 | 95 | 147 | <i>ZNF281</i> | 0.0031658 | NA |
| 148 | <i>INPP5K</i> | 0.0013301 | 625 | 148 | <i>TRAPPC4</i> | 0.0031895 | 1059 |
| 149 | <i>RASGRP3</i> | 0.0013602 | 753 | 149 | <i>METTL25</i> | 0.0032413 | 986 |
| 150 | <i>MYF6</i> | 0.0013753 | 649 | 150 | <i>SPNS3</i> | 0.0032844 | 842 |
| 151 | <i>ARHGAP28</i> | 0.0013939 | 608 | 151 | <i>NYAP2</i> | 0.0032931 | 1106 |
| 152 | <i>HMGCS2</i> | 0.0014041 | 884 | 152 | <i>NUAK2</i> | 0.0033028 | 465 |
| 153 | <i>PRKCB</i> | 0.0014105 | 832 | 153 | <i>PDGFRA</i> | 0.0033385 | NA |
| 154 | <i>FAM21A</i> | 0.001421 | 752 | 154 | <i>SNRPN</i> | 0.0033399 | NA |
| 155 | <i>CMPK1</i> | 0.0014284 | 647 | 155 | <i>ZNF222</i> | 0.0033739 | 281 |
| 156 | <i>FOLR1</i> | 0.0014569 | 578 | 156 | <i>STRADB</i> | 0.0033967 | 589 |
| 157 | <i>NEXN</i> | 0.0014595 | 861 | 157 | <i>UMOD</i> | 0.0034022 | 303 |
| 158 | <i>GOLGA6L4</i> | 0.0014705 | NA | 158 | <i>PTCHD3</i> | 0.0034373 | 477 |
| 159 | <i>ZNF581</i> | 0.0014938 | 944 | 159 | <i>TMUB2</i> | 0.003494 | 442 |
| 160 | <i>VPS35</i> | 0.0014987 | 18 | 160 | <i>IL16</i> | 0.0035003 | 499 |
| 161 | <i>EOGT</i> | 0.0015046 | 994 | 161 | <i>MED10</i> | 0.0035021 | NA |
| 162 | <i>IFNAR2</i> | 0.0015309 | 165 | 162 | <i>GAR1</i> | 0.003552 | NA |
| 163 | <i>KIF3A</i> | 0.0015369 | 569 | 163 | <i>DIO2</i> | 0.0035843 | NA |

| | | | | | | | |
|-----|----------------------------|-----------|-----|-----|----------------|-----------|------|
| 164 | <i>HSPA4</i> | 0.0015423 | 782 | 164 | <i>ZSCAN4</i> | 0.0035994 | NA |
| 165 | <i>ZSCAN32</i> | 0.0015434 | 968 | 165 | <i>IL37</i> | 0.0036038 | 140 |
| 166 | <i>RAB1F</i> | 0.0015451 | 6 | 166 | <i>HS3ST4</i> | 0.0036266 | NA |
| 167 | <i>ZNF213</i> | 0.0015527 | 859 | 167 | <i>ZFP57</i> | 0.0036438 | 613 |
| 168 | <i>PLEKHF2</i> | 0.0015698 | 81 | 168 | <i>IL18BP</i> | 0.0036476 | NA |
| 169 | <i>NEO1</i> | 0.0015777 | 303 | 169 | <i>FBXL13</i> | 0.0036556 | 421 |
| 170 | <i>CLCNKB</i> | 0.0015931 | 467 | 170 | <i>CRYL1</i> | 0.0036716 | NA |
| 171 | <i>SLC22A14</i> | 0.0015938 | 72 | 171 | <i>CRP</i> | 0.0036907 | 546 |
| 172 | <i>TNFK</i> | 0.00161 | 114 | 172 | <i>RIOK3</i> | 0.0037074 | 1046 |
| 173 | <i>CBLB</i> | 0.001617 | 749 | 173 | <i>CYP4X1</i> | 0.0037591 | 539 |
| 174 | <i>TCF7</i> | 0.001618 | 264 | 174 | <i>LHFPL5</i> | 0.0037925 | 866 |
| 175 | <i>EDA2R</i> | 0.0016261 | 597 | 175 | <i>GTF2A1</i> | 0.0038109 | 436 |
| 176 | <i>CDIP1</i> | 0.0016346 | 457 | 176 | <i>COL4A2</i> | 0.0038123 | NA |
| 177 | <i>C17orf75</i> | 0.0016456 | 598 | 177 | <i>TMEM44</i> | 0.0038627 | 1006 |
| 178 | <i>CGGBP1</i> | 0.0016528 | 339 | 178 | <i>KIF2A</i> | 0.0038824 | NA |
| 179 | <i>ZNF816- ZNF321P</i> | 0.0016606 | 473 | 179 | <i>KLHL30</i> | 0.0038847 | 376 |
| 180 | <i>KRTAP19-2</i> | 0.0016615 | 251 | 180 | <i>DDX60</i> | 0.0039144 | 726 |
| 181 | <i>ZNF138</i> | 0.0016774 | 150 | 181 | <i>NSUN5</i> | 0.00392 | 958 |
| 182 | <i>C1orf100</i> | 0.0016796 | 911 | 182 | <i>RRP15</i> | 0.0039662 | 771 |
| 183 | <i>AKT1SI</i> | 0.0016865 | 869 | 183 | <i>PLAA</i> | 0.0039845 | NA |
| 184 | <i>AOX1</i> | 0.0016992 | 401 | 184 | <i>ADNP</i> | 0.0040179 | 277 |
| 185 | <i>IMMT</i> | 0.0017015 | 651 | 185 | <i>ZNF185</i> | 0.0040428 | NA |
| 186 | <i>GCKR</i> | 0.0017166 | 83 | 186 | <i>TLX1NB</i> | 0.0040541 | NA |
| 187 | <i>SMARCE1</i> | 0.0017288 | 724 | 187 | <i>CRMP1</i> | 0.0040697 | 574 |
| 188 | <i>GRSF1</i> | 0.0017454 | 1 | 188 | <i>ARIH2</i> | 0.0041146 | 832 |
| 189 | <i>DISC1</i> | 0.0017471 | 653 | 189 | <i>HLA-DRA</i> | 0.0041327 | 190 |
| 190 | <i>SIX6</i> | 0.0017509 | 336 | 190 | <i>VWA9</i> | 0.0041479 | 62 |
| 191 | <i>LRRC20</i> | 0.0017537 | 361 | 191 | <i>SPANXN3</i> | 0.0041757 | 269 |
| 192 | <i>DLEC1</i> | 0.0017902 | 945 | 192 | <i>SEL1L3</i> | 0.0041857 | NA |
| 193 | <i>EPB42</i> | 0.0017968 | 773 | 193 | <i>KCNH5</i> | 0.0041906 | 935 |
| 194 | <i>FH</i> | 0.0018158 | 558 | 194 | <i>KCND3</i> | 0.0041989 | NA |
| 195 | <i>NMNAT2</i> | 0.0018301 | 858 | 195 | <i>CASK</i> | 0.0042023 | NA |
| 196 | <i>ODF3</i> | 0.0018421 | 184 | 196 | <i>LAMA1</i> | 0.0042223 | 991 |
| 197 | <i>LONP2</i> | 0.0018656 | 735 | 197 | <i>FAM169A</i> | 0.004225 | 535 |
| 198 | <i>ZNF737</i> | 0.001902 | 64 | 198 | <i>COMMD6</i> | 0.0042642 | 559 |
| 199 | <i>UBL3</i> | 0.0019083 | 75 | 199 | <i>HOMEZ</i> | 0.0042767 | 819 |
| 200 | <i>ACY1</i> | 0.00191 | 426 | 200 | <i>LITD1</i> | 0.0042934 | 582 |
| 201 | <i>C9orf172</i> | 0.0019217 | 291 | 201 | <i>CTH</i> | 0.0043284 | 678 |
| 202 | <i>C8orf31</i> | 0.0019223 | 677 | 202 | <i>PRTFDC1</i> | 0.0043334 | 208 |
| 203 | <i>C2orf91</i> | 0.0019254 | 951 | 203 | <i>SAP30L</i> | 0.0043504 | NA |
| 204 | <i>TMED2</i> | 0.0019311 | 579 | 204 | <i>HOXC6</i> | 0.0043802 | 1061 |
| 205 | <i>ZNF221</i> | 0.0019446 | 560 | 205 | <i>NDFIP2</i> | 0.0043896 | NA |

| | | | | | | | |
|-----|-----------------|-----------|------|-----|-----------------|-----------|------|
| 206 | <i>CRISP3</i> | 0.0019457 | 839 | 206 | <i>FAM171B</i> | 0.0044085 | 352 |
| 207 | <i>SLC9A3R2</i> | 0.0019483 | 589 | 207 | <i>KLF9</i> | 0.0044102 | NA |
| 208 | <i>EPAS1</i> | 0.0019867 | 874 | 208 | <i>AAED1</i> | 0.0044837 | 475 |
| 209 | <i>ASB8</i> | 0.0019976 | 1023 | 209 | <i>PRPF40B</i> | 0.0045261 | NA |
| 210 | <i>C16orf58</i> | 0.0020199 | 850 | 210 | <i>YTHDC2</i> | 0.0045354 | 656 |
| 211 | <i>RASGEF1A</i> | 0.0020238 | 107 | 211 | <i>MLH3</i> | 0.0045743 | 67 |
| 212 | <i>GABRG2</i> | 0.002028 | 136 | 212 | <i>ZNF418</i> | 0.004583 | 803 |
| 213 | <i>CD84</i> | 0.0020282 | 316 | 213 | <i>HOXC10</i> | 0.0045871 | 937 |
| 214 | <i>ZCWPW1</i> | 0.0020426 | 463 | 214 | <i>IFNA5</i> | 0.0046389 | 518 |
| 215 | <i>MUC4</i> | 0.0020455 | 419 | 215 | <i>TMEM199</i> | 0.0046906 | 872 |
| 216 | <i>ZNF251</i> | 0.0020475 | 309 | 216 | <i>AFAP1</i> | 0.0047048 | 981 |
| 217 | <i>WDR12</i> | 0.0020612 | 1105 | 217 | <i>PRMT3</i> | 0.0047399 | NA |
| 218 | <i>ACSM2B</i> | 0.0020689 | 121 | 218 | <i>SEC63</i> | 0.0047423 | 1105 |
| 219 | <i>KHDC1L</i> | 0.0020782 | 626 | 219 | <i>UBE2L6</i> | 0.004743 | NA |
| 220 | <i>ZNF708</i> | 0.0021013 | 84 | 220 | <i>MSS51</i> | 0.0047529 | NA |
| 221 | <i>STAC2</i> | 0.0021034 | 465 | 221 | <i>C12orf43</i> | 0.0047941 | 259 |
| 222 | <i>NDUFS7</i> | 0.0021065 | 26 | 222 | <i>ZNF765</i> | 0.0048209 | NA |
| 223 | <i>RNF151</i> | 0.0021307 | 930 | 223 | <i>EMB</i> | 0.0048342 | NA |
| 224 | <i>FCHO2</i> | 0.0021448 | 772 | 224 | <i>ARL8A</i> | 0.0048361 | 1095 |
| 225 | <i>ZNF845</i> | 0.0021455 | 131 | 225 | <i>GPS1</i> | 0.0048458 | 895 |
| 226 | <i>C2CD4A</i> | 0.0021531 | 1090 | 226 | <i>OR2Z1</i> | 0.0048597 | NA |
| 227 | <i>MRPS31</i> | 0.0021574 | 35 | 227 | <i>PIP5KL1</i> | 0.0048975 | 948 |
| 228 | <i>AIF1L</i> | 0.002158 | 221 | 228 | <i>DLGAP5</i> | 0.0049112 | 510 |
| 229 | <i>OIP5</i> | 0.0021787 | 1033 | 229 | <i>PSPH</i> | 0.004946 | 823 |
| 230 | <i>BEST3</i> | 0.00219 | 85 | 230 | <i>DCSTAMP</i> | 0.0049492 | 893 |
| 231 | <i>FBXW11</i> | 0.0021908 | 929 | 231 | <i>CAP2</i> | 0.004957 | NA |
| 232 | <i>PDXDC1</i> | 0.0022004 | 428 | 232 | <i>METRNL</i> | 0.0049607 | NA |
| 233 | <i>DCAF17</i> | 0.0022103 | 760 | 233 | <i>PRRC2A</i> | 0.004971 | NA |
| 234 | <i>SREBF2</i> | 0.002229 | 703 | 234 | <i>RAB31</i> | 0.0049845 | 717 |
| 235 | <i>NDUFA1</i> | 0.0022313 | 9 | 235 | <i>KLRD1</i> | 0.0050526 | 299 |
| 236 | <i>SERINC5</i> | 0.0022364 | 528 | 236 | <i>ACER3</i> | 0.0051022 | NA |
| 237 | <i>ARHGEF15</i> | 0.0022568 | 928 | 237 | <i>SLFN1L</i> | 0.0051044 | 694 |
| 238 | <i>SYN1</i> | 0.0022646 | 450 | 238 | <i>PEA15</i> | 0.0051113 | NA |
| 239 | <i>RAB4A</i> | 0.0022806 | 519 | 239 | <i>SIRPB2</i> | 0.0051561 | 1073 |
| 240 | <i>PIK3CB</i> | 0.0022922 | 194 | 240 | <i>EMC7</i> | 0.0052078 | 1083 |
| 241 | <i>SMIM18</i> | 0.0023031 | 825 | 241 | <i>OR11G2</i> | 0.0052166 | NA |
| 242 | <i>KLHL6</i> | 0.0023085 | 657 | 242 | <i>OR2W1</i> | 0.0052199 | NA |
| 243 | <i>STATH</i> | 0.0023086 | 853 | 243 | <i>USP17L8</i> | 0.0052534 | NA |
| 244 | <i>ROCK2</i> | 0.0023144 | 710 | 244 | <i>VASP</i> | 0.0052595 | 565 |
| 245 | <i>HMOX2</i> | 0.0023163 | 793 | 245 | <i>FRMD7</i> | 0.005295 | 761 |
| 246 | <i>SLC22A13</i> | 0.002317 | 955 | 246 | <i>NUDT7</i> | 0.0053112 | 541 |
| 247 | <i>PKDIL3</i> | 0.0023273 | NA | 247 | <i>SLC17A1</i> | 0.0053629 | 201 |
| 248 | <i>RGS9BP</i> | 0.0023604 | 1063 | 248 | <i>WBSCR27</i> | 0.0054146 | 706 |

| | | | | | | | |
|-----|------------------|-----------|-----|-----|-----------------|-----------|------|
| 249 | <i>PDSS1</i> | 0.0023707 | 15 | 249 | <i>ASCC2</i> | 0.0054254 | 874 |
| 250 | <i>PF4</i> | 0.0023778 | 265 | 250 | <i>RND3</i> | 0.0054663 | 193 |
| 251 | <i>KRTAP3-2</i> | 0.0023778 | 617 | 251 | <i>DUSP7</i> | 0.0054959 | 661 |
| 252 | <i>SPATA19</i> | 0.0023844 | 738 | 252 | <i>SOX9</i> | 0.005518 | 665 |
| 253 | <i>C2orf54</i> | 0.0023845 | 671 | 253 | <i>C19orf60</i> | 0.0055242 | NA |
| 254 | <i>GALNTL6</i> | 0.0023942 | 371 | 254 | <i>COLEC12</i> | 0.0055697 | 580 |
| 255 | <i>FHL2</i> | 0.0024123 | 185 | 255 | <i>PCDHB10</i> | 0.0056191 | 283 |
| 256 | <i>TMEM192</i> | 0.002448 | 721 | 256 | <i>HNRNPA3</i> | 0.0056213 | 286 |
| 257 | <i>C12orf39</i> | 0.0024641 | 691 | 257 | <i>ADAM28</i> | 0.0056286 | 1043 |
| 258 | <i>NPAS3</i> | 0.0024678 | 917 | 258 | <i>DPYSL3</i> | 0.005673 | 294 |
| 259 | <i>DBC1</i> | 0.0024735 | NA | 259 | <i>MOGAT3</i> | 0.0057247 | 379 |
| 260 | <i>COLGALT2</i> | 0.0025106 | 891 | 260 | <i>POSTN</i> | 0.0057764 | NA |
| 261 | <i>GREB1</i> | 0.0025154 | 341 | 261 | <i>NPFFR2</i> | 0.0058281 | 700 |
| 262 | <i>ABR</i> | 0.0025159 | 304 | 262 | <i>MPZ</i> | 0.0058305 | NA |
| 263 | <i>SH3GL2</i> | 0.0025366 | 812 | 263 | <i>R3HCC1</i> | 0.0058645 | 786 |
| 264 | <i>FEM1C</i> | 0.0025421 | 823 | 264 | <i>FOXR2</i> | 0.0058798 | 361 |
| 265 | <i>NPNT</i> | 0.0025525 | 176 | 265 | <i>C9orf64</i> | 0.0058839 | NA |
| 266 | <i>AQP11</i> | 0.0025566 | 705 | 266 | <i>KIF21B</i> | 0.0059831 | 467 |
| 267 | <i>MAB21L3</i> | 0.0025665 | 638 | 267 | <i>ALPP</i> | 0.0060348 | 78 |
| 268 | <i>TSKS</i> | 0.0025686 | 461 | 268 | <i>KCNN4</i> | 0.0060555 | 155 |
| 269 | <i>ZNF670</i> | 0.0025829 | 838 | 269 | <i>ALMS1</i> | 0.0060653 | 767 |
| 270 | <i>MMADHC</i> | 0.0026312 | 160 | 270 | <i>GCNT2</i> | 0.0061346 | 10 |
| 271 | <i>PREX2</i> | 0.0026334 | 146 | 271 | <i>MYB</i> | 0.0061898 | 297 |
| 272 | <i>ATP1B3</i> | 0.0026456 | 261 | 272 | <i>PPP2R5A</i> | 0.0061993 | NA |
| 273 | <i>NPPB</i> | 0.0026553 | 186 | 273 | <i>RBM15</i> | 0.0062043 | 1102 |
| 274 | <i>SLCO4C1</i> | 0.002669 | 236 | 274 | <i>MXD3</i> | 0.0062414 | 1098 |
| 275 | <i>OR5K1</i> | 0.0026714 | NA | 275 | <i>WASF3</i> | 0.0062543 | 884 |
| 276 | <i>HOXB5</i> | 0.0026742 | 273 | 276 | <i>MRGPRD</i> | 0.0062744 | 1007 |
| 277 | <i>SSTR2</i> | 0.002678 | 477 | 277 | <i>CLU</i> | 0.0062931 | 862 |
| 278 | <i>C1orf226</i> | 0.002679 | 926 | 278 | <i>PMP22</i> | 0.0063398 | 615 |
| 279 | <i>DEFB116</i> | 0.0026868 | 112 | 279 | <i>FAM161A</i> | 0.0063448 | 914 |
| 280 | <i>GPATCH2L</i> | 0.002704 | 622 | 280 | <i>C1orf105</i> | 0.0063723 | NA |
| 281 | <i>PRKCDBP</i> | 0.002716 | 711 | 281 | <i>HKDC1</i> | 0.0063964 | 313 |
| 282 | <i>LOC200726</i> | 0.0027232 | NA | 282 | <i>TMED8</i> | 0.0064105 | 164 |
| 283 | <i>PHLDB2</i> | 0.0027271 | 501 | 283 | <i>DBNDD1</i> | 0.0064207 | NA |
| 284 | <i>FAM84A</i> | 0.0027521 | 972 | 284 | <i>WNT10B</i> | 0.0064308 | NA |
| 285 | <i>NDUFS2</i> | 0.0027743 | 25 | 285 | <i>LTBR</i> | 0.0064481 | 68 |
| 286 | <i>C15orf62</i> | 0.0027809 | 79 | 286 | <i>PPP1R15B</i> | 0.0064511 | 558 |
| 287 | <i>EZH1</i> | 0.0027815 | 37 | 287 | <i>HERC3</i> | 0.0064997 | 203 |
| 288 | <i>MTUS2</i> | 0.002801 | 688 | 288 | <i>CDC14B</i> | 0.0065583 | 199 |
| 289 | <i>ZNF234</i> | 0.0028042 | 98 | 289 | <i>NCKAP5L</i> | 0.0065839 | 278 |
| 290 | <i>COQ4</i> | 0.0028145 | 32 | 290 | <i>PRR4</i> | 0.006603 | 336 |
| 291 | <i>IRS2</i> | 0.0028219 | 45 | 291 | <i>FPR3</i> | 0.0066547 | NA |

| | | | | | | | |
|-----|-----------------|-----------|------|-----|------------------|-----------|------|
| 292 | <i>ZNF207</i> | 0.0028282 | 989 | 292 | <i>GOPC</i> | 0.0066818 | 978 |
| 293 | <i>NDUFAF7</i> | 0.002835 | 10 | 293 | <i>CCL28</i> | 0.0066869 | 183 |
| 294 | <i>TRMT10B</i> | 0.0028398 | 399 | 294 | <i>STK39</i> | 0.0067063 | 848 |
| 295 | <i>MFAP3</i> | 0.0028488 | 209 | 295 | <i>COL1A2</i> | 0.0067283 | NA |
| 296 | <i>NR4A1</i> | 0.0028868 | 1031 | 296 | <i>SCAMP3</i> | 0.0067579 | 542 |
| 297 | <i>TBX5</i> | 0.0029172 | 750 | 297 | <i>EMC1</i> | 0.0068096 | 916 |
| 298 | <i>CLVS2</i> | 0.0029204 | 324 | 298 | <i>OR52I2</i> | 0.0068585 | NA |
| 299 | <i>LPHN2</i> | 0.0029304 | 715 | 299 | <i>ADAM11</i> | 0.0069057 | 889 |
| 300 | <i>ARHGDIG</i> | 0.0029784 | 202 | 300 | <i>FUT11</i> | 0.0069128 | 820 |
| 301 | <i>COX16</i> | 0.0029822 | 334 | 301 | <i>C18orf8</i> | 0.0069645 | 1144 |
| 302 | <i>NAGPA</i> | 0.0029824 | 1037 | 302 | <i>C8orf44</i> | 0.0069696 | 409 |
| 303 | <i>STK17A</i> | 0.003034 | 380 | 303 | <i>OR8H1</i> | 0.0070161 | NA |
| 304 | <i>MRPS16</i> | 0.0030556 | 59 | 304 | <i>ZNF664</i> | 0.007064 | NA |
| 305 | <i>PLCH1</i> | 0.0030839 | 485 | 305 | <i>CRIP3</i> | 0.0070677 | 306 |
| 306 | <i>TDP1</i> | 0.0030858 | 1127 | 306 | <i>COL4A5</i> | 0.0070956 | 754 |
| 307 | <i>ARHGAP8</i> | 0.003088 | 658 | 307 | <i>SORCS3</i> | 0.0071194 | 137 |
| 308 | <i>KRT38</i> | 0.0030894 | 494 | 308 | <i>PIGK</i> | 0.0071331 | 606 |
| 309 | <i>MACROD2</i> | 0.0031376 | 829 | 309 | <i>NXPH4</i> | 0.0071417 | 75 |
| 310 | <i>SNRPB2</i> | 0.0031411 | 787 | 310 | <i>SHKBP1</i> | 0.0072508 | 684 |
| 311 | <i>ZNF709</i> | 0.0031455 | 269 | 311 | <i>EXD2</i> | 0.0072723 | 909 |
| 312 | <i>PRKG2</i> | 0.0031631 | 789 | 312 | <i>CHAT</i> | 0.0072742 | 147 |
| 313 | <i>ILIRAPL1</i> | 0.003167 | 223 | 313 | <i>PCK2</i> | 0.0073423 | 44 |
| 314 | <i>MIS18BP1</i> | 0.0031888 | 809 | 314 | <i>ROSI</i> | 0.0074127 | 749 |
| 315 | <i>ASTN2</i> | 0.0031956 | 674 | 315 | <i>MLLT3</i> | 0.0074291 | 405 |
| 316 | <i>SBSPPON</i> | 0.0031999 | 672 | 316 | <i>KCNK5</i> | 0.0074807 | 899 |
| 317 | <i>ACAD10</i> | 0.0032055 | 739 | 317 | <i>TOX2</i> | 0.0075543 | 892 |
| 318 | <i>ENPP2</i> | 0.0032401 | 292 | 318 | <i>TRABD2A</i> | 0.0075839 | 138 |
| 319 | <i>POU3F1</i> | 0.0032425 | 263 | 319 | <i>ATOH1</i> | 0.0075982 | 142 |
| 320 | <i>STK16</i> | 0.0032453 | 764 | 320 | <i>DCAF8L1</i> | 0.0076477 | 323 |
| 321 | <i>NDUFS1</i> | 0.0032757 | 7 | 321 | <i>CDRT15</i> | 0.0076532 | 1128 |
| 322 | <i>DNAJC16</i> | 0.0032929 | 1007 | 322 | <i>ECSIT</i> | 0.0076697 | NA |
| 323 | <i>LNPEP</i> | 0.0032934 | 472 | 323 | <i>NMUR1</i> | 0.0076862 | 545 |
| 324 | <i>PRR23C</i> | 0.0033085 | 189 | 324 | <i>TLR1</i> | 0.0076871 | 139 |
| 325 | <i>AGER</i> | 0.0033085 | 599 | 325 | <i>MRPS31</i> | 0.0077387 | 816 |
| 326 | <i>NUP160</i> | 0.0033138 | 1050 | 326 | <i>IRX1</i> | 0.0077903 | 961 |
| 327 | <i>RYR1</i> | 0.0033311 | 947 | 327 | <i>HIST1H2BG</i> | 0.0078419 | 602 |
| 328 | <i>CENPQ</i> | 0.0033328 | 636 | 328 | <i>GNA15</i> | 0.007945 | 907 |
| 329 | <i>ZNF322</i> | 0.0033447 | 813 | 329 | <i>ZNF154</i> | 0.0079813 | 660 |
| 330 | <i>HAUS7</i> | 0.0033503 | 247 | 330 | <i>TRIM77</i> | 0.0079966 | NA |
| 331 | <i>PION</i> | 0.0033537 | NA | 331 | <i>LSR</i> | 0.0079981 | 647 |
| 332 | <i>ITIH4</i> | 0.0033731 | 805 | 332 | <i>ITGB1BP2</i> | 0.0080206 | NA |
| 333 | <i>LCP2</i> | 0.0033959 | 729 | 333 | <i>TTC26</i> | 0.0080482 | 272 |
| 334 | <i>PIAS2</i> | 0.0033965 | 374 | 334 | <i>HDGF</i> | 0.0080998 | 810 |

| | | | | | | | |
|-----|----------------|-----------|------|-----|-------------------|-----------|------|
| 335 | <i>TAF12</i> | 0.0034128 | 918 | 335 | <i>CSF1R</i> | 0.0081514 | 561 |
| 336 | <i>TGOLN2</i> | 0.0034257 | 718 | 336 | <i>MAP1B</i> | 0.0081562 | 506 |
| 337 | <i>OCA2</i> | 0.0034348 | 138 | 337 | <i>KIAA0907</i> | 0.0081676 | 878 |
| 338 | <i>ULK2</i> | 0.0034457 | 697 | 338 | <i>KLHL33</i> | 0.008203 | 178 |
| 339 | <i>WNT2B</i> | 0.0034483 | 464 | 339 | <i>ZNF106</i> | 0.0082545 | 877 |
| 340 | <i>GPR116</i> | 0.0034634 | 799 | 340 | <i>MSX1</i> | 0.0082643 | 861 |
| 341 | <i>KCNH5</i> | 0.0034798 | 896 | 341 | <i>MAP1LC3A</i> | 0.008266 | 549 |
| 342 | <i>CCDC147</i> | 0.0035001 | 141 | 342 | <i>KCNE2</i> | 0.0083061 | NA |
| 343 | <i>AXIN1</i> | 0.0035075 | 615 | 343 | <i>APOE</i> | 0.0083215 | 857 |
| 344 | <i>CRLF3</i> | 0.0035387 | 479 | 344 | <i>SIGLEC11</i> | 0.0083846 | NA |
| 345 | <i>CKM</i> | 0.0035433 | 1001 | 345 | <i>BRINP2</i> | 0.0083931 | 104 |
| 346 | <i>CAAP1</i> | 0.0035473 | 830 | 346 | <i>ATXN7L2</i> | 0.0084092 | 184 |
| 347 | <i>C5orf34</i> | 0.0035518 | 732 | 347 | <i>ZNF513</i> | 0.0084608 | 922 |
| 348 | <i>UTS2B</i> | 0.0035658 | 231 | 348 | <i>ARHGAP29</i> | 0.0085124 | 501 |
| 349 | <i>PIGX</i> | 0.0035883 | 855 | 349 | <i>HLX</i> | 0.0085288 | 742 |
| 350 | <i>HSPB9</i> | 0.0035898 | 893 | 350 | <i>NETO1</i> | 0.008552 | 38 |
| 351 | <i>CD300C</i> | 0.0036036 | 400 | 351 | <i>CYSLTR1</i> | 0.0086155 | 37 |
| 352 | <i>PLEKHO2</i> | 0.0036062 | 1113 | 352 | <i>CDON</i> | 0.0086858 | 603 |
| 353 | <i>NDUFAF4</i> | 0.0036231 | 20 | 353 | <i>NCBP2</i> | 0.0087151 | NA |
| 354 | <i>ING2</i> | 0.0036535 | 80 | 354 | <i>CDKN2AIPNL</i> | 0.0087186 | 144 |
| 355 | <i>USP38</i> | 0.0036554 | 452 | 355 | <i>DCUNID5</i> | 0.0087443 | 102 |
| 356 | <i>FAM107A</i> | 0.0036796 | 713 | 356 | <i>ZFP14</i> | 0.0087702 | 186 |
| 357 | <i>PACRGL</i> | 0.0037057 | 281 | 357 | <i>GBF1</i> | 0.0087913 | 649 |
| 358 | <i>UGT2B7</i> | 0.0037072 | 164 | 358 | <i>MMP16</i> | 0.0088089 | 929 |
| 359 | <i>APOA2</i> | 0.0037192 | 149 | 359 | <i>TMEM205</i> | 0.0088217 | 597 |
| 360 | <i>FKBP1B</i> | 0.0037213 | 104 | 360 | <i>DNAJC2</i> | 0.0088265 | 1021 |
| 361 | <i>MPG</i> | 0.0037331 | 806 | 361 | <i>TTLL4</i> | 0.0088733 | 633 |
| 362 | <i>BCAP31</i> | 0.003741 | 888 | 362 | <i>TREM1</i> | 0.0088914 | NA |
| 363 | <i>SALL4</i> | 0.0037704 | 343 | 363 | <i>RNF167</i> | 0.0089248 | 967 |
| 364 | <i>PRX</i> | 0.0037715 | 587 | 364 | <i>DPCD</i> | 0.0089763 | 502 |
| 365 | <i>RNF183</i> | 0.0037965 | 895 | 365 | <i>C14orf105</i> | 0.008992 | 519 |
| 366 | <i>TTC4</i> | 0.0038243 | 411 | 366 | <i>SNAPC1</i> | 0.0090279 | NA |
| 367 | <i>EVA1A</i> | 0.0038491 | 564 | 367 | <i>SESNI</i> | 0.0090794 | 372 |
| 368 | <i>DDHD1</i> | 0.0038625 | 354 | 368 | <i>MFGE8</i> | 0.0091051 | 736 |
| 369 | <i>VCX3B</i> | 0.0038767 | 385 | 369 | <i>GPX4</i> | 0.009131 | 822 |
| 370 | <i>NGFRAP1</i> | 0.0039035 | 390 | 370 | <i>ZNF853</i> | 0.0091589 | NA |
| 371 | <i>MTMR1</i> | 0.0039142 | 875 | 371 | <i>FOXD4L1</i> | 0.0091825 | 1069 |
| 372 | <i>APOBEC4</i> | 0.0039156 | 226 | 372 | <i>FAM122B</i> | 0.0091949 | 257 |
| 373 | <i>SORT1</i> | 0.0039477 | 211 | 373 | <i>TTC13</i> | 0.009261 | 928 |
| 374 | <i>NT5C</i> | 0.0039567 | 938 | 374 | <i>RNF5</i> | 0.009267 | 237 |
| 375 | <i>TLL2</i> | 0.0039649 | 1044 | 375 | <i>KCNA4</i> | 0.009279 | 480 |
| 376 | <i>KLHDC8A</i> | 0.003966 | 1009 | 376 | <i>CCL2</i> | 0.0092911 | NA |
| 377 | <i>HOXC10</i> | 0.003966 | 842 | 377 | <i>VASN</i> | 0.0093635 | 288 |

| | | | | | | | |
|-----|----------------|-----------|------|-----|---------------------|-----------|------|
| 378 | <i>RFC1</i> | 0.003976 | 1002 | 378 | <i>KCNJ12</i> | 0.0093665 | 444 |
| 379 | <i>ATG3</i> | 0.0039921 | 633 | 379 | <i>SUN5</i> | 0.0093886 | 941 |
| 380 | <i>FGFBP1</i> | 0.003996 | 484 | 380 | <i>GRM4</i> | 0.0094401 | NA |
| 381 | <i>DNAJC15</i> | 0.0039981 | 682 | 381 | <i>RNF7</i> | 0.0094544 | 173 |
| 382 | <i>PRH2</i> | 0.0040372 | 90 | 382 | <i>NDNL2</i> | 0.0094666 | NA |
| 383 | <i>BIRC6</i> | 0.0040608 | 844 | 383 | <i>ANGPTL5</i> | 0.0095214 | 837 |
| 384 | <i>TMEM261</i> | 0.0040716 | 28 | 384 | <i>LOC100862671</i> | 0.0095824 | NA |
| 385 | <i>SYNGR4</i> | 0.0040735 | 694 | 385 | <i>PON2</i> | 0.0095947 | 1087 |
| 386 | <i>ITCH</i> | 0.0040858 | 444 | 386 | <i>JMJD4</i> | 0.0096977 | 271 |
| 387 | <i>ENTPD6</i> | 0.0041186 | 942 | 387 | <i>SIGLEC10</i> | 0.0097379 | 266 |
| 388 | <i>XAGE2</i> | 0.0041212 | 606 | 388 | <i>EMR3</i> | 0.0097492 | 162 |
| 389 | <i>CALD1</i> | 0.0041398 | 880 | 389 | <i>SERBP1</i> | 0.0098007 | 357 |
| 390 | <i>PAAF1</i> | 0.0041633 | 499 | 390 | <i>C19orf82</i> | 0.0098474 | 989 |
| 391 | <i>RIN2</i> | 0.0041764 | 948 | 391 | <i>NUP62</i> | 0.0098522 | NA |
| 392 | <i>NDUFB4</i> | 0.0041801 | 4 | 392 | <i>REG3G</i> | 0.0098531 | NA |
| 393 | <i>JMJD8</i> | 0.0041851 | 686 | 393 | <i>COX6A1</i> | 0.0099037 | 637 |
| 394 | <i>COL17A1</i> | 0.0041888 | 245 | 394 | <i>CD6</i> | 0.0099404 | NA |
| 395 | <i>SENP8</i> | 0.0041967 | 233 | 395 | <i>MAGEC1</i> | 0.0099552 | 563 |
| 396 | <i>IRAK4</i> | 0.0042147 | 353 | 396 | <i>CCDC30</i> | 0.0099711 | 624 |
| 397 | <i>TMEM45A</i> | 0.004222 | 53 | 397 | <i>SLC39A9</i> | 0.010015 | 96 |
| 398 | <i>ZBTB14</i> | 0.0042247 | 287 | 398 | <i>STEAP2</i> | 0.010021 | 799 |
| 399 | <i>OR6N1</i> | 0.0042261 | NA | 399 | <i>MMP25</i> | 0.010058 | 775 |
| 400 | <i>STXBP6</i> | 0.0042334 | 794 | 400 | <i>STXBP1</i> | 0.010065 | NA |
| 401 | <i>DMTN</i> | 0.0042765 | 900 | 401 | <i>FLT3LG</i> | 0.01009 | 370 |
| 402 | <i>LEKR1</i> | 0.0043141 | NA | 402 | <i>SPDL1</i> | 0.01011 | 591 |
| 403 | <i>ALS2</i> | 0.0043245 | 491 | 403 | <i>STAT5B</i> | 0.010127 | NA |
| 404 | <i>NOSTRIN</i> | 0.0043415 | 377 | 404 | <i>KRTAP10-5</i> | 0.010134 | NA |
| 405 | <i>ZNF19</i> | 0.0043679 | 255 | 405 | <i>MIER3</i> | 0.010146 | 626 |
| 406 | <i>CBLC</i> | 0.004373 | 1012 | 406 | <i>LOC100130705</i> | 0.010161 | NA |
| 407 | <i>BACE2</i> | 0.0043764 | 119 | 407 | <i>DIAPH1</i> | 0.010196 | 592 |
| 408 | <i>TUBA1A</i> | 0.00438 | 588 | 408 | <i>TMEM140</i> | 0.010228 | 673 |
| 409 | <i>PUS7L</i> | 0.0043899 | 533 | 409 | <i>C18orf63</i> | 0.010264 | 757 |
| 410 | <i>MBD4</i> | 0.0043907 | 854 | 410 | <i>TFF2</i> | 0.010278 | 479 |
| 411 | <i>INSR</i> | 0.0043944 | 162 | 411 | <i>FGD4</i> | 0.01031 | 1117 |
| 412 | <i>DPY19L2</i> | 0.0044088 | 849 | 412 | <i>GSTZ1</i> | 0.010316 | 923 |
| 413 | <i>PDZD9</i> | 0.0044212 | 117 | 413 | <i>DPY19L1</i> | 0.010365 | 234 |
| 414 | <i>MTMR9</i> | 0.0044218 | 266 | 414 | <i>MSL1</i> | 0.010367 | 181 |
| 415 | <i>SLC33A1</i> | 0.0044293 | 1080 | 415 | <i>GOLIM4</i> | 0.0104 | 368 |
| 416 | <i>CCDC137</i> | 0.0044317 | 1109 | 416 | <i>CAPN9</i> | 0.010419 | 263 |
| 417 | <i>ZNF683</i> | 0.0044456 | 244 | 417 | <i>UBL7</i> | 0.01047 | NA |
| 418 | <i>CRB3</i> | 0.0044793 | 912 | 418 | <i>SMUG1</i> | 0.010522 | 710 |
| 419 | <i>G3BP2</i> | 0.0044834 | 441 | 419 | <i>SOX5</i> | 0.010526 | 852 |
| 420 | <i>SAFB</i> | 0.0044837 | 504 | 420 | <i>MKKS</i> | 0.010577 | 666 |

| | | | | | | | |
|-----|-----------------|-----------|------|-----|------------------|----------|------|
| 421 | <i>TFDP2</i> | 0.0045068 | 395 | 421 | <i>TMEM27</i> | 0.010728 | 77 |
| 422 | <i>PIK3R4</i> | 0.0045136 | 76 | 422 | <i>IP6K1</i> | 0.01077 | NA |
| 423 | <i>PPP1R9A</i> | 0.0045138 | 865 | 423 | <i>ZSWIM7</i> | 0.010779 | NA |
| 424 | <i>CHDC2</i> | 0.0045148 | 868 | 424 | <i>HORMAD2</i> | 0.010783 | 880 |
| 425 | <i>SPC25</i> | 0.0045237 | 601 | 425 | <i>SLC7A3</i> | 0.01083 | 1048 |
| 426 | <i>GAGE10</i> | 0.0045299 | 1095 | 426 | <i>MFHAS1</i> | 0.010882 | 654 |
| 427 | <i>SIKE1</i> | 0.0045307 | 227 | 427 | <i>VAMP8</i> | 0.010886 | 608 |
| 428 | <i>TMIGD1</i> | 0.0045352 | 685 | 428 | <i>LEMD2</i> | 0.010902 | 1002 |
| 429 | <i>LAMP5</i> | 0.0045381 | 239 | 429 | <i>PTX3</i> | 0.010933 | 124 |
| 430 | <i>SSMEM1</i> | 0.0045437 | 451 | 430 | <i>LRCH1</i> | 0.010977 | NA |
| 431 | <i>GABRB1</i> | 0.0045765 | 543 | 431 | <i>MATN3</i> | 0.010984 | NA |
| 432 | <i>C21orf2</i> | 0.0045922 | 61 | 432 | <i>SUSD3</i> | 0.010985 | 801 |
| 433 | <i>GTPBP1</i> | 0.0045922 | 327 | 433 | <i>MOGAT1</i> | 0.01099 | 72 |
| 434 | <i>CXorf64</i> | 0.0046248 | 116 | 434 | <i>ROPNIL</i> | 0.011036 | NA |
| 435 | <i>BZW2</i> | 0.0046482 | 347 | 435 | <i>ANXA7</i> | 0.011088 | 702 |
| 436 | <i>B3GNTL1</i> | 0.004651 | 872 | 436 | <i>PRKCZ</i> | 0.011139 | 1058 |
| 437 | <i>ZNF879</i> | 0.004661 | 302 | 437 | <i>CDR1</i> | 0.011191 | 377 |
| 438 | <i>BRC1</i> | 0.0046659 | 1106 | 438 | <i>POLR2H</i> | 0.011242 | 1080 |
| 439 | <i>RAD9B</i> | 0.0046825 | 96 | 439 | <i>IGF2BP1</i> | 0.011246 | 453 |
| 440 | <i>ULBP3</i> | 0.0046827 | 610 | 440 | <i>TMEM40</i> | 0.011259 | 514 |
| 441 | <i>MCAT</i> | 0.0046833 | 1068 | 441 | <i>TM7SF3</i> | 0.011285 | 886 |
| 442 | <i>GPR174</i> | 0.0046869 | 623 | 442 | <i>LOC728819</i> | 0.011292 | NA |
| 443 | <i>SUMF2</i> | 0.0047258 | 416 | 443 | <i>GALK1</i> | 0.011294 | 537 |
| 444 | <i>C5orf28</i> | 0.0047266 | 387 | 444 | <i>ELMO3</i> | 0.011345 | 925 |
| 445 | <i>AAAS</i> | 0.0047307 | 596 | 445 | <i>ERI2</i> | 0.011371 | NA |
| 446 | <i>ACSL1</i> | 0.0047421 | 993 | 446 | <i>SIAH1</i> | 0.011448 | 57 |
| 447 | <i>PDZK1</i> | 0.0047513 | 785 | 447 | <i>B3GNT7</i> | 0.011457 | 334 |
| 448 | <i>CLEC4F</i> | 0.0047594 | 837 | 448 | <i>OR10X1</i> | 0.01147 | NA |
| 449 | <i>GPR157</i> | 0.0047785 | 346 | 449 | <i>SCLT1</i> | 0.011499 | NA |
| 450 | <i>PXDN</i> | 0.0047938 | 828 | 450 | <i>TUB</i> | 0.011537 | 737 |
| 451 | <i>RTBDN</i> | 0.0048002 | 506 | 451 | <i>TRPV4</i> | 0.011551 | 515 |
| 452 | <i>FBXW7</i> | 0.004812 | 1142 | 452 | <i>SLC16A8</i> | 0.01159 | 779 |
| 453 | <i>STAM</i> | 0.0048137 | 815 | 453 | <i>SEMA5B</i> | 0.011597 | 1060 |
| 454 | <i>XYLT1</i> | 0.004844 | 282 | 454 | <i>RFPL1</i> | 0.011602 | NA |
| 455 | <i>PHYKPL</i> | 0.004851 | 952 | 455 | <i>CCNK</i> | 0.011705 | NA |
| 456 | <i>SLC5A2</i> | 0.0048541 | 690 | 456 | <i>POU2AF1</i> | 0.011751 | NA |
| 457 | <i>PNMT</i> | 0.0048932 | 270 | 457 | <i>VCL</i> | 0.011756 | 917 |
| 458 | <i>C1orf177</i> | 0.0048937 | 770 | 458 | <i>ZNF883</i> | 0.011757 | NA |
| 459 | <i>VSIG8</i> | 0.004895 | 135 | 459 | <i>RPL27</i> | 0.011808 | 1141 |
| 460 | <i>USP10</i> | 0.0048965 | 990 | 460 | <i>CLPS</i> | 0.011811 | NA |
| 461 | <i>PTCHD4</i> | 0.0048972 | 577 | 461 | <i>LGALS13</i> | 0.011909 | 508 |
| 462 | <i>HYKK</i> | 0.0049236 | 495 | 462 | <i>INHBE</i> | 0.011911 | NA |
| 463 | <i>MYCL1</i> | 0.0049261 | NA | 463 | <i>SERINC1</i> | 0.011933 | 319 |

| | | | | | | | |
|-----|-----------------|-----------|-----|-----|-----------------|----------|------|
| 464 | <i>FKBP9</i> | 0.0049394 | 219 | 464 | <i>SIAH3</i> | 0.011962 | 679 |
| 465 | <i>GREB1L</i> | 0.004943 | 650 | 465 | <i>CLDN16</i> | 0.011967 | 172 |
| 466 | <i>PKP4</i> | 0.004949 | 210 | 466 | <i>PYGO2</i> | 0.012013 | 617 |
| 467 | <i>SENP6</i> | 0.0049526 | 714 | 467 | <i>LSG1</i> | 0.012065 | NA |
| 468 | <i>SLC22A6</i> | 0.0049818 | 824 | 468 | <i>SAPCD2</i> | 0.012089 | 335 |
| 469 | <i>PLEKHA8</i> | 0.0050007 | 89 | 469 | <i>ERG</i> | 0.012116 | 575 |
| 470 | <i>C11orf86</i> | 0.005002 | 797 | 470 | <i>CAND1</i> | 0.012123 | 1103 |
| 471 | <i>NIM1</i> | 0.0050156 | 424 | 471 | <i>MMP19</i> | 0.012168 | NA |
| 472 | <i>TMEM135</i> | 0.0050157 | 520 | 472 | <i>GM2A</i> | 0.012211 | NA |
| 473 | <i>SUMO1</i> | 0.0050158 | 458 | 473 | <i>CAPRN2</i> | 0.012271 | 76 |
| 474 | <i>MAFB</i> | 0.0050382 | 137 | 474 | <i>NLGN2</i> | 0.012322 | 698 |
| 475 | <i>RHBDL3</i> | 0.0050668 | 229 | 475 | <i>ADRA2A</i> | 0.012348 | NA |
| 476 | <i>MAGEA6</i> | 0.0050732 | 284 | 476 | <i>XPR1</i> | 0.012397 | 818 |
| 477 | <i>C19orf44</i> | 0.0050913 | 995 | 477 | <i>ALOX5AP</i> | 0.012431 | 869 |
| 478 | <i>PRR4</i> | 0.0051275 | 746 | 478 | <i>BAIAP2L1</i> | 0.012476 | 422 |
| 479 | <i>GRB2</i> | 0.005129 | 174 | 479 | <i>KLRG1</i> | 0.012527 | 494 |
| 480 | <i>APOL1</i> | 0.0051525 | 326 | 480 | <i>DEPDC7</i> | 0.012562 | 1092 |
| 481 | <i>COQ7</i> | 0.0051656 | 86 | 481 | <i>SPECCIL</i> | 0.012579 | NA |
| 482 | <i>COL6A5</i> | 0.0051727 | NA | 482 | <i>NFX1</i> | 0.012597 | 662 |
| 483 | <i>LIF</i> | 0.0051747 | 101 | 483 | <i>TMEM9</i> | 0.01263 | NA |
| 484 | <i>TMEM41B</i> | 0.0051782 | 836 | 484 | <i>MAN1C1</i> | 0.012687 | NA |
| 485 | <i>ALG3</i> | 0.0051967 | 235 | 485 | <i>HVCN1</i> | 0.012733 | NA |
| 486 | <i>BTG1</i> | 0.0051976 | 409 | 486 | <i>TGM7</i> | 0.012784 | 205 |
| 487 | <i>LEMD1</i> | 0.0052013 | 498 | 487 | <i>MCC</i> | 0.012834 | 355 |
| 488 | <i>TCAP</i> | 0.0052013 | 637 | 488 | <i>TECPR2</i> | 0.012836 | NA |
| 489 | <i>OR52B6</i> | 0.0052013 | NA | 489 | <i>CKMT1B</i> | 0.012868 | NA |
| 490 | <i>GGA1</i> | 0.0052096 | 412 | 490 | <i>ATP13A5</i> | 0.012876 | NA |
| 491 | <i>MTERF</i> | 0.0052153 | 54 | 491 | <i>ACCS</i> | 0.012911 | 214 |
| 492 | <i>G2E3</i> | 0.005216 | 762 | 492 | <i>GOT1</i> | 0.012939 | 338 |
| 493 | <i>SLC25A36</i> | 0.0052459 | 330 | 493 | <i>TMEM194B</i> | 0.013041 | 302 |
| 494 | <i>CLEC1A</i> | 0.0052478 | 645 | 494 | <i>SPON2</i> | 0.013065 | NA |
| 495 | <i>CACHD1</i> | 0.0052592 | 396 | 495 | <i>E2F6</i> | 0.013093 | NA |
| 496 | <i>USP34</i> | 0.005263 | 981 | 496 | <i>RFPL4B</i> | 0.013093 | 226 |
| 497 | <i>MORN4</i> | 0.0052642 | 207 | 497 | <i>PLN</i> | 0.0131 | 571 |
| 498 | <i>KCTD9</i> | 0.0052918 | 471 | 498 | <i>PTPN5</i> | 0.013129 | 415 |
| 499 | <i>IGSF6</i> | 0.0053054 | 580 | 499 | <i>CAPN12</i> | 0.013144 | 362 |
| 500 | <i>EML4</i> | 0.0053109 | 118 | 500 | <i>ACSS1</i> | 0.013195 | 245 |
| 501 | <i>PXK</i> | 0.0053334 | 487 | 501 | <i>DMPK</i> | 0.013206 | 790 |
| 502 | <i>WHSC1</i> | 0.0053626 | 652 | 502 | <i>PAEP</i> | 0.013249 | NA |
| 503 | <i>ASCL5</i> | 0.0053738 | 172 | 503 | <i>RNF14</i> | 0.013298 | 119 |
| 504 | <i>ANKS6</i> | 0.005388 | 905 | 504 | <i>GBX2</i> | 0.01332 | 1104 |
| 505 | <i>ARPP21</i> | 0.0053964 | 440 | 505 | <i>CSNK2B</i> | 0.013327 | 1133 |
| 506 | <i>USP26</i> | 0.0054067 | 286 | 506 | <i>SIGIRR</i> | 0.013334 | 639 |

| | | | | | | | |
|-----|-----------------|-----------|------|-----|------------------|----------|------|
| 507 | <i>TBCEL</i> | 0.0054164 | 115 | 507 | <i>DDT</i> | 0.013345 | NA |
| 508 | <i>ZNF292</i> | 0.0054325 | 300 | 508 | <i>LAPTM5</i> | 0.013349 | 481 |
| 509 | <i>ATRNL1</i> | 0.0054526 | 648 | 509 | <i>NTN5</i> | 0.013401 | NA |
| 510 | <i>MTMR2</i> | 0.005466 | 741 | 510 | <i>OGFOD1</i> | 0.013441 | 594 |
| 511 | <i>PTGIS</i> | 0.0055001 | 1014 | 511 | <i>SOWAHB</i> | 0.013452 | NA |
| 512 | <i>USP31</i> | 0.0055412 | 565 | 512 | <i>FAM110D</i> | 0.013503 | 579 |
| 513 | <i>DCAF8L2</i> | 0.0055596 | 667 | 513 | <i>ESPN</i> | 0.013555 | 360 |
| 514 | <i>STAG3</i> | 0.0055694 | 1087 | 514 | <i>RRP1</i> | 0.013556 | 1081 |
| 515 | <i>IFNA4</i> | 0.0055994 | 816 | 515 | <i>SCARB1</i> | 0.013591 | NA |
| 516 | <i>SYTL2</i> | 0.0056168 | 920 | 516 | <i>PPP1R37</i> | 0.01362 | NA |
| 517 | <i>PTMA</i> | 0.0056211 | 1101 | 517 | <i>LYRMI</i> | 0.013627 | NA |
| 518 | <i>OGN</i> | 0.005625 | 134 | 518 | <i>ZNF587B</i> | 0.013657 | NA |
| 519 | <i>NDUFA11</i> | 0.0056499 | 22 | 519 | <i>EIF3F</i> | 0.013706 | 1075 |
| 520 | <i>CIQTNF5</i> | 0.0056519 | 695 | 520 | <i>ZNF148</i> | 0.013709 | NA |
| 521 | <i>STX3</i> | 0.0056567 | 529 | 521 | <i>LIF</i> | 0.01376 | 81 |
| 522 | <i>TMEM132D</i> | 0.0056567 | 208 | 522 | <i>USP29</i> | 0.013811 | NA |
| 523 | <i>CTNNA2</i> | 0.0056615 | 847 | 523 | <i>OXTR</i> | 0.013844 | 746 |
| 524 | <i>MTNRI1A</i> | 0.0056776 | 329 | 524 | <i>SMAD6</i> | 0.01396 | 723 |
| 525 | <i>NBPF9</i> | 0.0056811 | NA | 525 | <i>C3orf36</i> | 0.013965 | 1052 |
| 526 | <i>GRAMD1C</i> | 0.005695 | 350 | 526 | <i>PARP6</i> | 0.014007 | 73 |
| 527 | <i>MPP5</i> | 0.005719 | 295 | 527 | <i>SYN1</i> | 0.014011 | 762 |
| 528 | <i>ANKRD1</i> | 0.0057244 | 389 | 528 | <i>NKD2</i> | 0.014068 | NA |
| 529 | <i>C8orf46</i> | 0.0057371 | 480 | 529 | <i>ONECUT1</i> | 0.014119 | NA |
| 530 | <i>VNIR2</i> | 0.0057623 | 337 | 530 | <i>MYOM3</i> | 0.014134 | NA |
| 531 | <i>ZYG11A</i> | 0.0057665 | 1116 | 531 | <i>NARR</i> | 0.014149 | NA |
| 532 | <i>TRIML1</i> | 0.0057914 | 418 | 532 | <i>OR4K5</i> | 0.014171 | NA |
| 533 | <i>FANCD2</i> | 0.005797 | 1129 | 533 | <i>COG3</i> | 0.014171 | 1 |
| 534 | <i>ARPC1A</i> | 0.0058197 | 1036 | 534 | <i>OR6C76</i> | 0.014193 | NA |
| 535 | <i>HMOX1</i> | 0.0058275 | 514 | 535 | <i>NFIX</i> | 0.0142 | 469 |
| 536 | <i>AVL9</i> | 0.0058278 | 730 | 536 | <i>HIST1H2BF</i> | 0.014222 | NA |
| 537 | <i>C6orf62</i> | 0.0058278 | 99 | 537 | <i>HYAL2</i> | 0.014222 | NA |
| 538 | <i>CLDN11</i> | 0.0058378 | 319 | 538 | <i>PRR5</i> | 0.014238 | NA |
| 539 | <i>DACT3</i> | 0.0058674 | 139 | 539 | <i>STX8</i> | 0.014376 | NA |
| 540 | <i>BRK1</i> | 0.0058795 | 969 | 540 | <i>TC2N</i> | 0.014376 | NA |
| 541 | <i>OR2T2</i> | 0.0058833 | NA | 541 | <i>BRSK1</i> | 0.014524 | 381 |
| 542 | <i>SLC25A52</i> | 0.0058912 | 1093 | 542 | <i>RAB1B</i> | 0.01453 | NA |
| 543 | <i>BCKDK</i> | 0.0058939 | 997 | 543 | <i>DAZL</i> | 0.014568 | NA |
| 544 | <i>RAB15</i> | 0.0059115 | 744 | 544 | <i>CSDC2</i> | 0.014581 | NA |
| 545 | <i>MPPE1</i> | 0.0059208 | 733 | 545 | <i>PXDNL</i> | 0.014606 | NA |
| 546 | <i>PLA2G4E</i> | 0.0059272 | 712 | 546 | <i>POMK</i> | 0.014616 | NA |
| 547 | <i>ALDH1A1</i> | 0.0059311 | 644 | 547 | <i>GPR75</i> | 0.014633 | 581 |
| 548 | <i>PPIL3</i> | 0.0059354 | 242 | 548 | <i>CNOT6</i> | 0.014665 | NA |
| 549 | <i>MDH1B</i> | 0.0059488 | 548 | 549 | <i>MAGEB4</i> | 0.014684 | NA |

| | | | | | | | |
|-----|---------------------|-----------|------|-----|-----------------|----------|------|
| 550 | <i>POC5</i> | 0.0059554 | 1016 | 550 | <i>PDLIM3</i> | 0.014732 | NA |
| 551 | <i>KIAA2018</i> | 0.0059564 | 531 | 551 | <i>CDH19</i> | 0.014735 | NA |
| 552 | <i>PSMG2</i> | 0.0059859 | 1020 | 552 | <i>RSF1</i> | 0.014762 | NA |
| 553 | <i>SOD3</i> | 0.0060259 | 398 | 553 | <i>PACS2</i> | 0.014791 | 93 |
| 554 | <i>SNX17</i> | 0.0060301 | 1077 | 554 | <i>IMMT</i> | 0.014806 | 652 |
| 555 | <i>PRELID1</i> | 0.0060345 | 1136 | 555 | <i>TDP1</i> | 0.014821 | 1124 |
| 556 | <i>CD177</i> | 0.006036 | NA | 556 | <i>AQP4</i> | 0.014838 | NA |
| 557 | <i>KLHL1</i> | 0.0060401 | 1041 | 557 | <i>VPS36</i> | 0.014851 | NA |
| 558 | <i>SECTM1</i> | 0.0060706 | 922 | 558 | <i>ROCK2</i> | 0.014918 | 347 |
| 559 | <i>ACHE</i> | 0.006081 | 277 | 559 | <i>CEP85L</i> | 0.01494 | NA |
| 560 | <i>RELA</i> | 0.0060825 | 897 | 560 | <i>CYP4F8</i> | 0.014948 | NA |
| 561 | <i>ACADS</i> | 0.0060861 | 1089 | 561 | <i>CNOT7</i> | 0.014992 | 111 |
| 562 | <i>JAM2</i> | 0.0060867 | 950 | 562 | <i>FSCB</i> | 0.014993 | NA |
| 563 | <i>AES</i> | 0.0060894 | 546 | 563 | <i>PLP1</i> | 0.015031 | 625 |
| 564 | <i>CLEC12B</i> | 0.0061054 | 41 | 564 | <i>OR8B12</i> | 0.015043 | NA |
| 565 | <i>L1TD1</i> | 0.0061076 | 678 | 565 | <i>TAX1BP3</i> | 0.015053 | 473 |
| 566 | <i>FOXD4</i> | 0.0061106 | 892 | 566 | <i>PPAPDC3</i> | 0.015094 | NA |
| 567 | <i>TTC12</i> | 0.0061124 | 36 | 567 | <i>PRELID1</i> | 0.015197 | 1140 |
| 568 | <i>ACTL6B</i> | 0.0061191 | 393 | 568 | <i>ZNF580</i> | 0.015248 | NA |
| 569 | <i>GRIN2A</i> | 0.006127 | 538 | 569 | <i>NDRG1</i> | 0.015257 | 860 |
| 570 | <i>WBSCR27</i> | 0.0061378 | 612 | 570 | <i>COG7</i> | 0.015272 | 9 |
| 571 | <i>LOC100862671</i> | 0.0061435 | NA | 571 | <i>BMP2K</i> | 0.015299 | NA |
| 572 | <i>COL19A1</i> | 0.0061564 | 819 | 572 | <i>OR3A2</i> | 0.015333 | NA |
| 573 | <i>FLII</i> | 0.0061678 | 198 | 573 | <i>B3GNTL1</i> | 0.015363 | 774 |
| 574 | <i>TAS2R39</i> | 0.0061702 | 534 | 574 | <i>ZFYVE26</i> | 0.015386 | 933 |
| 575 | <i>DEFB125</i> | 0.0061882 | 128 | 575 | <i>PSMA3</i> | 0.015402 | NA |
| 576 | <i>ANKZF1</i> | 0.0061895 | 224 | 576 | <i>LRRC26</i> | 0.015453 | NA |
| 577 | <i>BYSL</i> | 0.0062037 | 692 | 577 | <i>ASAH2</i> | 0.015504 | NA |
| 578 | <i>EPSTI1</i> | 0.0062411 | 786 | 578 | <i>DDX25</i> | 0.015523 | 170 |
| 579 | <i>SYT17</i> | 0.0062424 | 846 | 579 | <i>FCHO2</i> | 0.015607 | 16 |
| 580 | <i>FAM78B</i> | 0.0062637 | 42 | 580 | <i>NBEA</i> | 0.015637 | NA |
| 581 | <i>TGM7</i> | 0.0062776 | 1061 | 581 | <i>MAS1</i> | 0.015691 | 538 |
| 582 | <i>DNAJC17</i> | 0.0062805 | 256 | 582 | <i>MB21D2</i> | 0.015806 | 970 |
| 583 | <i>PRICKLE3</i> | 0.0062928 | 923 | 583 | <i>SLCO4C1</i> | 0.015812 | 416 |
| 584 | <i>LOC643669</i> | 0.0062938 | 940 | 584 | <i>HOXB1</i> | 0.015829 | 466 |
| 585 | <i>MUC16</i> | 0.0063294 | 1075 | 585 | <i>TTYH1</i> | 0.015863 | NA |
| 586 | <i>OR10G3</i> | 0.0063294 | NA | 586 | <i>SEMA4B</i> | 0.015883 | NA |
| 587 | <i>DDB2</i> | 0.0063538 | 777 | 587 | <i>CCDC129</i> | 0.01591 | NA |
| 588 | <i>HEPACAM2</i> | 0.0063623 | 167 | 588 | <i>KLHL41</i> | 0.015966 | NA |
| 589 | <i>GRIA3</i> | 0.0063723 | 196 | 589 | <i>BOD1L1</i> | 0.015975 | 640 |
| 590 | <i>CCL26</i> | 0.0063827 | 864 | 590 | <i>GALK2</i> | 0.016017 | NA |
| 591 | <i>ZNF764</i> | 0.0063945 | 1069 | 591 | <i>TRMT1L</i> | 0.016068 | NA |
| 592 | <i>ABCA3</i> | 0.0063961 | 628 | 592 | <i>C9orf170</i> | 0.016119 | 282 |

| | | | | | | | |
|-----|-----------------|-----------|------|-----|---------------------|----------|-----|
| 593 | <i>HGS</i> | 0.006402 | 363 | 593 | <i>RMI2</i> | 0.016134 | NA |
| 594 | <i>SGPP2</i> | 0.0064357 | 728 | 594 | <i>SEMA3F</i> | 0.016161 | 999 |
| 595 | <i>MCL1</i> | 0.0064457 | 1085 | 595 | <i>ZNF77</i> | 0.01617 | NA |
| 596 | <i>TMEM155</i> | 0.0064477 | 662 | 596 | <i>DYNC111</i> | 0.016207 | NA |
| 597 | <i>FAM53A</i> | 0.0064532 | 69 | 597 | <i>LOC100505841</i> | 0.016219 | NA |
| 598 | <i>DCUN1D2</i> | 0.0064691 | 551 | 598 | <i>NEURL2</i> | 0.016222 | NA |
| 599 | <i>GSX1</i> | 0.006475 | 683 | 599 | <i>KLK15</i> | 0.016273 | NA |
| 600 | <i>SNAP29</i> | 0.0064816 | 257 | 600 | <i>TMEM235</i> | 0.016277 | 425 |
| 601 | <i>C6orf136</i> | 0.0064994 | 103 | 601 | <i>SDK2</i> | 0.016316 | 460 |
| 602 | <i>TESPA1</i> | 0.0065014 | 443 | 602 | <i>C5orf15</i> | 0.016324 | 703 |
| 603 | <i>HDHD1</i> | 0.0065174 | 132 | 603 | <i>GLUD1</i> | 0.016375 | 693 |
| 604 | <i>CD2</i> | 0.00656 | 1013 | 604 | <i>PRDX2</i> | 0.016394 | 834 |
| 605 | <i>PADI6</i> | 0.0065783 | NA | 605 | <i>TMEM184C</i> | 0.01641 | NA |
| 606 | <i>PSEN1</i> | 0.0065853 | 213 | 606 | <i>TIPARP</i> | 0.016427 | NA |
| 607 | <i>TBCE</i> | 0.0065929 | 1112 | 607 | <i>DDX3Y</i> | 0.016473 | 655 |
| 608 | <i>AAED1</i> | 0.0066027 | 192 | 608 | <i>RC3H2</i> | 0.016478 | 577 |
| 609 | <i>CLPTMIL</i> | 0.0066184 | 967 | 609 | <i>PRSS35</i> | 0.016504 | NA |
| 610 | <i>PPIC</i> | 0.006643 | 65 | 610 | <i>FAM200B</i> | 0.016551 | NA |
| 611 | <i>FCERIA</i> | 0.0066431 | 276 | 611 | <i>RPS3A</i> | 0.016575 | NA |
| 612 | <i>NUSAP1</i> | 0.0066543 | 216 | 612 | <i>GLIPR1</i> | 0.01658 | 244 |
| 613 | <i>PELI1</i> | 0.0066728 | 522 | 613 | <i>GLB1L</i> | 0.016582 | 520 |
| 614 | <i>DNAJB2</i> | 0.0067009 | 166 | 614 | <i>RBM24</i> | 0.016606 | 215 |
| 615 | <i>IZUMO4</i> | 0.006718 | 998 | 615 | <i>CCDC90B</i> | 0.016631 | NA |
| 616 | <i>ENG</i> | 0.0067216 | 550 | 616 | <i>SLIT1</i> | 0.016661 | NA |
| 617 | <i>ARHGEF19</i> | 0.0067348 | 218 | 617 | <i>TMPRSS5</i> | 0.016677 | NA |

EXPERIMENTAL PROCEDURES

Generation of GLUT reporter cell lines

HeLa cells, 293T cells, and mouse preadipocytes (derived from inguinal white adipocyte tissues, a gift from Dr. Shingo Kajimura) were maintained in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% FBS and penicillin/streptomycin. To differentiate into adipocytes, preadipocytes were cultured to ~95% confluence before a differentiation cocktail was added to the following concentrations: 5 $\mu\text{g}/\text{mL}$ insulin (Sigma, #I0516), 1 nM T3 (Sigma, #T2877), 125 nM indomethacin (Sigma, #I-7378), 5 μM dexamethasone (Sigma, #D1756), and 0.5 mM IBMX (Sigma, #I5879). After two days, the cells were switched to DMEM supplemented with 10% FBS, 5 $\mu\text{g}/\text{mL}$ insulin, and 1 nM T3. After another two days, fresh media of the same composition were supplied. Differentiated adipocytes were usually analyzed six days after addition of the differentiation cocktail.

To generate cell lines expressing the GFP-GLUT4-HA reporter, lentiviruses were produced by transfecting 293T cells with a mixture of plasmids including GFP-GLUT4-HA (Muretta et al., 2008) pAdVantage (Promega, #E1711), pCMV-VSVG, and psPax2. Lentiviral particles were collected 40 hours after transfection and every 24 hours thereafter for a total of four collections. Lentiviruses were pooled and concentrated by centrifugation in a Beckman SW28 rotor at 25,000 RPM for 1.5 hours. The viral pellets were resuspended in PBS and used to transduce HeLa cells and preadipocytes. HeLa cells expressing the reporter were enriched for the strongest responses to insulin using fluorescence activated cell sorting (FACS) on a MoFlo cell sorter (Beckman

Coulter). A clonal cell line with the strongest insulin response was used in the genetic screens. Mouse preadipocytes expressing the reporter were similarly generated except that pooled cell populations were used.

Flow cytometry analysis of insulin-triggered GLUT translocation

HeLa cells or adipocytes were washed three times with KRH buffer (121 mM NaCl, 4.9 mM KCl, 1.2 mM MgSO₄, 0.33 mM CaCl₂, and 12 mM HEPES [pH7.0]). After incubation in the KRH buffer for two hours, the cells were treated with 100 nM insulin for 30 minutes. When applicable, 100 nM wortmannin (Sigma, #W1628) was added 10 minutes prior to insulin treatment. After insulin stimulation, the cells were rapidly chilled on an ice bath and their surface reporters were stained using anti-HA antibodies (BioLegend, #901501) and allophycocyanin (APC)-conjugated secondary antibodies (eBioscience, #17-4014). The cells were dissociated from the plates using Accutase (Innovative Cell Technologies, #AT 104) and their APC and GFP fluorescence was measured on a CyAN ADP analyzer. Data from populations of >5,000 cells were analyzed using the FlowJo software. Statistical significance was calculated based on experiments run in triplicate.

Genome-wide CRISPR mutagenesis of HeLa reporter cells

HeLa cells expressing the GFP-GLUT4-HA reporter were mutagenized using the GeCKO V2 CRISPR Knockout Pooled Library (Addgene, #1000000048), following previously described procedures with minor modifications (Marceau et al., 2016; Parnas et al., 2015; Sanjana et al.,

2014; Shalem et al., 2014; Sidik et al., 2016; Zhang et al., 2016). When delivered into targeted cells, Cas9 and sgRNAs encoded by the library introduced loss-of-function indel mutations through non-homologous end joining (Cong et al., 2013; Doudna and Charpentier, 2014; Fu et al., 2014; Hart et al., 2015; Mali et al., 2013; Marceau et al., 2016; Xiong et al., 2016). Lentiviruses were produced by transfecting the GeCKO V2 library plasmids (Parts A and B) into 293T cells using procedures similar to the generation of GFP-GLUT4-HA reporter cell lines. Starting at 48 hours after transfection, media containing lentiviruses were collected every 24 hours for a total of four collections. Lentiviral particles were pelleted in a Beckman SW28 ultracentrifuge rotor at 25,000 RPM for 1.5 hours. The lentiviral pellets were resuspended in PBS and stored at -70 °C.

To test viral titers, one million HeLa cells were seeded into each well of a 12-well plate. The cells were spin infected by lentiviruses produced from the Part A or B of the CRISPR library at 2,000 RPM for two hours. The plate was subsequently transferred to a 37 °C incubator. On the following day, the cells were dissociated and seeded in replicate wells of a 24-well plate. Fresh media were supplied on the following day and 1 µg/ml puromycin (Sigma, #P8833) was added to half of the duplicate wells. After 24 hours, attached cells were washed once with PBS and counted using CountBright beads (Thermo, #C36950) on a CyAN ADP analyzer. Numbers of cells in puromycin-treated wells were divided by those in the parallel untreated wells to calculate multiplicity of infection (MOI). Viral concentrations that yielded an MOI of ~0.4 were chosen for large-scale preparations.

In large-scale preparations, 45 million HeLa reporter cells were seeded for each part of the library. Small-scale replicates of these mutagenized populations were separately treated with puromycin and counted to verify the MOI. After puromycin treatment, the large-scale mutant populations were combined at a 1:1 ratio and frozen on the sixth day after viral transduction.

Genome-wide CRISPR screens

In each screen, 40 million mutagenized HeLa reporter cells were seeded at 1.2 million cells per 10-cm dish. On the following day, the cells were incubated in KRH buffer for two hours. In the translocation defective screen, the cells were treated with 100 nM insulin for 30 minutes. In the constitutive translocation screen, the cells were left untreated. The dishes were subsequently chilled on an ice bath and the cells were stained with anti-HA antibodies and APC-conjugated secondary antibodies. After dissociation from the plates by Accutase, the cells were concentrated by centrifugation and sorted by FACS. The cells in the bottom 3% of the APC channel were collected in the translocation defective screen while the top 1.2% of the cells were sorted in the constitutive translocation screen. The collected cells were expanded and sorted for another two rounds using the same fluorescence gating.

Illumina deep sequencing

Genomic DNA was isolated using a genomic DNA isolation kit (Thermo, #K0721). The unsorted control population contained 50 million cells whereas each of the sorted populations contained five million cells. The isolated genomic DNA was used as template to amplify guide

sequences. In the first round of PCR, each reaction was performed in a total volume of 100 μ L containing 10 μ g genomic DNA and the following primers:

Forward: AATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTTCG

Reverse: AATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTTCG

The second round of PCR reactions was performed in a total volume of 50 μ L, using 5 μ L of the PCR products from the first round as template. Of the 12 forward barcoded primers, six were used for the sorted populations and six were used for the unsorted control population. The barcoded forward primers (F01-12) and the reverse primer (R01) are listed below with barcodes highlighted in bold. Stagger sequences are shown to the 5' of the barcode in lower case, while the priming sites are shown to the 3' of the barcode in lower case (Table 1.2).

PCR products were pooled, purified using a gel purification kit (Clontech, #740609), and sequenced on an Illumina HiSeq2000 using 1x125 v4 Chemistry. Sequencing reads were demultiplexed and processed to contain only the 20-bp unique guide sequences using the FASTX-toolkit (http://hannonlab.cshl.edu/fastx_toolkit/). Readcount tables and gene enrichment analysis were performed using the MAGeCK algorithm (<http://sourceforge.net/projects/mageck/>).

Table 1.2: Illumina sequencing primers

| | |
|-----|---|
| F01 | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTt AAGTAGAG tcttgtgaaaggacgaaacaccg |
| F02 | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTat ACACGATC tcttgtgaaaggacgaaacaccg |
| F03 | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTgat CGCGGGT tcttgtgaaaggacgaaacaccg |
| F04 | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTcgat CATGATCG tcttgtgaaaggacgaaacaccg |
| F05 | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTt cgatCGTTACCA tcttgtgaaaggacgaaacaccg |
| F06 | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTatcgat TCCTTGGT tcttgtgaaaggacgaaacaccg |
| F07 | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTgatcgat AACGCATT tcttgtgaaaggacgaaacaccg |
| F08 | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTcgatcgat ACAGGTAT tcttgtgaaaggacgaaacaccg |
| F09 | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTacgatcgat AGGTAAGG tcttgtgaaaggacgaaacaccg |
| F10 | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTt AACAATGG tcttgtgaaaggacgaaacaccg |
| F11 | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTat ACTGTATC tcttgtgaaaggacgaaacaccg |
| F12 | AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTgat AGGTTCGA tcttgtgaaaggacgaaacaccg |
| R01 | CAAGCAGAAGACGGCATAACGAGATAAGTAGAGGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTt TCTACTAT TCTTTCCCTGCACTGT |

Pooled secondary CRISPR screens

We constructed a pooled secondary CRISPR library based on the guide sequences of an activity-optimized library (Wang et al., 2015). Ten sgRNAs were selected for each of the top 1,170 genes from the genome-wide genetic screens (598 genes from the translocation defective screen and 572 genes from the constitutive translocation screen). The secondary library also contained 1,000 non-targeting control sgRNAs. Oligonucleotides containing the guide sequences were synthesized by CustomArray and amplified by PCR using the following primers:

ArrayF: TAACTTGAAAGTATTTTCGATTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCG

ArrayR: ACTTTTTCAAGTTGATAACGGACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAC

PCR products were ligated into the pLenti-CRISPR vector (addgene, #49535) using a Gibson assembly kit (Synthetic Genomics, #GA1200). pLenti-CRISPR vector was digested using BsmBI followed by alkaline phosphatase treatment and gel purification. Each Gibson assembly reaction contained 100 ng vector and 40 ng PCR products in triplicate. The reactions were subsequently dialyzed against deionized water and transformed into electrocompetent *E. coli* cells (Lucigen, #60242). *E. coli* colonies were counted to ensure >20x coverage of the library. HeLa cells expressing the GLUT reporter were mutagenized by the secondary CRISPR library and sorted as described in the primary screens.

CRISPR-Cas9 genome editing of candidate genes

To edit a candidate gene, two independent guide sequences were selected within the early constitutive exons of the gene (Table 1.3). Oligonucleotides containing one guide sequence were cloned into the pLenti-CRISPR-V2 vector (Addgene, #52961) as we previously described (Davis et al., 2015). Oligonucleotides containing the other guide sequence were cloned in a modified version of the CRISPR vector in which the puromycin selection marker was replaced with a hygromycin selection marker (pLenti-CRISPR-Hygro). Lentiviruses produced from the CRISPR plasmids were used to infect target cells. The infected cells were consecutively selected using 1 $\mu\text{g}/\text{mL}$ puromycin and 500 $\mu\text{g}/\text{mL}$ hygromycin B (Thermo, #10687010). Supplementary Table 7 lists the gRNAs used to edit individual genes.

| Table 1.3 gRNAs used in individual CRISPR KO experiments | | | |
|---|-----------------|------------------------|----------------------|
| Species | Gene | Target 1 | Target 2 |
| mouse | <i>Exoc7</i> | GGCACTGACGCAGTGAATGT | ATGGCGGATGATGGCTTTCC |
| mouse | <i>Rabif</i> | GAACGAGCTCGTGTGTCAGCCG | CATGAGAAAGAAGCCAGATC |
| mouse | <i>Rab10</i> | CCACTCCCGAGTCCCGATC | GTTCTCAAAGCTTTTACCGT |
| mouse | <i>Vps35</i> | AAAGTTTTTCCTGCTCATCC | TTACCAGGCATCTTTTCATC |
| mouse | <i>Ankrd13d</i> | GTGGCTCTCTTTGCCACGT | CCCTCTGGAAGTCCCGATAC |
| mouse | <i>Osbp18</i> | TCTCCCAAAGGTTTTGAAAG | GGAAAGATGAGTCAGCGCCA |
| mouse | <i>Osbp110</i> | CCAGGACCTGCTTCTCCTGA | CCGCCAGTGCCAACATAACA |
| mouse | <i>Tbc1d4</i> | AGCCGGAAGCGCTTGTCGCC | ATCTGTGACTCGGGGTCGTC |
| mouse | <i>Ap2s1</i> | CCGGGCAGGCAAGACGCGCC | GGATGTCAACGACAACAATC |
| mouse | <i>Aagab</i> | GCTAGCTGAGGTGATGATCC | CAACTTCCAGCGATGCTGTG |
| human | <i>AP2S1</i> | GCGTCTTGCTGCCCCGGTTC | GGTCCAGTTCACAGACATTG |
| human | <i>AAGAB</i> | CAGCTGGTCTCCTGAGAAGA | GCAGTAACAAGAAATTTGTT |
| human | <i>RABIF</i> | GCACCCGGGAGCCGCAACGC | TCCTGGAGGAGATCGCCGTC |
| human | <i>RAB10</i> | CCTGATCGGGGATTCCGGAG | ATCAAAACAGTTGAATTACA |
| human | <i>TBC1D4</i> | AAGTCAGCCAGGTCCTCTCC | CTGGGTCATCCTCCCCAGAC |

Chapter 2

AAGAB regulates Adapter protein 2 complex formation on the plasma membrane

Introduction

In the constitutive translocation screen we sought to generate a list of all proteins whose loss resulted in constitutive translocation of the GLUT reporter to the cell surface. One prominent class of genes identified in this screen were those predicted to be involved in the endocytosis of GLUT4. There are four main forms of endocytosis: clathrin-mediated endocytosis, caveolae, macropinocytosis, and phagocytosis. In our screen, we recovered genes involved in clathrin-mediated endocytosis, which is consistent with previous reports indicating GLUT4 internalization is dependent on clathrin-mediated endocytosis. Among the genes identified were the adapter protein complex 2 constituents, AP2S1 and AP2M1 and a known binding partner AAGAB.

Clathrin mediated endocytosis

Clathrin-mediated endocytosis occurs through five steps: nucleation, cargo selection, clathrin coat assembly, vesicle scission, uncoating and recycling (McMahon and Boucrot, 2011). Initially, during nucleation, there is a slight membrane invagination concurrent with the assembly of the nucleation module which includes FCH domain only (FCHO) proteins, EGFR pathway

substrate protein (EPS15) and intersectins (McMahon and Boucrot, 2011). Subsequently, during cargo selection, adaptor protein 2 (AP2) is recruited to the site of endocytosis. AP2 can bind directly to the membrane through a phosphatidylinositol-4,5-bisphosphate (PIP2) binding domain, and interacts directly with cargo through its μ -subunit (Bonifacino and Glick, 2004). Next, the clathrin coat assembles into a lattice that helps to stabilize the membrane's curvature. It is thought that some accessory proteins such as EPS15 move to the periphery where the curvature is most dramatic, thus stabilizing the expanding invaginated membrane bud (Tebar et al., 1996). BAR domain-containing proteins then bind to the severe curvature at the neck of the developing vesicle where they recruit dynamin (Ferguson et al., 2009). It is thought that GTP hydrolysis of dynamin causes a conformational change, which results in the scission of the vesicle (Stowell et al., 1999). Once scission has occurred, the clathrin coat is disassembled by ATPase heat shock cognate 70 (HSC70) (Böcking et al., 2011). This allows the uncoated vesicle to be competent for fusion with the endosome and the clathrin coat and accessory proteins to be recycled for another round of endocytosis.

***AAGAB* mutation in human disease**

AAGAB was first identified in a yeast-2-hybrid experiment that used the γ -adaptin subunit of AP1 as bait (Page et al., 1999b). Although AAGAB was shown to bind both AP1 and AP2 complex no further progress was made on the function of AAGAB (Page et al., 1999b). Later, the disease-causing locus of a collection of families with autosomal dominant palmoplantar keratoderma (PPK) was mapped to *AAGAB* (Pohler et al., 2012). PPK is hereditary skin disorder resulting in thickening of the epidermis on the palms and the soles of the feet. Onset occurs in

the first twenty years of life and is first noticeable with the development of small growths on the palms and soles. As the disease progresses these growths converge resulting in larger lesions (Pohler et al., 2012) (Fig 2.1).



Figure 2.1 Phenotype observed in patients with loss of function mutation in AAGAB. (Pohler et al., 2012)

***AAGAB* KO results in trafficking defect and acts downstream of insulin signaling**

Given that *AAGAB* was among the highest scoring genes we identified, its known association with human disease, and its unknown function, we decided to investigate the molecular mechanism of *AAGAB*. KO of *AAGAB* using CRISPR-Cas9 strongly increased the basal surface levels of GLUT reporter in both HeLa cells and adipocytes (Figs. 2.2a, 2.3a,b). Insulin-induced AKT phosphorylation was intact in *AAGAB* KO cells (Fig 2.2b), suggesting that *AAGAB* acts downstream of insulin signaling.

a





Figure 2.2 *AAGAB* knockout results in a trafficking defect and acts downstream of insulin signaling.

a, Normalized surface levels of the GLUT reporter in WT or mutant HeLa cells (in the absence of insulin). All error bars in this figure indicate standard deviation. **b**, Immunoblots showing total AKT and insulin-stimulated AKT phosphorylation in WT or mutant HeLa cells.

b







Figure 2.3: AAGAB KO results in GLUT4 plasma membrane localization.

a. Normalized surface levels of the GLUT reporter in WT or mutant adipocytes were measured by flow cytometry. Error bars indicate standard deviation. **b.** Confocal images showing the surface or intracellular localization of GFP-GLUT4 in WT or mutant adipocytes. Bar: 10 μ m. Imaging was performed by Jingshi Shen.

***AAGAB* KO results in an endocytosis defect**

We hypothesized that *AAGAB* mutation disrupts the retrieval of cargo proteins through clathrin-mediated endocytosis (CME). Indeed, using a fluorescent antibody-based endocytosis assay, we observed that the endocytosis of the GLUT reporter was abolished in *AAGAB* KO cells or in cells deficient in *AP2S1* (Fig. 2.4), which encodes the σ subunit of the AP2 adaptor. Thus, *AAGAB* is crucial to the endocytic retrieval of the GLUT reporter.





Figure 2.4: *AAGAB* KO disrupts endocytosis.

Relative endocytosis was measured by flow cytometry using fluorescent antibodies against GLUT4 and measuring increased fluorescence over time.

AAGAB regulates AP2 adaptor formation on the plasma membrane

To further determine the molecular mechanism of AAGAB, we examined whether AAGAB may regulate AP2 adaptor complex formation on the plasma membrane, a key step in CME (Brodsky, 2012; Martens and McMahon, 2008; Traub and Bonifacino, 2013). Confocal imaging of wild-type (WT) cells using anti- α -adaptin antibodies revealed abundant AP2 puncta on the cell surface (Fig. 2.5a). Strikingly, AP2 puncta disappeared in *AAGAB* deficient cells (Fig. 2.5a). Total internal reflection fluorescence microscopy (TIRFM), which selectively visualizes events near the plasma membrane, confirmed that AP2 puncta were eliminated in *AAGAB* KO cells (Fig. 2.5b). These data suggest that AAGAB is essential to the formation of AP2 adaptor complex on the plasma membrane. Furthermore, the total cell levels of α -adaptin was decreased in *AAGAB* KO cells (Fig. 2.6). Overexpression of α -adaptin was able to rescue GLUT4 internalization (Fig. 2.7) demonstrating that AAGAB is not directly required for CME. Although AAGAB interacts with α -adaptin, they did not show significant co-localization in the cell (Fig. 2.8), suggesting that AAGAB regulates AP2 adaptor formation via transient interactions. AAGAB also binds to γ -adaptin, a subunit of the AP1 adaptor required for clathrin-mediated transport from the *trans*-Golgi to the lysosome (Page et al., 1999a). However, lysosomal morphology (based on LAMP1 staining) was not impaired in *AAGAB* KO cells (Fig. 2.9), suggesting that the function of AAGAB is dispensable for AP1-dependent cargo transfer.

a



b




Figure 2.5: AAGAB regulates AP2 formation on the plasma membrane.

a. Representative confocal images showing the localization of α -adaptin and GLUT reporter in WT or mutant HeLa cells. Bar: 10 μ m. **b.** Representative TIRFM images showing the localization of α -adaptin in WT or mutant HeLa cells. Bar: 10 μ m. Imaging was performed by Jingshi Shen.




Figure 2.6: AAGAB regulates total α -adaptin levels.

Immunoblots showing total cell α -adaptin levels in WT, *AP2S1* KO and *AAGAB* KO cells.




Figure 2.7: α -adaptin overexpression partially rescues AAGAB KO.

Normalized surface levels of the GLUT reporter in WT or mutant adipocytes with or without α -adaptin were measured by flow cytometry. Error bars indicate standard deviation.




Figure 2.8: AAGAB does not colocalize with α -adaptin.

AAGAB-V5 was transiently expressed in HeLa cells. The cells were either untreated or treated with 100 nM insulin for 30 minutes before AAGAB-V5 and α -adaptin were stained and visualized by confocal microscopy. Bar: 10 μ m. Imaging was performed by Jingshi Shen.




Figure 2.9: LAMP1 trafficking is intact in *AAGAB* KO cells.

Representative confocal images showing the localization of LAMP1 and GLUT reporter in WT or mutant HeLa cells. Bar: 10 μ m. Imaging was performed by Jingshi Shen.

Surface proteomics identifies many cargo similarly regulated by *AAGAB* or *AP2S1* KO

Finally, we used mass spectrometry (MS)-based proteomics to identify cargo proteins regulated by *AAGAB*. Cell surface proteins were biotinylated, purified and analyzed by MS. Surface levels of many proteins such as TFRC (transferrin receptor), a known CME cargo (Conner and Schmid, 2003; Page et al., 1999a), were markedly elevated in *AAGAB* KO cells (Fig. 2.10a, Table 2.1). Other surface proteins such as FAS and PVR were not significantly affected in *AAGAB* KO cells (Fig. 2.10a, Table 2.1). Using flow cytometry, we confirmed that the surface levels of TFRC were strongly elevated in *AAGAB* KO cells, whereas FAS and PVR remained unchanged (Fig. 2.10b). The ability of *AAGAB* to regulate a large number of cargo proteins is in agreement with its crucial role in AP2-dependent CME. To further validate that *AAGAB* functions by regulating AP2 complex subunits we compared the surface proteomics of *AAGAB* KO cells to *AP2S1* KO cells. Overall, many of the quantified proteins were similarly affected by either *AAGAB* or *AP2S1* knockout (Table 2.1). Together, these data demonstrate that *AAGAB* plays an essential role in CME by regulating AP2 adaptor formation on the plasma membrane. Thus, our unbiased CRISPR screens allowed us to uncover a new component even in the extensively investigated CME pathway.



A**B**

Figure 2.10 AAGAB KO effects the cellular localization of endogenous CME cargo.

a. Proteomic analysis of surface proteins in *AAGAB* KO cells. Top 20 proteins with greatest increases in surface levels are shown. FAS and PVR are included as representative cargo proteins not affected in *AAGAB* KO cells. Average values of two technical replicates are shown. For proteins quantified only in one replicate, the values are shown without error bars. Dashed line indicates the basal levels in WT cells. **b.** Normalized surface levels of the indicated molecules in WT or mutant HeLa cells (FAS and PVR) or adipocytes (TFRC) were measured by flow cytometry. Error bars indicate standard deviation. *n.s.*: not significant.

Discussion

AAGAB was one of the strongest scoring genes observed in our constitutive translocation screen. Validation in both HeLa cells and adipocytes confirmed that AAGAB knockout was one of the most severe phenotypes of all genes we have tested to date. AAGAB loss of function causes type I punctate palmoplantar keratoderma (PPKP1) through an unknown mechanism. Together, this made AAGAB a strong candidate for mechanistic study. In this work we have demonstrated that AAGAB functions by regulating the surface localization of the AP2 complex, thereby regulating CME.

Further work is needed to clarify which CME cargos contribute to the development of PPKP1. In the *Nature Genetics* paper (and in later work from other labs), Pohler *et al.* provide strong evidence that AAGAB is the causal mutation; however, to date the mis-regulated cargo causing the disease is still unresolved (Pohler et al., 2012). Pohler *et al.* suggested that AAGAB mutation drives constitutive surface localization of EGFR, which leads to constitutive EGFR signaling. Our proteomics analysis in either *AAGAB* KO or *AP2S1* KO did not reveal an EGFR trafficking defect in HeLa cells, though this does not exclude a defect in other cell types such as keratinocytes. Additionally, our assay may not have captured all changes in surface localization.

In our surface proteomics experiments we set out to identify all endogenous CME cargo. Surprisingly, although surface expression was changed for a large number of proteins, only a small subset of those proteins showed a dramatic change. This could be due to technical limitations of our experiment, redundancy of endocytic pathways for the majority of CME cargo,

or the relative rate of recycling amongst the CME cargo. Among the proteins whose surface localization was dramatically increased in the absence of either *AP2S1* or *AAGAB* was TFRC, which is known to have a very high recycling rate between the plasma membrane and the endosome. Another protein with a high surface expression change with the loss of AP2S1 was amyloid beta precursor protein like 2 (APLP2). APLP2 has heparin, copper, and zinc binding domains, but its recycling rate and molecular role remains unclear. It would be interesting to test if APLP2 has a rapid recycling rate similar to TFRC. Another surprising result from our surface proteomics experiments were the large number of proteins not previously predicted to be CME cargo. Many of the proteins localize to a wide array of cellular organelles. Further work is needed to validate these candidates as bona fide CME cargo, but if confirmed this would underline the vast dynamics of the secretory pathway in regulating cellular localization.

Table 2.1: Surface proteomics for either *AP2S1* or *AAGAB* KO

| Gene | Expression level AP2S1:WT | Rank | Expression level AAGAB:WT | Rank |
|----------------------|--------------------------------------|-------------|--------------------------------------|-------------|
| APLP2 | NA | NA | 8.8855 | 1 |
| TFRC | 3.1995 | 1 | 7.4854 | 2 |
| KMT2C | NA | NA | 6.8903 | 3 |
| LINGO2 | NA | NA | 4.4446 | 4 |
| TPBG | NA | NA | 4.0023 | 5 |
| SET | NA | NA | 2.8679 | 6 |
| SLC38A1 | 2.0594 | 10 | 2.85935 | 7 |
| ALYREF | 2.352 | 3 | 2.74365 | 8 |
| SLC39A14 | 2.4664 | 2 | 2.6114 | 9 |
| PTPRJ | 2.0932 | 7 | 2.5247 | 10 |
| RTN4 | NA | NA | 2.51865 | 11 |
| MTX2 | NA | NA | 2.4608 | 12 |
| WLS | NA | NA | 2.45445 | 13 |
| CSRP2 | NA | NA | 2.3802 | 14 |
| TAF15 | 1.168 | 186 | 2.3656 | 15 |
| BCAP31 | NA | NA | 2.32595 | 16 |
| NISCH | NA | NA | 2.2193 | 17 |
| ANXA1 | NA | NA | 2.2177 | 18 |
| GPR56 | NA | NA | 2.1898 | 19 |
| TNFSF9 | 1.3933 | 56 | 2.1816 | 20 |
| FH | NA | NA | 2.1688 | 21 |
| ANXA4 | NA | NA | 2.1563 | 22 |
| LMAN1 | NA | NA | 2.1533 | 23 |
| FLOT1 | NA | NA | 2.1392 | 24 |
| SLC2A4 | 1.2517 | 111 | 2.12695 | 25 |
| CD97 | 1.451 | 39 | 2.11725 | 26 |
| GNAS;GNAL | NA | NA | 2.1168 | 27 |
| PSME3 | 1.3661 | 65 | 2.1003 | 28 |
| NPR3 | NA | NA | 2.1 | 29 |
| CPOX | NA | NA | 2.0844 | 30 |
| P4HB | 1.6468 | 19 | 2.0827 | 31 |
| HSPE1;HSPE1- MOB4 | NA | NA | 2.079 | 32 |
| PRDX4 | 1.2176 | 142 | 2.0665 | 33 |
| DDR2 | NA | NA | 2.0645 | 34 |

| | | | | |
|-----------------------|---------|-----|---------|----|
| MCM4 | NA | NA | 2.0477 | 35 |
| HDGF | NA | NA | 2.0265 | 36 |
| LGALS3BP | 1.7202 | 15 | 2.0225 | 37 |
| PODXL | 1.155 | 217 | 2.0018 | 38 |
| HSD17B4 | NA | NA | 1.9972 | 39 |
| MCM2 | 0.88049 | 752 | 1.9918 | 40 |
| CLU | NA | NA | 1.9561 | 41 |
| CKMT1B;CKMT1A | NA | NA | 1.9556 | 42 |
| PDIA3 | 1.757 | 13 | 1.9531 | 43 |
| PHB | 1.4148 | 49 | 1.9346 | 44 |
| COLGALT1 | NA | NA | 1.9251 | 45 |
| CPS1 | 1.2422 | 120 | 1.92395 | 46 |
| PHB2 | 1.3242 | 76 | 1.92 | 47 |
| AIFM1 | NA | NA | 1.9195 | 48 |
| PCDH1 | NA | NA | 1.9193 | 49 |
| NRP1 | NA | NA | 1.8896 | 50 |
| YES1;FYN | NA | NA | 1.8886 | 51 |
| PRKCSH | NA | NA | 1.88165 | 52 |
| LONP2 | NA | NA | 1.8813 | 53 |
| COX4I1 | NA | NA | 1.8753 | 54 |
| ACTN4 | NA | NA | 1.8724 | 55 |
| NCSTN | 1.4684 | 35 | 1.8555 | 56 |
| YTHDC2 | NA | NA | 1.8423 | 57 |
| AP2M1 | 0.54299 | 908 | 1.8353 | 58 |
| PSG11 | NA | NA | 1.8352 | 59 |
| LDLR | NA | NA | 1.8233 | 60 |
| NCL | 1.362 | 66 | 1.82225 | 61 |
| PDIA4 | NA | NA | 1.8198 | 62 |
| EBP | NA | NA | 1.8164 | 63 |
| GANAB | 1.6908 | 16 | 1.81255 | 64 |
| HNRNPA1;HNRNP A1L2 | 1.5029 | 29 | 1.8087 | 65 |
| FLOT2 | NA | NA | 1.802 | 66 |
| SPTBN1 | NA | NA | 1.789 | 67 |
| HSP90B1 | 1.4508 | 40 | 1.78845 | 68 |
| CALR | NA | NA | 1.7807 | 69 |
| TPM4;TPM2 | NA | NA | 1.7748 | 70 |
| TKT | 1.1688 | 183 | 1.768 | 71 |
| SSB | NA | NA | 1.76095 | 72 |
| CYB5R3 | NA | NA | 1.7596 | 73 |
| SLC1A1 | NA | NA | 1.7586 | 74 |

| | | | | |
|-------------------------|---------|-----|---------|-----|
| SAMM50 | 1.3172 | 81 | 1.7558 | 75 |
| GNAI3;GNAI1;GNAO1;GNAI2 | NA | NA | 1.7503 | 76 |
| TNFRSF10A | NA | NA | 1.7468 | 77 |
| PDIA6 | 1.3854 | 60 | 1.74675 | 78 |
| AK2 | 2.2591 | 4 | 1.74465 | 79 |
| MDH2 | NA | NA | 1.733 | 80 |
| ERP29 | NA | NA | 1.7219 | 81 |
| HNRNPR | 0.78117 | 853 | 1.7216 | 82 |
| NCLN | NA | NA | 1.7204 | 83 |
| HNRNPAB | NA | NA | 1.7131 | 84 |
| UQCRC1 | NA | NA | 1.7048 | 85 |
| RCN1 | 1.3945 | 55 | 1.6962 | 86 |
| HDAC2;HDAC1 | NA | NA | 1.69 | 87 |
| ATAD3A;ATAD3B | 1.1393 | 242 | 1.68515 | 88 |
| HSPD1 | 1.2599 | 106 | 1.68215 | 89 |
| ANXA6 | 1.9326 | 12 | 1.676 | 90 |
| ACLY | NA | NA | 1.676 | 91 |
| PTGES2 | NA | NA | 1.6743 | 92 |
| FUBP1 | NA | NA | 1.66805 | 93 |
| PDCD6 | NA | NA | 1.6667 | 94 |
| PTPN1 | NA | NA | 1.6653 | 95 |
| GEMIN5 | 0.98055 | 577 | 1.6638 | 96 |
| SFXN1 | 1.267 | 101 | 1.65985 | 97 |
| RAB7A | NA | NA | 1.6575 | 98 |
| ULBP2;RAET1G;RAET1L | NA | NA | 1.6532 | 99 |
| PHGDH | 0.99869 | 533 | 1.6498 | 100 |
| CAV1 | NA | NA | 1.6449 | 101 |
| SLC25A4 | NA | NA | 1.6424 | 102 |
| GART | NA | NA | 1.6365 | 103 |
| HNRNPA1 | NA | NA | 1.6318 | 104 |
| HNRNPUL1 | 1.2718 | 98 | 1.626 | 105 |
| PCNA | 1.094 | 317 | 1.6255 | 106 |
| CLPTM1L | NA | NA | 1.6221 | 107 |
| ANXA6 | 1.9326 | 12 | 1.619 | 108 |
| GPR89B;GPR89A;GPR89C | NA | NA | 1.6182 | 109 |
| VCP | 1.4419 | 42 | 1.6175 | 110 |
| UGGT1 | NA | NA | 1.6114 | 111 |
| RPN2 | 1.4585 | 37 | 1.6107 | 112 |
| ZC3HAV1 | 1.0626 | 386 | 1.60595 | 113 |

| | | | | |
|-------------|---------|-----|---------|-----|
| MYBBP1A | 0.95174 | 646 | 1.6046 | 114 |
| CHCHD3 | 1.3198 | 79 | 1.6014 | 115 |
| CBX3 | 1.0319 | 453 | 1.59985 | 116 |
| HMMR | 1.1412 | 238 | 1.5994 | 117 |
| GOT2 | NA | NA | 1.5966 | 118 |
| MTCH2 | 1.2277 | 133 | 1.5905 | 119 |
| PDIA3 | 1.757 | 13 | 1.58695 | 120 |
| NENF | NA | NA | 1.5796 | 121 |
| SURF4 | 1.0608 | 390 | 1.57685 | 122 |
| PABPC4 | 1.3403 | 73 | 1.5742 | 123 |
| UBA1 | 0.75625 | 862 | 1.5715 | 124 |
| NOP9 | NA | NA | 1.5707 | 125 |
| DDB1 | NA | NA | 1.567 | 126 |
| BAG2 | 1.1034 | 302 | 1.56535 | 127 |
| SPTAN1 | 1.3853 | 61 | 1.5637 | 128 |
| STT3A | NA | NA | 1.5636 | 129 |
| CANX | 2.0793 | 8 | 1.5587 | 130 |
| CD81 | 1.1597 | 208 | 1.5557 | 131 |
| PRPF19 | 1.2127 | 146 | 1.5515 | 132 |
| HLA-B | 0.44627 | 917 | 1.5448 | 133 |
| MATR3 | 1.1228 | 266 | 1.54305 | 134 |
| PSMD13 | NA | NA | 1.543 | 135 |
| ACTN4;ACTN1 | NA | NA | 1.5427 | 136 |
| S100A4 | NA | NA | 1.54 | 137 |
| SIGMAR1 | 1.2569 | 107 | 1.5362 | 138 |
| CD320 | NA | NA | 1.534 | 139 |
| CAD | 1.0312 | 456 | 1.527 | 140 |
| ASNS | NA | NA | 1.5263 | 141 |
| VDAC2 | 1.3466 | 69 | 1.52625 | 142 |
| HSD17B11 | NA | NA | 1.5259 | 143 |
| SLC31A1 | NA | NA | 1.5218 | 144 |
| POR | 0.68754 | 888 | 1.5194 | 145 |
| NUP155 | 1.2897 | 94 | 1.5192 | 146 |
| PFDN2 | NA | NA | 1.5103 | 147 |
| SERPINH1 | 1.1509 | 226 | 1.50725 | 148 |
| IMMT | 1.1945 | 161 | 1.5069 | 149 |
| HNRNPA0 | 1.0288 | 463 | 1.5068 | 150 |
| ATP5B | 1.0315 | 454 | 1.5052 | 151 |
| ESYT2 | NA | NA | 1.5019 | 152 |
| PUM1 | NA | NA | 1.5005 | 153 |
| MBOAT7 | NA | NA | 1.5002 | 154 |

EXPERIMENTAL PROCEDURES

Endocytosis assay

HeLa cells were incubated with the KRH buffer for two hours prior to treatment with 100 nM insulin for 30 minutes. The plates were then transferred to a 37 °C water bath and, where appropriate, treated with 200 μM Dynasore (Sigma, #D7693) for five minutes. After addition of 5 μg/mL anti-HA antibodies, the cells were incubated at 37 °C for another five minutes. The cells were then washed with a wash buffer (KRH buffer supplemented with 5% FBS) and dissociated from the plate using Accutase. The cells were then fixed by 2% paraformaldehyde (PFA) for 15 minutes at room temperature. After washing with wash buffer, the cells were incubated with APC-conjugated anti-mouse antibodies at room temperature for one hour in the KRH buffer supplemented with 2% FBS and 0.2 % saponin (Sigma, #47036). Subsequently the cells were washed and analyzed on a Cyan ADP Analyzer. Endocytosis Index was calculated using the following formula: $(\alpha - \delta)/\delta$, where α is the mean fluorescence of the wells without dynasore treatment whereas δ is the mean fluorescence of the dynasore-treated wells.

Immunoblotting

Cells grown in 24-well plates were lysed in 1x SDS protein sample buffer and the cell lysates were resolved on 8% Bis-Tris SDS-PAGE. Proteins were detected using primary antibodies and

horseradish peroxidase-conjugated secondary antibodies. Primary antibodies used in immunoblotting were: anti-AKT antibodies (Cell Signaling Technology, #9272), anti-phospho-AKT antibodies (Cell Signaling Technology, #5473), anti- α -adaptin antibodies (BD Biosciences, #610502), anti- α -tubulin antibodies (eBioscience, #14-4502-82),

Immunostaining and imaging

HeLa cells were seeded on coverslips coated with fibronectin (Sigma, #F1144). The cells were fixed using 2% PFA and permeabilized in PBS supplemented with 5% FBS and 0.2% saponin. Antigens were stained using the following primary antibodies: anti- α -adaptin antibodies (Thermo, #MAL-064), anti-LAMP1 antibodies (SCBT, clone H5G11), anti-Myc antibodies (SCBT, clone#9E10), anti-FLAG antibodies (Sigma, #F7425), anti-V5 antibodies, anti-CD47 antibodies (eBioscience, #14-0479-82), anti-CD95 antibodies (eBioscience, #14-0959-80), and anti-PVR antibodies (BioLegend, #337602). The cells were subsequently incubated with Alexa Fluor 488- or Alexa Fluor 568-conjugated secondary antibodies. After mounting on glass slides using the ProLong Antifade mountant with DAPI (Thermo, #P36931), the cells were visualized on a Carl Zeiss LSM780 confocal microscope. Cell images were captured and processed using the Carl Zeiss Zen 2 and Adobe Photoshop software. To visualize the GFP-GLUT4-HA reporter in adipocytes, the cells were fixed and permeabilized similarly to HeLa cells.

In TIRF imaging, cells grown on Delta T dishes (Bioprotechs, #04200417B) were fixed and stained in a similar way as in confocal imaging. The cells were submerged in the PBS-based Citifluor AF3 anti-fade solution (EMS, #17972-25) and visualized on a Carl Zeiss Observer Z1

microscope equipped with a Stable Z heating system (Bioptechs) for maintenance at 37°C. The TIRF angle was set at 66° for Alexa Fluor 488 fluorescence and 68° for Alexa Fluor 568 fluorescence.

Surface proteomics

Quantitative proteomic analysis of protein levels was performed using stable isotope labeling with amino acids in cell culture (SILAC) and mass spectrometry (MS). Cells were grown in SILAC media (Thermo, #88423) supplemented with 10% dialyzed FBE (Seradigm, #3100). WT HeLa cells were grown in the presence of light lysine and arginine (Sigma, #L1262 and A5131), whereas AAGAB or AP2S1 KO cells were grown in the presence of heavy lysine and arginine (Cambridge Isotope Laboratories, #CNLM-291 and CNLM-539). After five days, surface proteins were biotinylated prior to the cells being harvested at ~60% confluence in a lysis buffer (4% SDS and 50 mM Tris-HCl [pH 6.8]). Surface proteins were biotinylated by incubation with 1mg/mL Sulfo-NHS-biotin (Thermo, #21217) for 20 minutes at 4 °C prior to quenching with 100mM glycine and subsequent lysis in IP buffer (25 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1 mM EDTA, 1% NP-40, 5% glycerol, and a protease inhibitor cocktail). Protein content from WT and AAGAB or AP2S1 KO cell lysates were quantified by Bradford assay and combined in equal proportion prior to immunoprecipitation with streptavidin-paramagnetic beads (Promega, Z5482). Streptavidin-biotin binding was carried out overnight at 4 °C. Beads were washed twice with IP buffer, twice with IP buffer with NaCl level adjusted to 500mM, and twice with TE buffer. Beads were boiled in lysis buffer (4% SDS and 50mM Tris-HCl [pH 6.8]) prior to mass spectrometry analysis.

The cell lysates were processed for MS analysis following the filter-aided sample preparation (FASP) protocol (Erde et al., 2014; Wisniewski et al., 2009). Briefly, after addition of 20 mM DTT, equal amounts of whole-cell lysates were mixed and loaded onto a spin filter with a molecular weight cutoff of 30 kDa. The sample was then washed with the UA solution (8 M Urea and 0.1 M Tris-HCl [pH 7.9]) and alkylated using 0.1 M iodoacetamide. The sample was further washed with the UA solution and equilibrated with 0.1 M ammonium bicarbonate and 0.01% deoxycholic acid. The sample was then digested using 1% (w/w) trypsin at 37 °C for 16 hours. The resulting tryptic peptides were eluted by centrifugation, and acidified using formic acid. Deoxycholic acid was removed using phase transfer with ethyl acetate. The tryptic peptides were fractionated by a Pierce high pH reversed-phase spin column using 18 step gradients (4% acetonitrile for the first fraction, 1% increment for each fraction to the 17th fraction, and 50% acetonitrile for the 18th fraction). The fractions were dried using vacuum centrifugation.

One third of each fraction (5 µL) from high pH fractionation was analyzed by UPLC-MS/MS. The tryptic peptides were loaded onto a Waters nanoACQUITY UPLC BEH C18 column (130 Å, 1.7 µm × 75 µm × 250 mm) equilibrated with 0.1% formic acid/3% acetonitrile/water. Mobile phase A was 0.1% formic acid/water, while B was 0.1% formic acid/acetonitrile. The peptides were eluted at 0.3 mL/min using a gradient of 3-8% B (0-5 minutes) and 8-35% B (5-123 minutes).

Precursor ions between 300-1800 m/z (1×10^6 ions, 60,000 resolution) were scanned on a LTQ Orbitrap Velos mass spectrometer. The 10 most intense ions for MS/MS were selected with 180-second dynamic exclusion, 10 ppm exclusion width, with a repeat count=1, and a 30-second

repeat duration. Ions with unassigned charge state and MH+1 were excluded from MS/MS. Maximal ion injection times were 500 milliseconds for FT (one microscan) and 250 milliseconds for LTQ, and the AGC was 1×10^4 . The normalized collision energy was 35% with activation Q 0.25 for 10 milliseconds.

Raw data files from MS were searched against the Uniprot human proteome database (Consortium, 2015) (total 88,479 entries), using the MaxQuant/Andromeda search engine (version 1.5.2.8) (Cox et al., 2011). Searches allowed trypsin specificity with two missed cleavages, and included fixed Cys carbamidomethylation, and variable acetylation (protein N-terminus) and methionine oxidation. Mass tolerances were set to 20 ppm (first search) and 4.5 ppm (main search) for precursor ions, and 0.5 Da for ITMS MS/MS ions. MaxQuant/Andromeda used the top 8 MS/MS peaks per 100 Da and seven amino acid minimum peptide length, with 0.01 false discovery rate for both protein and peptide identification. For SILAC ratio measurements, minimum two independent peptide ratios were used to calculate a protein ratio.

Chapter 3

RABIF regulates RAB10 expression

Introduction

In the translocation defective screens we sought to generate a list of all genes whose protein products positively regulate insulin stimulated GLUT4 exocytosis. In this screen we identified nearly all known positive regulators including members of the insulin signaling pathway, the exocyst complex, and RAB10, which is thought to be the main RAB regulating insulin stimulated GLUT4 exocytosis. Since RAB10 could be considered an inflection point in the pathway, where the insulin signaling pathway converges to initiate vesicle trafficking, we expected to recover regulators of RAB10. We did not recover the Rab10 GEF, Dennd4c, which is consistent with the current model which suggests that there is redundancy among the Dennd4 family. One protein we did recover that is known to interact with RAB10 was RABIF.

RABIF KO results in defective insulin response

RABIF/MSS4 (not the lipid kinase MSS4) is a 14 kDa soluble protein that has been predicted to act as a Rab GEF, but its biological function and molecular mechanism remain unknown (Wixler et al., 2011; Zhu et al., 2001). KO of *RABIF* strongly reduced insulin-triggered GLUT4 translocation in both adipocytes and HeLa cells (Figs. 3.1, 3.2). Insulin signaling was intact (Fig.

3.3a) suggesting that RABIF acts downstream of insulin signaling. Furthermore, surface levels of insulin receptor were not affected, suggesting that insulin receptor moves to the plasma membrane via a distinct route (Fig. 3.4b).




Figure 3.1: RABIF KO results in decreased insulin response.

WT or mutant adipocytes were untreated or treated with 100 nM insulin for 30 minutes before surface levels of GLUT reporter were measured by flow cytometry. When applicable, 100 nM wortmannin was added prior to insulin treatment. Error bars indicate standard deviation. **a**, HeLa cells. **b**, Adipocytes.




Figure 3.2: *RABIF* KO results in decreased insulin response.

WT or *RAFIF*-deficient adipocytes were either untreated or treated with 100 nM insulin for 30 minutes before the localization of the GLUT reporter was visualized by confocal microscopy. Bar: 10 μ m. Data generated by Jingshi Shen.




Figure 3.3: Rabif acts downstream of insulin signaling to regulate GLUT4 exocytosis.
A. Immunoblots showing total AKT and insulin-stimulated AKT phosphorylation in WT or mutant HeLa cells. **B.** Normalized surface levels of insulin receptor in WT or mutant adipocytes. Error bars indicate standard deviation.

RABIF interacts with RAB10 and prevents RAB10 degradation

RABIF was identified in the same screen as RAB10 (Figs. 1.7, 1.12), an established mediator of exocytic vesicle fusion in GLUT translocation (Figs. 1.2, 1.10a) (Sano et al., 2007). We observed that RABIF interacted with RAB10 both on membranes and in solution (Fig. 3.4 a,b). Furthermore, RABIF and RAB10 exhibited partial co-localization in the cell (Fig. 3.4c). These data raise the possibility that RABIF directly regulates RAB10 in GLUT translocation. Interestingly, RAB10 protein levels were strongly reduced in *RABIF* KO cells (Fig. 3.5). Treatment with proteasomal inhibitors restored RAB10 expression in *RABIF* KO cells (Fig. 3.5), indicating that RAB10 is subject to proteasomal degradation in the absence of RABIF. This is an unexpected finding because no GEF was previously shown to regulate the stability of cognate Rab GTPases.




Figure 3.4: RABIF interacts with RAB10.

A. Top: diagram of the liposome co-flotation assay. Bottom: coomassie blue-stained denaturing gels showing the interaction between RABIF and RAB10 in the liposome co-flotation assay. PF: protein free. **B.** RABIF-FLAG was transiently expressed in *RABIF* KO HeLa cells. RABIF-FLAG was immunoprecipitated using anti-FLAG antibodies and the presence of RABIF-FLAG and RAB10 in the precipitates were detected by immunoblotting. **C.** Representative confocal images showing the localization of RAB10-Myc and RABIF-FLAG in HeLa cells with or without 30 min of insulin treatment (100 nM). Bar: 10 μ m. Imaging data was generated by Jingshi Shen. Flotation assay was performed by Haijia Yu.




Figure 3.5: *RABIF* KO results in RAB10 degradation via proteasome. *RABIF* KO cells (HeLa or Adipocytes) were either untreated or treated with the indicated proteasome inhibitors for 16 hours. The expression levels of RAB10 and α -tubulin were probed by immunoblotting.

RABIF's role in GLUT4 trafficking is independent of its putative GEF domain

We next examined whether the GEF catalytic activity of RABIF is required for GLUT4 translocation. Structural studies suggested that the conserved residues D73, M74 and F75 are likely required for the GEF catalytic activity of RABIF (3.6a) (Zhu et al., 2001). Indeed, in an *in vitro* nucleotide release assay, the GEF activity of RABIF was largely abolished by a single F75A substitution (M1) or the triple D73A/M74A/F75A mutations (M2) (Fig. 3.6 b,d). Strikingly, these GEF-defective mutants rescued GLUT translocation to similar levels as WT RABIF (Fig. 3.7 b,c). RAB10 expression was also restored by the expression of these RABIF GEF mutants (Fig. 3.7a). Finally, overexpression of RAB10 could rescue GLUT4 exocytosis in RABIF KO cells (Fig. 3.8). By contrast, overexpression of DENND4C, a known GEF for RAB10 (Sano et al., 2011) failed to rescue GLUT4 translocation or RAB10 expression in *RABIF* KO cells (Fig. 3.9), further suggesting that the stability of RAB10 is regulated by RABIF independent of its GEF catalytic activity. Thus, RAB10 exploits RABIF itself, rather than its GEF catalytic activity, to regulate GLUT4 translocation.




Figure 3.6: Catalytic domain mutants disrupt RABIF GEF activity.

A. Diagram showing RABIF point mutations predicted to impair GEF activity. **B.** Kinetics of fluorescence changes resulting from RABIF-catalyzed mant-GDP release. The reactions were carried out in the presence of WT or mutant RABIF, using RAB10 as the substrate. **C.** Coomassie blue-stained gel showing purified WT and mutant RABIF proteins. **D.** Initial rates of the reactions in h. Data are shown as percentage of fluorescence change within the first three minutes of the reactions. This data was generated by Haijia Yu.




Figure 3.7: GEF catalytic domain mutation does not disrupt GLUT4 exocytosis activity.
A. Immunoblots showing the expression levels of endogenous RAB10 and α -tubulin in the indicated HeLa cells. **B.** Normalized surface levels of the GLUT reporter in the indicated HeLa cells. *** $P < 0.001$. **C.** Normalized surface levels of the GLUT reporter in the indicated adipocytes cells. *** $P < 0.001$.




Figure 3.8: *RAB10* overexpression rescues *RABIF* KO GLUT4 exocytosis.

A. Immunoblots showing the expression levels of FLAG-tagged RAB10, total RAB10 and α -tubulin in the indicated HeLa cells. **B.** Normalized surface levels of the GLUT reporter in the indicated HeLa cells. *** $P < 0.001$.





Figure 3.9: Overexpression of *DENND4C* does not rescue GLUT translocation defects in *RABIF* KO cells. **A**, *DENND4C* was overexpressed in WT or *RABIF*- deficient HeLa cells. Effects of *DENND4C* overexpression on GLUT reporter translocation were measured by flow cytometry. Error bars indicate standard deviation. **B**, Immunoblots showing the expression of *DENND4C*, RAB10 and α -tubulin in the indicated cells.

Whole cell proteomics show that RABIF regulates a small subset of RABs

Finally, we determined whether RABIF regulates other Rabs in addition to RAB10. To this end, we performed mass spectrometry-based quantitative proteomic analysis of WT and *RABIF* deficient cells. Among the 19 Rab GTPases detected by mass spectrometry, RAB10 level was reduced by over 10-fold in *RABIF* null cells (Fig. 3.10), consistent with the immunoblotting results (Fig. 3.5, 3.7a). Besides RAB10, RAB8A expression was also diminished in *RABIF* deficient cells. Using overexpression of a panel of fluorescently labeled RAB proteins we confirmed that RAB8a expression was also effected by *RABIF* KO (Fig 3.11a) while endogenous expression of RAB5a, RAB6 and RAB7 were not effected (Fig 3.11b). Therefore, the protein stabilizing function of RABIF is restricted to a subset of Rab GTPases. RAB8A was not recovered in our screens (Extended Data Fig. 2), confirming that RAB10 is the molecular target of RABIF in the GLUT translocation pathway. Together, these data demonstrate that, although predicted as a GEF, RABIF regulates RAB10 through a new function independent of its GEF catalytic activity (Fig. 3.12).





Figure 3.10: RABIF regulates a small subset of RAB proteins.

Proteomic analysis of Rab GTPase expression in *RABIF* KO cells. Data are presented as percentage of expression levels in WT cells. Average values of two technical replicates are shown (RAB1B levels were identical in the replicates, while RAB5A was only quantified in one replicate).

a



b




Figure 3.11: RABIF regulates a subset of RAB proteins.

A. Cerulean tagged RABS were transiently transfected in indicated HeLa cells. Fluorescence was quantified by flow cytometry. Error bars indicate standard deviation.

B. Immunoblots showing the endogenous expression of the indicated RAB proteins.




Figure 3.12: RABIF regulates the expression of RAB10

Discussion

In this work we demonstrated that RABIF regulates RAB10 expression independent of its canonical GEF domain. Further work is needed to distinguish whether RABIF protects the mature form of RAB10 from degradation or if it is required for maturation of RAB10. Furthermore, the precise role of RAB10 in the cell remains unresolved. While RAB10 is clearly required for a large insulin response in both adipocytes and HeLa cells, it remains unclear if it is playing a direct role in vesicle trafficking and fusion or if it is required for a more upstream step such as sorting GLUT4 into the insulin responsive vesicles.

The whole cell proteomics revealed that RABIF is regulating a small subset of RABs. Other proteins with a more mild reduction may be secondary in nature, for example down regulated in response to Rab10 reduction rather than Rabif. Among the mildly down-regulated proteins (~25% reduction) were a large number of mitochondrial-localized proteins. This is a very

interesting finding because it would link the cells ability to import glucose to its ability to metabolize glucose. This is potentially related to the large number of genes whose protein products localize to the mitochondria, which were recovered in the GLUT4 exocytosis defective screen. These two findings could represent opposite sides of a feedback loop. Further work is needed to validate this feedback mechanism, and identify the specific mechanism of feedback inhibition.

| Table 3.1. Proteomic analysis of WT and <i>Rab1f</i> KO cells | | | |
|--|------------------|----------------|---------------------------|
| Protein name | Gene name | Average | Standard Deviation |
| Ras-related protein Rab-10 | RAB10 | 0.1 | 0.014 |
| Ras-related protein Rab-8A | RAB8A | 0.265 | 0.021 |
| Abhydrolase domain-containing protein 16A | ABHD16A | 0.39 | NA |
| Proteolipid protein 2 | PLP2 | 0.41 | NA |
| Lysosomal-associated transmembrane protein 4A | LAPTM4A | 0.495 | 0.049 |
| Syndecan-1 | SDC1 | 0.53 | NA |
| Monocarboxylate transporter 7 | SLC16A6 | 0.53 | NA |
| Folate receptor alpha | FOLR1 | 0.59 | 0.014 |
| Disco-interacting protein 2 homolog B | DIP2B | 0.595 | 0.615 |
| ATP synthase mitochondrial F1 complex assembly factor 1 | ATPAF1 | 0.6 | 0.255 |
| Microtubule-associated proteins 1A/1B light chain 3B | MAP1LC3B | 0.605 | 0.035 |
| Glucocorticoid modulatory element-binding protein 1 | GMEB1 | 0.61 | NA |
| Sin3 histone deacetylase corepressor complex component SDS3 | SUDS3 | 0.63 | NA |
| CD81 antigen | CD81 | 0.64 | 0.028 |
| NEDD4 family-interacting protein 1 | NDFIP1 | 0.645 | 0.007 |
| Deoxynucleotidyltransferase terminal-interacting protein 1 | DNTTIP1 | 0.65 | NA |
| Focadhesin | FOCAD | 0.65 | NA |
| Type 1 phosphatidylinositol 4,5-bisphosphate 4-phosphatase | TMEM55B | 0.65 | NA |
| Glutathione peroxidase | GPX4 | 0.655 | 0.078 |
| Cytochrome c oxidase subunit 1 | MT-CO1 | 0.655 | 0.007 |

| | | | |
|--|----------|-------|-------|
| Serine/threonine-protein phosphatase 1 regulatory subunit 10 | PPP1R10 | 0.665 | 0.078 |
| G antigen 12F | GAGE12F | 0.67 | 0.085 |
| 2-oxoisovalerate dehydrogenase subunit beta, mitochondrial | BCKDHB | 0.67 | NA |
| Ephrin type-A receptor 2 | EPHA2 | 0.67 | NA |
| Ferritin light chain | FTL | 0.67 | 0.014 |
| Glutathione peroxidase 1 | GPX1 | 0.675 | 0.021 |
| Neurogenic locus notch homolog protein 2 | NOTCH2 | 0.675 | 0.007 |
| G antigen 2D | GAGE2D | 0.685 | 0.035 |
| Ferritin | FTH1 | 0.69 | 0.014 |
| Integrin alpha-5 | ITGA5 | 0.69 | NA |
| Protein PML | PML | 0.69 | NA |
| E3 ubiquitin-protein ligase RNF149 | RNF149 | 0.695 | 0.021 |
| Alpha-adducin | ADD1 | 0.7 | NA |
| Nuclear factor 1 | NFIA | 0.7 | NA |
| Transmembrane protein 205 | TMEM205 | 0.7 | NA |
| CD70 antigen | CD70 | 0.705 | 0.064 |
| Endothelial protein C receptor | PROCR | 0.705 | 0.092 |
| Alanine aminotransferase 2 | GPT2 | 0.71 | 0.113 |
| MARCKS-related protein | MARCKSL1 | 0.71 | NA |
| 28S ribosomal protein S25, mitochondrial | MRPS25 | 0.72 | 0.085 |
| Protein MTO1 homolog, mitochondrial | MTO1 | 0.72 | NA |
| Lipid phosphate phosphohydrolase 2 | PPAP2C | 0.72 | NA |
| Prostaglandin F2 receptor negative regulator | PTGFRN | 0.72 | 0.028 |
| Folate transporter 1 | SLC19A1 | 0.72 | NA |
| Tumor necrosis factor ligand superfamily member 9 | TNFSF9 | 0.725 | 0.035 |
| Acyl-CoA synthetase family member 3, mitochondrial | ACSF3 | 0.73 | 0.085 |
| CD63 antigen | CD63 | 0.73 | 0.071 |
| Bifunctional ATP-dependent dihydroxyacetone kinase/FAD-AMP lyase (cyclizing) | DAK | 0.73 | NA |
| NADPH:adrenodoxin oxidoreductase, mitochondrial | FDXR | 0.73 | NA |
| Transmembrane protein 209 | TMEM209 | 0.73 | NA |
| Neural cell adhesion molecule L1 | L1CAM | 0.735 | 0.021 |
| Leukemia inhibitory factor receptor | LIFR | 0.735 | 0.035 |
| Receptor expression-enhancing protein 6 | REEP6 | 0.74 | NA |
| Splicing factor, arginine/serine-rich 15 | SCAF4 | 0.74 | NA |
| Leucine-rich repeat and WD repeat-containing protein 1 | LRWD1 | 0.745 | 0.191 |
| 39S ribosomal protein L45, mitochondrial | MRPL45 | 0.745 | 0.007 |
| Solute carrier family 35 member F2 | SLC35F2 | 0.745 | 0.049 |
| Disintegrin and metalloproteinase domain-containing protein 9 | ADAM9 | 0.75 | NA |

| | | | |
|---|----------|-------|-------|
| Quinone oxidoreductase-like protein 1 | CRYZL1 | 0.75 | NA |
| Protein FAM115A | FAM115A | 0.75 | NA |
| HIG1 domain family member 2A, mitochondrial | HIGD2A | 0.75 | NA |
| Interferon-induced transmembrane protein 1 | IFITM2 | 0.75 | NA |
| 39S ribosomal protein L3, mitochondrial | MRPL3 | 0.75 | NA |
| Brain acid soluble protein 1 | BASPI | 0.755 | 0.049 |
| DNA-directed RNA polymerase I subunit RPA34 | CD3EAP | 0.755 | 0.021 |
| 28S ribosomal protein S18b, mitochondrial | MRPS18B | 0.755 | 0.021 |
| ATP synthase subunit f, mitochondrial | ATP5J2 | 0.76 | NA |
| 1,4-alpha-glucan-branching enzyme | GBE1 | 0.76 | NA |
| Glutaryl-CoA dehydrogenase, mitochondrial | GCDH | 0.76 | NA |
| General transcription factor IIH subunit 2-like protein | GTF2H2C | 0.76 | NA |
| Haloacid dehalogenase-like hydrolase domain-containing protein 3 | HDHD3 | 0.76 | NA |
| Homeodomain-interacting protein kinase 4 | HIPK4 | 0.76 | NA |
| HLA class I histocompatibility antigen, B-42 alpha chain | HLA-B | 0.76 | NA |
| 28S ribosomal protein S30, mitochondrial | MRPS30 | 0.76 | 0.170 |
| NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 11, mitochondrial | NDUFB11 | 0.76 | NA |
| Pituitary tumor-transforming gene 1 protein-interacting protein | PTTG1IP | 0.76 | NA |
| Zinc transporter ZIP10 | SLC39A10 | 0.76 | NA |
| Zinc transporter ZIP14 | SLC39A14 | 0.76 | NA |
| Activating transcription factor 7-interacting protein 1 | ATF7IP | 0.765 | 0.078 |
| Cdc42 effector protein 1 | CDC42EP1 | 0.77 | NA |
| Epsin-1 | EPN1 | 0.77 | NA |
| HCLS1-associated protein X-1 | HAX1 | 0.77 | 0.028 |
| Myristoylated alanine-rich C-kinase substrate | MARCKS | 0.77 | 0.085 |
| NADH-ubiquinone oxidoreductase chain 5 | MT-ND5 | 0.77 | 0.071 |
| Putative nascent polypeptide-associated complex subunit alpha-like protein | NACAP1 | 0.77 | NA |
| Polypyrimidine tract-binding protein 2 | PTBP2 | 0.77 | 0.014 |
| Parathyrosin | PTMS | 0.77 | 0.283 |
| All-trans-retinol 13,14-reductase | RETSAT | 0.77 | NA |
| Shugoshin-like 2 | SGOL2 | 0.77 | NA |
| Sequestosome-1 | SQSTM1 | 0.77 | 0.000 |
| 28S ribosomal protein S35, mitochondrial | MRPS35 | 0.775 | 0.078 |
| Creatine kinase U-type, mitochondrial | CKMT1A | 0.775 | 0.021 |
| Acylpyruvase FAHD1, mitochondrial | FAHD1 | 0.775 | 0.134 |
| ATPase family AAA domain-containing protein 3B | ATAD3B | 0.78 | NA |
| Interferon-induced transmembrane protein 3 | IFITM3 | 0.78 | NA |
| NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 3 | NDUFB3 | 0.78 | NA |

| | | | |
|--|---------|-------|-------|
| NAD-dependent protein deacylase sirtuin-5, mitochondrial | SIRT5 | 0.78 | NA |
| Synaptophysin-like protein 1 | SYPL1 | 0.78 | 0.042 |
| Mitochondrial import receptor subunit TOM6 homolog | TOMM6 | 0.78 | 0.014 |
| Tetraspanin-3 | TSPAN3 | 0.78 | NA |
| UBX domain-containing protein 8 | UBXN8 | 0.78 | NA |
| Lysosomal alpha-glucosidase | GAA | 0.785 | 0.092 |
| High mobility group protein HMG-I/HMG-Y | HMGA1 | 0.785 | 0.049 |
| Heterogeneous nuclear ribonucleoproteins C1/C2 | HNRNPC | 0.785 | 0.049 |
| Scavenger receptor class B member 1 | SCARB1 | 0.785 | 0.092 |
| Zinc finger CCCH domain-containing protein 18 | ZC3H18 | 0.785 | 0.064 |
| Neutral amino acid transporter B(0) | SLC1A5 | 0.785 | 0.007 |
| A-kinase anchor protein 13 | AKAP13 | 0.79 | NA |
| HMG box transcription factor BBX | BBX | 0.79 | NA |
| 2-methoxy-6-polyprenyl-1,4-benzoquinol methylase, mitochondrial | COQ5 | 0.79 | NA |
| Protein SGT1 | ECD | 0.79 | 0.057 |
| Integrin alpha-2 | ITGA2 | 0.79 | 0.057 |
| Microtubule-associated protein 2 | MAP2 | 0.79 | NA |
| 39S ribosomal protein L4, mitochondrial | MRPL4 | 0.79 | 0.042 |
| 39S ribosomal protein L54, mitochondrial | MRPL54 | 0.79 | NA |
| Phosphoenolpyruvate carboxykinase [GTP], mitochondrial | PCK2 | 0.79 | 0.057 |
| [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrial | PDK3 | 0.79 | NA |
| Membralin | TMEM259 | 0.79 | 0.028 |
| Dystroglycan | DAG1 | 0.795 | 0.106 |
| ATP-binding cassette sub-family G member 2 | ABCG2 | 0.795 | 0.021 |
| Mitochondrial inner membrane protein OXA1L | OXA1L | 0.795 | 0.163 |

EXPERIMENTAL PROCEDURES

Recombinant protein expression and purification

Recombinant RAB10 proteins were produced in *Sf9* insect cells using baculovirus infection. The full-length mouse *Rab10* gene was cloned into the baculovirus transfer vector pFastBac to generate a construct encoding a His₆-tagged RAB10 protein with a tobacco etch virus (TEV) protease cleavage site. His₆-Rab10 was expressed in *Sf9* cells as we previously described for other proteins (Yu et al., 2016; Yu et al., 2013b). The cells were harvested in a lysis buffer (25 mM HEPES [pH 7.4], 400 mM KCl, 10% glycerol, 20 mM imidazole, 5 mM MgCl₂, 1% Triton, 2 mM β-mercaptoethanol, and a protease inhibitor cocktail). RAB10 proteins were purified by nickel affinity chromatography and the His₆ tag was removed by TEV protease digestion.

Recombinant RABIF proteins were expressed and purified from *E. coli* as we previously described for other soluble proteins (Rathore et al., 2010; Yu et al., 2013a; Yu et al., 2013c). The human *RABIF* gene was cloned into a pET28a-based SUMO vector. Purified His₆-SUMO-RABIF fusion proteins were digested by SUMO proteases to obtain untagged RABIF proteins. RABIF mutants were generated by site-directed mutagenesis and expressed using the same procedure as the WT protein.

Liposome co-flotation assay

Protein-free or RAB10 liposomes were prepared using POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine), following a liposome reconstitution protocol previously established in our group (Rathore et al., 2011; Shen et al., 2010; Yu et al., 2013c). Soluble RABIF proteins were incubated with liposomes at 4 °C with gentle agitation. After one hour, an equal volume of 80% nycodenz (w/v) in reconstitution buffer was added and transferred to 5 mm by 41 mm centrifuge tubes. The liposomes were overlaid with 200 μ l each of 35% and 30% Nycodenz, and then with 20 μ l reconstitution buffer on the top. The gradients were centrifuged for 4 hours at 52,000 RPM in a Beckman SW55 rotor. Samples were collected from the 0/30% Nycodenz interface (2 x 20 μ l) and analyzed by SDS-PAGE.

Guanine nucleotide release assay

Recombinant RAB10 proteins were incubated with the fluorescent GDP analogue 2'-(or-3')-*O*-(*N*-Methylanthraniloyl) Guanosine 5'-Diphosphate (mant-GDP, Molecular Probes, #M12414) at room temperature for one hour in a loading buffer (20 mM HEPES [pH 7.4], 50 mM NaCl, 5 mM EDTA, and a 25-fold molar excess of mant-GDP). The loading reaction was terminated by addition of 10 mM MgCl₂. Free mant-GDP was removed using desalting columns (GE Healthcare, #17-0853-02). Mant-GDP-bound RAB10 was diluted to 0.2 μ M using the exchange buffer (20 mM HEPES [pH 7.4], 50 mM NaCl, and 5 mM MgCl₂) in the absence or presence of 10 μ M RABIF and 100 μ M unlabeled GDP. Fluorescence changes associated with mant-GDP

release were measured on a SpectraMax M5 microplate reader (Molecular Devices) at the excitation wavelength of 365 nm and emission wavelength of 440 nm.

Immunoblotting and immunoprecipitation

Cells grown in 24-well plates were lysed in 1x SDS protein sample buffer and the cell lysates were resolved on 8% Bis-Tris SDS-PAGE. Proteins were detected using primary antibodies and horseradish peroxidase-conjugated secondary antibodies. Primary antibodies used in immunoblotting were: anti-AKT antibodies (Cell Signaling Technology, #9272), anti-phospho-AKT antibodies (Cell Signaling Technology, #5473), anti-RAB10 antibodies (Cell Signaling Technology, #8127) anti- α -tubulin antibodies (eBioscience, #14-4502-82), and anti-FLAG antibodies (Sigma, #F1804).

In immunoprecipitation experiments, cells were lysed in a buffer containing 25 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1 mM EDTA, 1% NP-40, 5% glycerol, and a protease inhibitor cocktail. Proteins were precipitated by using anti-FLAG magnetic beads (Sigma, M8823). Proteins in the precipitates were detected by immunoblotting.

Immunostaining and imaging

HeLa cells were seeded on coverslips coated with fibronectin (Sigma, #F1144). The cells were fixed using 2% PFA and permeabilized in PBS supplemented with 5% FBS and 0.2% saponin. Antigens were stained using the following primary antibodies: anti-Myc antibodies (SCBT,

clone#9E10), anti-FLAG antibodies (Sigma, #F7425). The cells were subsequently incubated with Alexa Fluor 488- or Alexa Fluor 568-conjugated secondary antibodies. After mounting on glass slides using the ProLong Antifade mountant with DAPI (Thermo, #P36931), the cells were visualized on a Carl Zeiss LSM780 confocal microscope. Cell images were captured and processed using the Carl Zeiss Zen 2 and Adobe Photoshop software. To visualize the GFP-GLUT4-HA reporter in adipocytes, the cells were fixed and permeabilized similarly as HeLa cells.

Mass spectrometry

Quantitative proteomic analysis of protein levels was performed using stable isotope labeling with amino acids in cell culture (SILAC) and mass spectrometry (MS). Cells were grown in SILAC media (Thermo, #88423) supplemented with 10% dialyzed FBE (Seradigm, #3100). WT HeLa cells were grown in the presence of light lysine and arginine (Sigma, #L1262 and A5131), whereas RABIF null cells were grown in the presence of heavy lysine and arginine (Cambridge Isotope Laboratories, #CNLM-291 and CNLM-539). After five days, the cells were harvested at ~60% confluence in a lysis buffer (4% SDS and 50 mM Tris-HCl [pH 6.8]). The cell lysates were processed for MS analysis following the filter-aided sample preparation (FASP) protocol (Erde et al., 2014; Wisniewski et al., 2009). Briefly, after addition of 20 mM DTT, equal amounts of whole-cell lysates were mixed and loaded onto a spin filter with a molecular weight cutoff of 30 kDa. The sample was then washed with the UA solution (8 M Urea and 0.1 M Tris-HCl [pH 7.9]) and alkylated using 0.1 M iodoacetamide. The sample was further washed with the UA solution and equilibrated with 0.1 M ammonium bicarbonate and 0.01% deoxycholic

acid. The sample was then digested using 1% (w/w) trypsin at 37 °C for 16 hours. The resulting tryptic peptides were eluted by centrifugation, and acidified using formic acid. Deoxycholic acid was removed using phase transfer with ethyl acetate. The tryptic peptides were fractionated by a Pierce high pH reversed-phase spin column using 18 step gradients (4% acetonitrile for the first fraction, 1% increment for each fraction to the 17th fraction, and 50% acetonitrile for the 18th fraction). The fractions were dried using vacuum centrifugation.

One third of each fraction (5 µL) from high pH fractionation was analyzed by UPLC-MS/MS. The tryptic peptides were loaded onto a Waters nanoACQUITY UPLC BEH C18 column (130 Å, 1.7 µm × 75 µm × 250 mm) equilibrated with 0.1% formic acid/3% acetonitrile/water. Mobile phase A was 0.1% formic acid/water, while B was 0.1% formic acid/acetonitrile. The peptides were eluted at 0.3 mL/min using a gradient of 3-8% B (0-5 minutes) and 8-35% B (5-123 minutes).

Precursor ions between 300-1800 m/z (1×10^6 ions, 60,000 resolution) were scanned on a LTQ Orbitrap Velos mass spectrometer. The 10 most intense ions for MS/MS were selected with 180-second dynamic exclusion, 10 ppm exclusion width, with a repeat count=1, and a 30-second repeat duration. Ions with unassigned charge state and MH+1 were excluded from MS/MS. Maximal ion injection times were 500 milliseconds for FT (one microscan) and 250 milliseconds for LTQ, and the AGC was 1×10^4 . The normalized collision energy was 35% with activation Q 0.25 for 10 milliseconds.

Raw data files from MS were searched against the Uniprot human proteome database (Consortium, 2015) (total 88,479 entries), using the MaxQuant/Andromeda search engine (version 1.5.2.8)(Cox et al., 2011). Searches allowed trypsin specificity with two missed cleavages, and included fixed Cys carbamidomethylation, and variable acetylation (protein N-terminus) and methionine oxidation. Mass tolerances were set to 20 ppm (first search) and 4.5 ppm (main search) for precursor ions, and 0.5 Da for ITMS MS/MS ions. MaxQuant/Andromeda used the top 8 MS/MS peaks per 100 Da and seven amino acid minimum peptide length, with 0.01 false discovery rate for both protein and peptide identification. For SILAC ratio measurements, minimum two independent peptide ratios were used to calculate a protein ratio.

REFERENCES

- Antonescu, C.N., McGraw, T.E., and Klip, A. (2014). Reciprocal regulation of endocytosis and metabolism. *Cold Spring Harbor perspectives in biology* 6, a016964.
- Böcking, T., Aguet, F., Harrison, S.C., and Kirchhausen, T. (2011). Single-molecule analysis of a molecular disassemblase reveals the mechanism of Hsc70-driven clathrin uncoating. *Nature structural & molecular biology* 18, 295-301.
- Bonifacino, J.S., and Glick, B.S. (2004). The mechanisms of vesicle budding and fusion. *Cell* 116, 153-166.
- Brodsky, F.M. (2012). Diversity of clathrin function: new tricks for an old protein. *Annu Rev Cell Dev Biol* 28, 309-336.
- Bryant, N.J., Govers, R., and James, D.E. (2002). Regulated transport of the glucose transporter GLUT4. *Nat Rev Mol Cell Biol* 3, 267-277.
- Cong, L., Ran, F.A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P.D., Wu, X., Jiang, W., Marraffini, L.A., *et al.* (2013). Multiplex genome engineering using CRISPR/Cas systems. *Science (New York, NY)* 339, 819-823.
- Conner, S.D., and Schmid, S.L. (2003). Differential requirements for AP-2 in clathrin-mediated endocytosis. *The Journal of cell biology* 162, 773-779.
- Cox, J., Neuhauser, N., Michalski, A., Scheltema, R.A., Olsen, J.V., and Mann, M. (2011). Andromeda: a peptide search engine integrated into the MaxQuant environment. *J Proteome Res* 10, 1794-1805.
- Davis, E.M., Kim, J., Menasche, B.L., Sheppard, J., Liu, X., Tan, A.C., and Shen, J. (2015). Comparative Haploid Genetic Screens Reveal Divergent Pathways in the Biogenesis and Trafficking of Glycophosphatidylinositol-Anchored Proteins. *Cell Rep* 11, 1727-1736.
- Doudna, J.A., and Charpentier, E. (2014). Genome editing. The new frontier of genome engineering with CRISPR-Cas9. *Science (New York, NY)* 346, 1258096.
- Dummler, B., Tschopp, O., Hynx, D., Yang, Z.Z., Dirnhofer, S., and Hemmings, B.A. (2006). Life with a single isoform of Akt: mice lacking Akt2 and Akt3 are viable but display impaired glucose homeostasis and growth deficiencies. *Mol Cell Biol* 26, 8042-8051.
- Eguez, L., Lee, A., Chavez, J.A., Miinea, C.P., Kane, S., Lienhard, G.E., and McGraw, T.E. (2005). Full intracellular retention of GLUT4 requires AS160 Rab GTPase activating protein. *Cell Metab* 2, 263-272.

- Erde, J., Loo, R.R., and Loo, J.A. (2014). Enhanced FASP (eFASP) to increase proteome coverage and sample recovery for quantitative proteomic experiments. *J Proteome Res* *13*, 1885-1895.
- Ferguson, S.M., Raimondi, A., Paradise, S., Shen, H., Mesaki, K., Ferguson, A., Destaing, O., Ko, G., Takasaki, J., Cremona, O., *et al.* (2009). Coordinated actions of actin and BAR proteins upstream of dynamin at endocytic clathrin-coated pits. *Developmental cell* *17*, 811-822.
- Fu, Y., Sander, J.D., Reyon, D., Cascio, V.M., and Joung, J.K. (2014). Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. *Nat Biotechnol* *32*, 279-284.
- Gilbert, L.A., Horlbeck, M.A., Adamson, B., Villalta, J.E., Chen, Y., Whitehead, E.H., Guimaraes, C., Panning, B., Ploegh, H.L., Bassik, M.C., *et al.* (2014). Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation. *Cell* *159*, 647-661.
- Hart, T., Chandrashekhar, M., Aregger, M., Steinhart, Z., Brown, K.R., MacLeod, G., Mis, M., Zimmermann, M., Fradet-Turcotte, A., Sun, S., *et al.* (2015). High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities. *Cell* *163*, 1515-1526.
- Huang, S., and Czech, M.P. (2007). The GLUT4 glucose transporter. *Cell Metab* *5*, 237-252.
- Koike-Yusa, H., Li, Y., Tan, E.P., Velasco-Herrera Mdel, C., and Yusa, K. (2014). Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. *Nat Biotechnol* *32*, 267-273.
- Li, W., Xu, H., Xiao, T., Cong, L., Love, M.I., Zhang, F., Irizarry, R.A., Liu, J.S., Brown, M., and Liu, X.S. (2014). MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. *Genome biology* *15*, 554.
- Mali, P., Yang, L., Esvelt, K.M., Aach, J., Guell, M., DiCarlo, J.E., Norville, J.E., and Church, G.M. (2013). RNA-guided human genome engineering via Cas9. *Science (New York, NY)* *339*, 823-826.
- Marceau, C.D., Puschnik, A.S., Majzoub, K., Ooi, Y.S., Brewer, S.M., Fuchs, G., Swaminathan, K., Mata, M.A., Elias, J.E., Sarnow, P., *et al.* (2016). Genetic dissection of Flaviviridae host factors through genome-scale CRISPR screens. *Nature* *535*, 159-163.
- Martens, S., and McMahon, H.T. (2008). Mechanisms of membrane fusion: disparate players and common principles. *Nat Rev Mol Cell Biol* *9*, 543-556.
- McMahon, H.T., and Boucrot, E. (2011). Molecular mechanism and physiological functions of clathrin-mediated endocytosis. *Nat Rev Mol Cell Biol* *12*, 517-533.
- Muretta, J.M., Romenskaia, I., and Mastick, C.C. (2008). Insulin releases Glut4 from static storage compartments into cycling endosomes and increases the rate constant for Glut4 exocytosis. *J Biol Chem* *283*, 311-323.

- Page, L.J., Sowerby, P.J., Lui, W.W., and Robinson, M.S. (1999a). Gamma-synergargin: an EH domain-containing protein that interacts with gamma-adaptin. *The Journal of cell biology* *146*, 993-1004.
- Page, L.J., Sowerby, P.J., Lui, W.W.Y., and Robinson, M.S. (1999b). γ -Synergargin: An Eh Domain-Containing Protein That Interacts with γ -Adaptin. *The Journal of Cell Biology* *146*, 993-1004.
- Palade, G. (1975). Intracellular aspects of the process of protein synthesis. *Science* *189*, 347-358.
- Parnas, O., Jovanovic, M., Eisenhaure, T.M., Herbst, R.H., Dixit, A., Ye, C.J., Przybylski, D., Platt, R.J., Tirosh, I., Sanjana, N.E., *et al.* (2015). A Genome-wide CRISPR Screen in Primary Immune Cells to Dissect Regulatory Networks. *Cell* *162*, 675-686.
- Pohler, E., Mamai, O., Hirst, J., Zamiri, M., Horn, H., Nomura, T., Irvine, A.D., Moran, B., Wilson, N.J., Smith, F.J., *et al.* (2012). Haploinsufficiency for AAGAB causes clinically heterogeneous forms of punctate palmoplantar keratoderma. *Nat Genet* *44*, 1272-1276.
- Rathore, S.S., Bend, E.G., Yu, H., Hammarlund, M., Jorgensen, E.M., and Shen, J. (2010). Syntaxin N-terminal peptide motif is an initiation factor for the assembly of the SNARE-Sec1/Munc18 membrane fusion complex. *Proc Natl Acad Sci U S A* *107*, 22399-22406.
- Rathore, S.S., Ghosh, N., Ouyang, Y., and Shen, J. (2011). Topological arrangement of the intracellular membrane fusion machinery. *Molecular biology of the cell* *22*, 2612-2619.
- Saltiel, A.R., and Kahn, C.R. (2001). Insulin signalling and the regulation of glucose and lipid metabolism. *Nature* *414*, 799-806.
- Sanjana, N.E., Shalem, O., and Zhang, F. (2014). Improved vectors and genome-wide libraries for CRISPR screening. *Nature methods* *11*, 783-784.
- Sano, H., Eguez, L., Teruel, M.N., Fukuda, M., Chuang, T.D., Chavez, J.A., Lienhard, G.E., and McGraw, T.E. (2007). Rab10, a target of the AS160 Rab GAP, is required for insulin-stimulated translocation of GLUT4 to the adipocyte plasma membrane. *Cell Metab* *5*, 293-303.
- Sano, H., Peck, G.R., Kettenbach, A.N., Gerber, S.A., and Lienhard, G.E. (2011). Insulin-stimulated GLUT4 Protein Translocation in Adipocytes Requires the Rab10 Guanine Nucleotide Exchange Factor Dennd4C. *J Biol Chem* *286*, 16541-16545.
- Schekman, R., and Novick, P. (2004). 23 genes, 23 years later. *Cell* *116*, S13-15, 11 p following S19.
- Shalem, O., Sanjana, N.E., Hartenian, E., Shi, X., Scott, D.A., Mikkelsen, T.S., Heckl, D., Ebert, B.L., Root, D.E., Doench, J.G., *et al.* (2014). Genome-scale CRISPR-Cas9 knockout screening in human cells. *Science (New York, NY)* *343*, 84-87.

Shen, J., Rathore, S., Khandan, L., and Rothman, J.E. (2010). SNARE bundle and syntaxin N-peptide constitute a minimal complement for Munc18-1 activation of membrane fusion. *J Cell Biology* 190, 55-63.

Sidik, S.M., Huet, D., Ganesan, S.M., Huynh, M.H., Wang, T., Nasamu, A.S., Thiru, P., Saeij, J.P., Carruthers, V.B., Niles, J.C., *et al.* (2016). A Genome-wide CRISPR Screen in *Toxoplasma* Identifies Essential Apicomplexan Genes. *Cell* 166, 1423-1435 e1412.

Simpson, I.A., Dwyer, D., Malide, D., Moley, K.H., Travis, A., and Vannucci, S.J. (2008). The facilitative glucose transporter GLUT3: 20 years of distinction. *Am J Physiol Endocrinol Metab* 295, E242-253.

Stowell, M.H.B., Marks, B., Wigge, P., and McMahon, H.T. (1999). Nucleotide-dependent conformational changes in dynamin: evidence for a mechanochemical molecular spring. *Nat Cell Biol* 1, 27-32.

Sudhof, T.C., and Rothman, J.E. (2009). Membrane fusion: grappling with SNARE and SM proteins. *Science* 323, 474-477.

Tebar, F., Sorkina, T., Sorkin, A., Ericsson, M., and Kirchhausen, T. (1996). Eps15 Is a Component of Clathrin-coated Pits and Vesicles and Is Located at the Rim of Coated Pits. *Journal of Biological Chemistry* 271, 28727-28730.

Traub, L.M., and Bonifacino, J.S. (2013). Cargo recognition in clathrin-mediated endocytosis. *Cold Spring Harbor perspectives in biology* 5, a016790.

Trefely, S., Khoo, P.S., Krycer, J.R., Chaudhuri, R., Fazakerley, D.J., Parker, B.L., Sultani, G., Lee, J., Stephan, J.P., Torres, E., *et al.* (2015). Kinome Screen Identifies PFKFB3 and Glucose Metabolism as Important Regulators of the Insulin/Insulin-like Growth Factor (IGF)-1 Signaling Pathway. *J Biol Chem* 290, 25834-25846.

Wang, T., Birsoy, K., Hughes, N.W., Krupczak, K.M., Post, Y., Wei, J.J., Lander, E.S., and Sabatini, D.M. (2015). Identification and characterization of essential genes in the human genome. *Science (New York, NY)* 350, 1096-1101.

Wang, T., Wei, J.J., Sabatini, D.M., and Lander, E.S. (2014). Genetic screens in human cells using the CRISPR-Cas9 system. *Science (New York, NY)* 343, 80-84.

Wisniewski, J.R., Zougman, A., Nagaraj, N., and Mann, M. (2009). Universal sample preparation method for proteome analysis. *Nature methods* 6, 359-362.

Wixler, V., Wixler, L., Altenfeld, A., Ludwig, S., Goody, R.S., and Itzen, A. (2011). Identification and characterisation of novel Mss4-binding Rab GTPases. *Biol Chem* 392, 239-248.

- Xiong, X., Chen, M., Lim, W.A., Zhao, D., and Qi, L.S. (2016). CRISPR/Cas9 for Human Genome Engineering and Disease Research. *Annu Rev Genomics Hum Genet* 17, 131-154.
- Yu, H., Liu, Y., Gulbranson, D.R., Paine, A., Rathore, S.S., and Shen, J. (2016). Extended synaptotagmins are Ca²⁺-dependent lipid transfer proteins at membrane contact sites. *Proc Natl Acad Sci U S A* 113, 4362-4367.
- Yu, H., Rathore, S.S., Davis, E.M., Ouyang, Y., and Shen, J. (2013a). Doc2b promotes GLUT4 exocytosis by activating the SNARE-mediated fusion reaction in a calcium- and membrane bending-dependent manner. *Mol Biol Cell* 24, 1176-1184.
- Yu, H., Rathore, S.S., Lopez, J.A., Davis, E.M., James, D.E., Martin, J.L., and Shen, J. (2013b). Comparative studies of Munc18c and Munc18-1 reveal conserved and divergent mechanisms of Sec1/Munc18 proteins. *Proc Natl Acad Sci U S A* 110, E3271-3280.
- Yu, H., Rathore, S.S., and Shen, J. (2013c). Synip arrests soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE)-dependent membrane fusion as a selective target membrane SNARE-binding inhibitor. *J Biol Chem* 288, 18885-18893.
- Zhang, R., Miner, J.J., Gorman, M.J., Rausch, K., Ramage, H., White, J.P., Zuiani, A., Zhang, P., Fernandez, E., Zhang, Q., *et al.* (2016). A CRISPR screen defines a signal peptide processing pathway required by flaviviruses. *Nature* 535, 164-168.
- Zhou, Y., Zhu, S., Cai, C., Yuan, P., Li, C., Huang, Y., and Wei, W. (2014). High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells. *Nature* 509, 487-491.
- Zhu, Z., Dumas, J.J., Lietzke, S.E., and Lambright, D.G. (2001). A helical turn motif in Mss4 is a critical determinant of Rab binding and nucleotide release. *Biochemistry* 40, 3027-3036.